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Abstract 
Familial amyloidotic polyneuropathy (FAP) is an autosomal dominant disorder directly 
related to the presence of mutations in the transthyretin (TTR) protein. Pathologically, FAP 
is characterized by the extracellular deposition of insoluble TTR -amyloid- in several 
organs, with a special involvement of the peripheral nerve, leading to cell damage, organ 
dysfunction and finally, death. The mechanisms underlying TTR amyloid formation as well 
as other factors intervening in the amyloidogenic cascade are unknown. The only treatment 
for FAP that has proven successful is liver transplantation, though limited by the availability 
of livers for transplantation and the requirement for lifelong immune suppression. A therapy 
in which a small molecule drug inhibits TTR amyloid formation would be preferable. 
Different markers have been used to identify amyloid throughout time. However, some of 
them are not appropriate for in vivo diagnosis and others imply very invasive methods. We 
studied the binding properties of a small protein, aprotinin, to different amyloid types and 
showed that this protease inhibitor binds insulin, TTR, P-amyloid peptide and 
immunoglobulin synthetic amyloid fibrils by a specific dot blot ligand binding assay. 
Aprotinin did not bind amorphous precipitates and/or the soluble fibril precursors. A Ka of 
2.9 uM"1 for the binding of aprotinin to insulin amyloid fibrils was determined by Scatchard 
analysis. We suggest that aprotinin interacts with amyloid fibrils through pairing of p-sheets 
with exposed structures of the same type at the surface of amyloid deposits. Our results also 
indicate an electrostatic component in the binding of aprotinin to amyloid fibrils. We also 
tested binding of short peptides derived from aprotinin (APR1 and APR2) to different types 
of synthetic amyloid fibrils and showed that they are able to specifically bind to fibrils. In 
the future, aprotinin and particularly its peptides can be used not only to perform non-
invasive diagnosis but also to follow up the progression of eventual treatments. 
In an attempt to gain more insights into the ultrastructural organization and assembly of 
amyloid fibrils, we studied the time progression of TTR wild-type (WT) amyloid-like fibrils 
produced by acidification and of TTR Leu55Pro fibrils under physiological conditions, 
finding that they are dynamically very similar and present the same features and 
dimensions. The main species was an 8 nm wide fibril with a left-handed twist as shown by 
transmission electron microscopy (TEM) after metal shadowing, and atomic force 
microscopy (AFM). The preparations evolved from non-fibrillar aggregates to short fibrils 
elongating over time. These fibrils were also analysed by scanning transmission electron 
microscopy (STEM) and we clearly showed that the basic unit is an altered monomer. In 
relation to ex vivo fibrils, nerve amyloid fibrils from an FAP patient revealed dimensions 
similar to the in vitro ones, while vitreous fibrils were shown to be significantly larger. 
However, the latter seemed to result from the assembly of several 8 nm wide fibrils, 
suggesting that the wider structures can result from the lateral association of smaller fibrils. 
Mature fibrils, as the ones extracted from FAP patients, do not enable a dynamic study and 
thus, this problem as well as the identification of the building blocks in the in vivo or ex vivo 
fibrils should be addressed in the future. 
The identification of different species present throughout the process of amyloid formation 
created the opportunity to evaluate the activity of different drugs interfering at different 
stages in the amyloidogenic cascade. A number of studies revealed that 4'-iodo-4'-
deoxydoxorubicin (I-DOX) interact with amyloid fibrils. To ascertain the action on TTR 
amyloid-like fibrils, we performed a time and concentration study and concluded that I-
DOX and I-DOX-like compounds tested do not inhibit formation of fibrils but rather disrupt 
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long fibrils, demonstrating the highest activity at 10"5 M/100 ug of fibrils, under the 
conditions tested. After assessing the toxicity of TTR Leu55Pro aggregates and fibrils at 
different stages, we concluded that only the initial aggregates are toxic; structures generated 
upon I-DOX treatment were also shown to be non-toxic. Further studies aiming at 
determining the toxicity associated with the treatment of other disrupters are required. 
The transformation of tetrameric soluble TTR into insoluble aggregates (priming stage) 
was morphologically studied by TEM making use of TTR Tyr78Phe. Under physiological 
conditions (PBS, 37°C) the protein preparation starts with round particles resembling native 
TTR WT and evolves to oligomers, large aggregates and finally fibrils approximately 8 nm 
wide, identical to the TTR Leu55Pro and TTR WT fibrils. This mutant was further used to 
select drugs acting at the priming stage. TTR Leu55Pro, previously investigated as 
described above, was used to identify drugs interfering with fibril elongation (extension 
stage). 
The screening methodology included an immunoassay with a monoclonal antibody 
(Mabl5), which recognizes differentially amyloidogenic structures. Mabl5 was previously 
demonstrated to recognize soluble TTR Tyr78Phe but our study revealed that once the 
amyloidogenic protein was incubated at 37°C for 48 hours, the reactivity lowered 
significantly. The antibody was also able to distinguish different TTR Leu55Pro species, 
reacting highly with the initial aggregates but not with amyloid-like fibrils. 
Different groups of drugs were tested for their ability to affect TTR fibrillogenesis, either by 
inhibiting priming, extension or both. The compounds included benzofurans, non-steroid 
anti-inflammatory drugs, TTR stabilizers and/or thyroxine (T4) competitors, extracellular 
matrix (ECM) components, a porphyrin, aprotinin, and an aprotinin peptide. 
Among the compounds tested, benzofurans were the most effective, inhibiting both priming 
and extension, at approximately 60%. Ibuprofen showed intermediate activity against both 
stages; diflunisal and diclofenac, the two other compounds included in the non-steroid anti-
inflammatory group, presented no inhibitory capacity. In the group of TTR stabilizers/T4 
competitors, diethylstilbestrol (DES) also showed a high degree of inhibition for both 
priming and extension (approximately 50%) whereas the remaining compounds in this 
group presented activity against only either priming or extension. Among the ECM 
components, laminin was the only molecule tested able to interfere with TTR fibrillogenesis 
and although it only inhibited extension, its activity was very high (70%). Hemin, the 
porphyrin included in this study, also showed to be an important inhibitor acting in both 
priming and extension (over 50% of inhibition). The results were confirmed by TEM. 
Although the structural determinants responsible for the interactions between Mabl5 and 
each one of the TTR species are not known nor the molecular mechanism behind the effects 
observed, results from TEM and the immunoassay seemed to correlate very well. In some 
cases, although some activity was observed by the immunoassay, visualization by TEM did 
not reveal important morphological differences implying that the sensitivity of the former 
method is higher. The selected drugs should be further tested in an amyloid animal model to 
establish dosage and related toxicity and finally to verify the in vitro results. 
We also developed a cellular system by transfecting a Schwanoma cell line with different 
TTR constructs and demonstrated that TTR Leu55Pro aggregates extracellularly, after 
secretion, using a dot blot filter assay. Furthermore, Mabl5 recognized TTR VaDOMet and 
Leu55Pro while TTR WT was not detected in the immunoassay. This result suggests that 
although TTR Val30Met is not detected in the dot blot filter assay, the protein presents an 
altered conformation, which exposes amyloidogenic epitopes. Therefore, the cellular model 
might constitute a system to investigate drugs able to inhibit the very early conformational 
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changes prior to TTR dissociation and aggregation, occurring during TTR fibrillogenesis. 
The developed model will contribute to the study of cellular factors intervening in amyloid 
formation. 
In conclusion, our studies provided new information on the ultrastructure of amyloid fibrils 
and important insights into the amyloidogenic pathway. The possibility of producing TTR 
fibrils under physiological conditions and the determination of the toxic species paved the 
way to search for molecules with therapeutic potential in FAP. 
i i i 
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A polineuropatia amiloidótica familiar (PAF) é uma doença directamente relacionada com a 
presença de mutações na proteína transtirretina (TTR). Patologicamente, a PAF é 
caracterizada por deposição extracelular de TTR insolúvel- amilóide- em vários órgãos, em 
especial no nervo periférico, resultando em danos celulares, disfunção orgânica e 
finalmente, em morte. O mecanismo responsável pela deposição de TTR, bem como outros 
factores intervenientes na cascata amiloidogénica, são desconhecidos. O transplante 
hepático é a única terapia aplicada à PAF com sucesso mas é limitado pela disponibilidade 
de órgãos e pela necessidade de realizar imunosupressão durante toda a vida. Métodos 
terapêuticos em que pequenas moléculas inibam a formação de amilóide são preferíveis. 
Ao longo do tempo, diferentes marcadores têm sido usados para identificar amilóide. No 
entanto, alguns deles não são apropriados a diagnósticos in vivo e outros implicam técnicas 
muito invasivas. Nós estudámos as propriedades de ligação de uma pequena proteína, 
aprotinina, a diferentes tipos de amilóide e verificámos que este inibidor de proteases 
apresenta ligação específica a fibras de insulina, de péptido p e de uma imunoglobulina. A 
aprotinina não apresentou ligação a precipitados amorfos nem aos precursores solúveis das 
fibras. A metodologia usada baseou-se num ensaio de retenção em filtro em que a 
aprotinina ligada a fibras de amilóide é retida no filtro, enquanto que a livre ou não ligada é 
filtrada. Para fibras de insulina, a constante de ligação da aprotinina é de 2.9 uM"1, 
determinada por análise Scatchard. Os resultados sugerem que a aprotinina interage com 
fibras de amilóide através do pareamento de folhas P com estruturas do mesmo tipo à 
superficie dos depósitos de amilóide. Dois pequenos péptidos derivados da aprotinina 
(APR1 e APR2) também foram testados e demonstrou-se que também eles ligam de forma 
específica a fibras de amilóide. No futuro, a aprotinina, e em particular os péptidos dela 
derivados, poderão ser utilizados não só para diagnosticar de forma não-invasiva doenças 
amiloidóticas mas também para seguir a progressão dos eventuais tratamentos. 
Na tentativa de alargar o conhecimento sobre a organização ultra-estrutural e o processo de 
formação das fibras de amilóide, estudou-se a progressão no tempo de fibras produzidas por 
acidificação a partir de TTR selvagem (WT) e de fibras produzidas em condições 
fisiológicas a partir de uma variante de TTR (TTR Leu55Pro). Concluímos que estas fibras 
apresentam dinâmicas, características morfológicas e dimensões semelhantes. A forma 
principal encontrada foi uma fibra de 8 nm de diâmetro, torcida para o lado esquerdo e com 
uma unidade de repetição de cerca de 17 nm. Esta última característica foi observada quer 
por microscopia electronica de transmissão (TEM) em amostras sombreadas metalicamente, 
quer por microscopia de força atómica (AFM). As preparações de TTR WT e de Leu55Pro 
apresentam-se inicialmente como agregados não fibrilares e evoluem para fibras curtas que 
crescem ao longo do tempo. Uma outra técnica foi empregue para analisar estas fibras-
microscopia electrónica de transmissão com varrimento (STEM)- permitindo concluir que 
as fibras amilóide de TTR são formadas a partir de monómeros de TTR, provavelmente 
com uma estrutura alterada. Neste trabalho, também foram analisadas fibras ex vivo de 
nervo e de vítreo de doentes PAF. Enquanto que as fibras de nervo apresentaram dimensões 
comparáveis às das fibras produzidas in vitro, as do vítreo revelaram diâmetros bastante 
superiores. No entanto, as fibras de vítreo pareciam resultar de associação lateral de várias 
fibras de 8 nm, sugerindo que as estruturas mais largas poderiam resultar da união de outras 
mais finas e de diâmetro semelhante ao das formadas in vitro. As fibras de amilóide 
maduras, como as que são extraídas dos doentes PAF não permitem o estudo da dinâmica 
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de formação das fibras. Por esta razão, esta questão bem como a identificação das unidades 
básicas de fibras ex vivo deve ser estudada no futuro. 
A identificação de diferentes espécies durante o processo de formação de amilóide criou a 
oportunidade para avaliar a actividade de diferentes drogas que interferem na cascata 
amiloidogénica em diferente passos da mesma. Estudos anteriores indicaram que 4'-iodo-
4'-deoxydoxorubicin (I-DOX) é capaz de interagir com fibras de amilóide. Para averiguar a 
acção deste composto nas fibras amilóide de TTR, fizemos um estudo de tempo e 
concentração e concluimos que o I-DOX e seus derivados não inibem a formação de fibras 
mas desagregam fibras longas originando pequenas particulas que se assemelham à proteína 
solúvel; o máximo de actividade foi observado para uma concentração de I-DOX de 10" 
M/100 ug nas condições testadas. Estudos de toxicidade realizados com as diferentes 
espécies detectadas durante a formação de fibras de TTR Leu55Pro demonstraram que os 
agregados não-fibrilares são as únicas espécies tóxicas. As estruturas resultantes da acção 
do I-DOX sobre as fibras de TTR Leu55Pro também se revelaram não tóxicas. Estudos 
respeitantes à toxicidade associada com o tratamento dos outros disruptores de fibras são 
necessários. 
A transformação de TTR solúvel tetramérica em agregados insolúveis (estádio priming) 
foi estudada morfologicamente por TEM e fazendo uso da variante de TTR Tyr78Phe. Em 
condições fisiológicas (PBS, 37°C) a amostra apresenta-se inicialmente como particulas 
circulares em tudo semelhantes à proteína selvagem e evolui para oligómeros, grandes 
agregados e finalmente fibras com aproximadamente 8 nm de diâmetro. Esta variante de 
TTR foi utilizada para seleccionar drogas capazes de interferir com o estádio priming. A 
variante de TTR Leu55Pro, já estudada como descrito nesta secção, foi usada para 
identificar compostos que afectam o crescimento das fibras (estádio extensão). 
A metodologia usada para o rastreio de compostos incluiu um ensaio imunológico com um 
anticorpo monoclonal (Mabl5), o qual reconhece diferencialmente estruturas 
amiloidogénicas. Foi anteriormente demonstrado que este anticorpo reconhece TTR 
Tyr78Phe na sua forma solúvel. No entanto, o nosso estudo revelou que, após incubação a 
37°C durante 48 horas, a reactividade baixa de forma muito significativa. Este anticorpo 
também é capaz de distinguir espécies de TTR Leu55Pro diferentes: reage fortemente com 
os agregados iniciais mas não com as fibras. 
Várias classes de compostos foram testados com o intuito de avaliar as suas capacidades 
inibitórias, quer de priming quer de extensão. Nos testes foram incluídos benzofuranos, 
drogas não-esteróides anti-inflamatórias, estabilizadores tetraméricos de TTR ou que 
competem com a tiroxina (T4), componentes da matrix extracelular, uma porfirina, 
aprotinina e um dos seus péptidos. 
De entre os compostos avaliados, os benzofuranos foram os mais eficazes, inibindo quer o 
priming quer a extensão em cerca de 60%. O ibuprofeno demonstrou ter uma actividade 
intermedia nas duas fases amiloidogénicas; o diflunisal e o diclofenac, os outros dois 
compostos incluídos no grupo dos não-esteroides anti-inflamatórios, não revelaram 
qualquer actividade. No grupo dos estabilizadores tetraméricos/competidores de T4, o 
dietilstilbestrol (DES) também apresentou um elevado grau de inibição quer do priming 
quer da extensão, enquanto que os restantes compostos deste grupo apenas apresentaram 
actividade inibitória numa das fases (priming ou extensão). De entre os componentes da 
matriz extracelular testados, a laminina foi a única capaz de interferir com a fibrilogénese 
da TTR e apesar de inibir apenas a extensão, a usa actividade foi muito elevada (70% de 
inibição). Quanto à hemina, a porfirina avaliada, também revelou ser um inibidor 
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importante, quer do priming quer da extensão, com cerca de 50% de inibição. Estes 
resultados foram confirmados por TEM. 
Apesar dos determinantes estruturais responsáveis pelas interaccções entre o Mabl5 e cada 
uma das espécies de TTR não serem conhecidos, bem como o mecanismo que explica os 
efeitos observados para cada uma das drogas testadas, os resultados obtidos por TEM e no 
ensaio imunológico com o Mabl5 parecem ser concordantes. Em alguns casos, apesar de se 
observar alguma actividade no ensaio imunológico, o TEM não revelou alterações 
morfológicas importantes. Esta discrepância parece indicar que a sensibilidade do método 
imunológico é superior. As drogas seleccionadas devem ser posteriormente caracterizadas 
num modelo animal de amilóide para assim se estabelecerem critérios de dosagem, 
toxicidade e verificação dos resultados in vitro. 
Neste trabalho também foi desenvolvido um sistema celular com uma linha celular de 
schanomas de rato transfectadas com diferentes cDNAs de TTR (TTR WT, Val30Met, 
Leu55Pro). Os resultados indicaram que a TTR Leu55Pro é capaz de formar agregados 
extracelularmente, depois da secreção da proteína. Além disso, o anticorpo Mabl5 foi capaz 
de reconhecer quer a TTR VaBOMet quer a Leu55Pro, enquanto que a TTR WT não 
apresentou qualquer reacção. Apesar da TTR VaBOMet secretada pelas células não ser 
detectada no ensaio de retenção em filtro, indicando que não forma agregados, esta proteína 
deve, no entanto, possuir uma conformação alterada em relação à WT de forma que 
epitopos amiloidogénicos ficam expostos. Desta forma, este modelo celular poderá 
constituir um sistema para estudar drogas capazes de inibir alterações conformacionais que 
ocorrem no início da processo de agregação e que são anteriores à dissociação do tetrâmero 
da TTR. Este modelo tem ainda a vantagem de permitir o estudo de factores celulares 
envolvidos na amiloidogénese. 
Em sumário, os nossos estudos forneceram novas informaçoões acerca da ultra-estrutura das 
fibras de amilóide e novos conhecimentos sobre o mecanismo amiloidogénico. A 
possibilidade de produzir fibras de TTR em condições fisiológicas, a determinação das 
espécies tóxicas e o desenvolvimento de um novo método (imunológico) facilitou a 
investigação de moléculas com potencial terapêutico em PAF. 
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La Polyneuropathie Amyloidotique Familiale (PAF) est une maladie génétique autosomale 
dominante directement liée à la présence de mutations de la protéine transthyrétine (TTR). 
La PAF est caractérisée par une déposition extracellulaire de TTR insoluble -amyloïde-
dans plusieurs organes avec un engagement exceptionnel du nerf périphérique, conduisant 
à des pertubations cellulaires, un dysfunctionnement des organes et finalement à la mort. 
Les mécanismes de formation d'amyloïde de TTR ainsi que d'autres facteurs qui 
interviennent dans la cascade amyloïdeogénique sont inconnus. Actuellement, le seul 
moyen disponible pour traiter la PAF est la transplantation du foie. Cependant, ce traitement 
presente des limitations à savoir l'indisponibilité de cette organe et le risque 
d'immunosupression. Pour cela, une thérapie basée sur l'utilisation d'une drogue inhibitrice 
de la formation du TTR amyloïde serait profitable. 
Plusieurs méthodes ont été utilisées pour identifier la substance amyloïde. Cependant, 
certaines de ces méthodes ne sont pas très adaptées au diagnostique in vivo et d'autres 
provoquent des complications à risque. Nous avons étudié les propriétés de ligation de 
l'aprotinine, protéine de petite taille, à des différents amyloïdes. Nous avons montré par un 
dot blot ligand binding assay spécifique que cette protéine se lie aux fibres de F insuline, de 
la TTR, de P-amyloïde et de F amyloïde synthétique d'immunoglobuline. Cependant, 
Faprotinine ne lie ni les précipités amorphes ni les précurseurs des fibres solubles. Un Ka 
de 2.9 uM"1 de la liaison de Faprotinine à des fibres amyloïde d'insuline a été déterminé par 
l'analyse de Scatchard. Nos résultats suggèrent que Faprotinine intéragit avec les fibres 
d'amyloïde par l'intermédiaire d'une interaction entre les feuillets beta de la protéine elle 
même et ceux des fibres d' amyloïde. Nos résultats indiquent également une liaison de 
type électrostatique entre l'aprotinine et les fibres d' amyloïde. Nous avons étudié la liaison 
de peptides dérivés de Faprotinine (APR1 et APR2) à différents types de fibres d"amyloïde 
synthétique et nous avons montré qu'ils peuvent se lier aux fibres. L'ensemble de ces 
résultats laisse suggérer que l'aprotinine et particulièrement ses peptides dérivés peuvent 
être utilisés non seulement dans le diagnostique non-invasif de la PAF mais également dans 
la progression d'éventuels traitements. 
Afin d'obtenir plus d'information sur l'assemblage ultrastructurale de f amyloïde, nous 
avons étudié la formation progressive des fibres de TTR WT produites par acidification 
ainsi que celle des fibres de TTR Leu55Pro produites sous conditions physiologiques. Le 
résultat de cette étude a montré que les fibres de TTR WT et TTR Leu55Pro sont 
dynamiquement similaires et qu'elles ont les mêmes caractéristiques et les même 
dimensions. La principale forme est une fibre de 8 irai de diamètre avec un gauche-handed 
twist comme a été indiqué par la microscopie de transmission d'électrons (TEM) après 
ombrage métalique et par la microscopie de force atomique. Les préparations évoluaient de 
Fétat non-fibrillaire à des petites fibres qui s'allongeaient au court du temps. L'analyse de 
ces fibres par microscopie scanning de transmission électronique (STEM) montre 
clairement que l'unité fondamentale de la fibre est un monomère altéré. Les fibres extraites 
apartir d'un nerf d'un malade de PAF ont révélé des dimensions similaires contrairement 
aux fibres du nerf vitreux qui sont significativement plus grandes. Ces dernières semblent 
être le résultat de l'assemblage de plusieurs fibres de 8 irai, suggérant que les structures plus 
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larges peuvent être le résultat d'une association latérale de plusieurs fibres de 8 nm. Fibres 
matures, comme celles extraitent des malades de PAF, ne permettent pas un étude 
dynamique. Ce problème ainsi que l'identification des constituants des fibres in vivo ou ex 
vivo doivent être adressés à l'avenir. 
L'identification de formes différentes présentent au court de la formation d^amyloïde a 
incité l'évaluation de l'activité de différents médicaments qui interfèrent aux étapes 
différentes de la cascade de formation de l'amyloïde. Plusieurs études ont révélé que 4'-
iodo-4'-deoxydoxorubicin (I-DOX) réagit avec les fibres d^amyloïde. Pour vérifier son 
action sur les fibres de TTR, nous avons effectué une étude au court du temps et à 
différentes concentrations. Cette étude a démontré que V I-DOX et également les composés 
similaires à 1T-DOX n'inhibent pas la formation de fibres. Son effet passe essentiellement 
par une destruction des fibres avec une activité optimale de 10'5 M/100 ug de fibres. Après 
avoir évalué la toxicité de la TTR Leu55Pro et ses fibres à différentes étapes, nous avons 
conclu que seulement les agrégas initiales sont toxiques; les structures crées après le 
traitement avec I-DOX ont aussi démontré être non-toxique. Des études visant la 
détermination de la toxicité associé au traitement avec d'autres molecules ayant le même 
effet que I-DOX sont requises. 
La transformation de la TTR soluble tétramérique en agrégas insolubles (l'étape 
d'initiation) a été morphologiquement étudié par le TEM utilisant TTR Tyr78Phe. Dans 
des conditions physiologiques (PBS, 37°C) la protéine forme des particules circulaires 
ressemblant à la TTR native et ensuite évolue en oligomères, grands agrégas et finalement 
en fibres d^approximativement 8 nm, identiques aux fibres de TTR WT et TTR Leu55Pro. 
Ce mutant a été également utilisé pour choisir des médicaments qui agissent à l'étape de 
d'initiation. TTR Leu55Pro, comme indiqué ci-dessous, a été utilisé pour identifier des 
médicaments qui interfèrent avec l'élongation de fibres (l'étape d'extension). 
La méthodologie de triage est basée sur l'utilisation d'un immunoassay avec un anticorps 
monoclonal (Mabl5), qui reconnaît différentiellement les structures d'amyloïde. Il a été 
démontré antérieurment que Mabl5 est capable de reconnaître TTR Tyr78Phe soluble. 
Cependant, notre étude a révélé que l'incubation de la protéine amyloïdeogenique à 37°C 
durant 48 heures réduit significativement la réactivité avec Mabl5. Cet anticorp est aussi 
capable de distinguer différentes formes de TTR Leu55Pro. Il réagit fortement avec les 
agrégas initiaux de TTR Leu55Pro mais pas avec ses fibres. Différent groupes de 
médicaments ont été étudiés afin de montrer leur capacité d^  affecter la formation de fibres 
de TTR, d'inhiber le le processus d'intiation ou de l'extension ou les deux à la fois. Les 
produits étudiés sont: benzofurans, drogues non-steroïdes anti-inflammatoires, TTR 
stabilisateurs et/ou thyroxine (T4) compétiteurs, composant de la matrice extracellulaire 
(ECM), une porphyrine, aprotinine, et un peptide d^aprotinine. L'évaluation des ces 
différentes molecules a montré que les benzofurans sont les plus efficaces . Ils inhibent 60% 
de la formation de fibres de TTR en agissant au niveau de l'initiation et f extension. 
L'ibuprofen montre une activité intermédiaire au niveau de ces deux étapes. Le diflunisal et 
le diclofenac, deux autres composés du groupe non-steroïde anti-inflammatoire, ne 
présentent aucune capacité inhibitoire. Dans le groupe de TTR stabilizers/T4 concurrents, le 
diethylstilbestrol (DES) a montré un haut degré d'inhibition pour l'initiation et f extension 
(approximativement 50%) tandis que le autres composants de ce groupe ont un potentiel 
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inhibiteur soit de l'initiation soit de l'extention. Parmis les composants de TECM évalués, 
la laminine est la seule molécule capable d'interférer avec la formation de fibres de TTR, 
bien qu'elle agisse seulement dans le processus de l'extension avec une activité maximale 
de 70%. L'hemine, la porphyrine inclue dans cette étude, a également un effet inhibiteur 
important. Elle est capable d'agir dans les processus d'initiation et de Y extension (plus de 
50% d'inhibition). Ces résultats ont été confirmés par le TEM. 
Bien que les déterminants structuraux responsables des interactions entre Mabl5 et chaqune 
des espèces de TTR ne soient pas connus ainsi que le méchanisme moléculaire responsable 
des effets observés, les résultats du TEM et de 1'immunoassay sont en accord. Le fait que 
dans certains cas une activité a été observée par le test d'immunoassay , la visualisation par 
TEM n'a pas révélé d'importantes différences morphologiques suggérant que la sensibilité 
de la méthode antérieure est supérieur. Une étude in vivo utilisant un modèle animale 
amyloïde premetterait de verifier les résulats des études in vitro et également d'obtenir des 
informations concernant le dosage de ces drogues ainsi que leur toxicité. 
Nous avons développé un système cellulaire par transfection d'une lignée cellulaire de 
Schwanoma avec différents constructions de TTR et nous avons démontré avec un dot blot 
filter assay que la TTR Leu55Pro forme des agrégas au niveau extracellulaire après 
secretion. De plus, Mabl5 reconnaît TTR VaBOMet et Leu55Pro alors que TTR WT n'a pas 
été détecté dans l'immunoassay. Ce résultat suggère que malgré la non detection de TTR 
VaBOMet par dot blot filter assay, la protéine présente un conformation altérée qui expose 
des epitopes amiloidogéniques. Pour cela, ce modèle cellulaire que nous avons mis au point 
pourrait être utilisé pour l'évaluation des médicaments qui ont le potentiel d'inhiber les 
altérations précoces de conformation qui se produisent avant la dissociation et l'agrégation 
de la TTR. Ce modèle cellulaire contribuera également à l'étude de facteurs cellulaires qui 
interviennent dans la formation d'amyloïde. 
En conclusion, nos études apportent une nouvelle information concerant 1" ultrastructure des 
fibres d'amyloïde ainsi qu'une nouvelle perspective dans la cascade amyloïdéogenique. La 
possibilité de produire des fibres de TTR sous des conditions physiologique et la 
détermination des formes toxique offrent des facilités dans le domaine de recherche des 
molécules dotées d'un potentiel thérapeutique dans la maladie de PAF. 
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P a r t I- Gene ra l in t roduct ion 
Transthyretin (TTR) is the key protein in familial amyloidotic polyneuropathy (FAP). Our 
research project dealt with TTR deposition in this type of amyloidosis, which conveys us to 
knowledge on native transthyretin, protein destabilization and aggregation, amyloid 
deposition, fibril formation, biological ligands, inhibitory molecules, and others. From the 
gene to the protein, from health to disease, and from disease to therapy, we discuss here 
several concepts we find important to understand the experimental work presented in the 
next chapters. 
l .TTR 
Transthyretin (TTR), formerly called prealbumin due to its electrophoretic characteristics, 
located just in front of the albumin band, is a plasma protein secreted mainly by the liver 
and choroid plexus (Soprano et al, 1985). The name "transthyretin" discloses its dual 
physiological role as a carrier for thyroid hormones (Woeber and Ingbar, 1968) and retinol, 
the latter through the binding to retinol-binding protein (RBP) (Goodman, 1987). TTR was 
first described in the cerebrospinal fluid (CSF) (Kabat et al, 1942) and shortly after in the 
plasma (Seibert and Nelson, 1942). 
1.1 TTR gene structure and expression 
TTR is codified by a single copy gene localized in the long arm of chromosome 18 
(Wallace et al, 1985) and is codified by a single copy gene. The entire nucleotide sequence 
including the 5' (transcription initiating site) and the 3' (untranslated region) flanking 
regions was determined (Sasaki et al, 1985; Tsuzuki et al, 1985) and attributed to the 
region 18qll.2-ql2.1 (Whitehead et al, 1984). The full gene is 7.6 kilobase (kb) long 
comprising 4 exons and 3 introns (Sasaki et al, 1985; Tsuzuki et al, 1985). Exon 1 
contains 95 baisepairs (bp), including 26 bp 5' untranslated and codes for a 20 aminoacid 
(aa) residue leader peptide and aa 1-3 of the mature protein; exon 2 (131 bp), 3 (136 bp), 
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and 4 (253 bp) hold the coding sequences for aa residues 4-47, 48-92 and 93-127, 
respectively. 
The introns (A, B and C) are 934 bp, 2090 bp and 3308 bp long, respectively. Introns A and 
C contain two open reading frames (orf) of unknown significance (Tsuzuki et al, 1985). 
Several consensus sequences were found upstream the mRNA cap site: a TATA box at 
position -30 to -24 bp followed by a GC rich region of approximately 20 bp, a CAAT box 
at position -101 to -96 bp and overlapping sequences homologous to glucocorticoid 
responsive elements at positions -224 and -212 bp. A polyadenylation signal (AATAAA) 
was identified 123 bp downstream from the coding sequence (Sasaki et al, 1985). 
The TTR mRNA spans -0.7 kb and contains a 5'-untranslated region (26-27 nucleotides), a 
coding region (441 nucleotides), and a 3'-untranslated region (145-148 nucleotides) 
preceding the poly(A) tail (Mita et al, 1984; Soprano et al. 1985). Human (Wallace et al, 
1985), rat (Sundelin et al, 1985; Dickson et al, 1985) and mouse (Costa et al, 1986) 
coding regions exhibit a considerable degree of homology (-85%), suggesting a 
phylogenetically preserved modulating role in gene expression. 
TTR is predominantly synthesized the by liver where more than 90% of the protein is 
produced. The remaining is produced in the choroid plexus and the retina. TTR is detected 
in the fetal blood very early during development, as soon as eight weeks after conception 
(Andreoli and Robbins, 1962). Fetal TTR is probably originated from 2 sources: one 
fraction seems to be inherited from the pregnant woman through transplacental filtration 
(Gitlin et al, 1964); the other fraction results from fetal hepatic synthesis, as shown by the 
presence of considerable amounts of TTR mRNA early in development of this organ 
(Makover etal, 1989). 
TTR plasma concentration is age dependent and in healthy newborns it is about half of that 
in adults (Stabilini et al, 1968; Vahlquist et al, 1975). TTR values vary from 20 to 40 mg/ 
dL (Gittlin and Gittlin, 1975). 
In addition to the liver, three other sites have been identified in mammals: visceral yolk sac 
endoderm (Sklan and Ross, 1986), retinal pigment epithelium (Martone et al, 1988), and 
choroid plexus epithelium (Herbert et al, 1986). For a long time, investigators supposed 
that the locally secreted TTR protein acted as a carrier of thyroid hormones between blood 
and brain, seeing that the blood brain barrier is not freely permeable to these molecules. 
TTR production within the central nervous system (CNS) was ascertained by 
immunochemical techniques demonstrating the participation of organelles involved in the 
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CSF secretory processes (Aleshire et al, 1983). Animal experiments have shown 
considerable amounts of TTR mRNA in specific CNS regions, varying from 11 to 30% of 
the hepatic levels (Soprano et al, 1985; Schreiber et al, 1990). A different study revealed 
that the highest TTR mRNA concentration occurs in the epithelial cells lining the 
ventricular surface of the choroid plexus (Stauder et al, 1986). In spite of the low TTR 
levels in CSF (~2 mg/ dL), the choroid plexus is presented as the major site of TTR 
expression, expressed as a ratio of tissue/ mass, corresponding to a ~3 0-fold higher than that 
found in plasma (Weisner and Roething, 1983). TTR represents 20% of the total CSF 
proteins (Weisner and Roething, 1983). 
As for mammals, the major sites of TTR synthesis in birds are the liver and choroid plexus, 
but in reptiles TTR is synthesized only in the latter. This observation seems to imply that 
the philogenetic expression of TTR occurred first in the choroid plexus (Schreiber et al, 
1993). However, recent work (Santos and Power, 1999; Power et al, 2000) reported the 
identification and cloning of TTR from the liver of amphibian and teleost fish, and its 
absence from the choroid plexus in both species, suggesting an alternative model for its 
evolution. 
1.2- TTR structure 
The TTR mRNA codifies for the TTR-monomer; the polypeptide of 147 aa residues whose 
N-terminal region is a hydrophobic signal peptide of 20 aa residues. The TTR monomer is 
subjected to a cleaving process during its migration through the endoplasmatic reticulum 
giving rise to the native TTR monomer after breaking of the signal peptide (Soprano et al, 
1985). Assembly of four identical subunits (13,745 Da) occurs yielding the mature 
tetrameric protein, with a molecular mass of 54,980 Daltons (Da) (Kanda et al, 1974). 
The tridimensional structure of TTR was made available at 1.8 Á resolution by X-ray 
diffraction studies on the crystallized protein (Blake et al, 1978). A considerable amount of 
the aa residues in each monomer (55%) are implicated in the formation of P-sheet structure 
(Blake et al, 1978). Each monomer contains two (5-sheets formed by strands DAGH and 
CBEF (figure 1). All, except strands A and G, display an antiparallel orientation, and 
arranged in a topology similar to the classic greek key barrel. The strands are 7 to 8 residues 
long, except strand D, which, is only 3 residues in length. 
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Only about 5% of the aa residues are located in one segment of a-helix (Blake et ai, 1978) 
comprising residues 75 to 83 (Blake et al. 1978), at the end of strand E. 
Figure 1- Schematic representation of the TTR monomer (PDB entry 1ETB; Hamilton et al, 1993). 
Two monomers associate forming the dimer by interactions between chains F and H of each 
monomer. Fixing the chains of one monomer as A-H and the ones of the other monomer as 
A'-H', the arrangement within a dimer is DAGHH'G'A'D' and CBEFF'E'B'C (figure 2). 
Figure 2- Representation of the TTR dimer. Each monomer contains two P-sheets composed of 
strands DAGH and CBEF, which extend to two 8-stranded P-sheets when two monomers associate 
forming a dimer (PDB entry 1ETB; Hamilton et al, 1993). 
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The tetramer consists of two dimers with connecting edges occurring between the AB loop 
of one dimer with the H strand of the other dimer. 
The quaternary structure of TTR has the shape of a globular protein with an overall size of 
70 Á x 55 Á x 50 Â (Blake et al, 1978). The two dimers are slightly rotated in relation to 
each other along the y axis (figure3). 
Figure 3- The human TTR tetramer (PDB entry 1ETB; Hamilton et al, 1993). 
1.3- Physiology and Metabolism 
1.3.1- Transport of thyroxine (T4) 
Thyroxine (T4) is the main secretory product of the thyroid gland. Triiodothyronine (T3) 
derives mostly from T4 deiodination occurring in the peripheral tissues (Kohrle et al, 1991). 
Thyroid hormones are transported in blood circulation and delivered in the target tissues. 
An incredible high amount of the hormones (99%) is bound to serum proteins. In human 
plasma, TTR, thyroxine-binding protein (TBG) and albumin are responsible for the delivery 
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of TTR into the target tissues (Robbins, 1991). Although TBG is much less concentrated in 
the plasma than TTR, it presents the highest affinity constant for T4 (Ka = 1 x 1010 M"1) and 
transports about 70% of the plasma T4. TTR has an intermediate affinity for T4 is 
intermediate (Ka = 7 x 107 M"1) and transports about 15% of the hormone, and ultimately, 
albumin presents the lowest binding affinity (Ka = 7 x 105 M"1) (Robbins, 1991; Loun and 
Hage, 1992). 
The four monomers within a TTR tetramer, demarcate through the molecule an open 
channel where two binding sites for thyroid hormones are located (Nilsson et al, 1971; 
Blake et al, 1978). These two binding sites present negative cooperativity (Ferguson et al, 
1975; Andrea et al, 1980) implying that when the first thyroid hormone molecule occupies 
the first site, the affinity for the second molecule is highly reduced. As a result, the ka 
estimated for the two binding sites for T4 are 1.05 x 108 M"1 and 9.55 x 10 5 M"1, 
respectively (Andrea et al, 1980); TTR also binds triiodothyronine (T3) but with lower 
affinity. 
T4 transport into the brain is of particular interest and has raised much controversy. There 
are two possible mechanisms for thyroid hormones to reach the brain: partioning and 
diffusion through the lipid plasma membrane both at the choroid plexus epithelial cells and 
at the cerebral capillaries endothelial cells; and mediated by the TTR synthesized by the 
choroid plexus and secreted into the CSF. Several evidences suggested that TTR might have 
an essential role in thyroid hormone transport into and within the brain: TTR is the major T4 
binding protein in the cerebrospinal fluid (Hagen and Solberg, 1974). It has been shown that 
rat choroid plexus expiants, in vitro, accumulate thyroid hormones from the surrounding 
media and that, when equilibrium is reached, the thyroid hormone intracellular/extracellular 
concentration ratio decreases when TTR media content is increased (Dickson et al, 1987). 
The same authors showed that after intravenous radioactive T4 injection, the radioactivity 
first appears in the choroid plexus, followed later by the brain. It was then proposed that T4 
is transported from the blood into the choroid plexus where by itself or bound to TTR it is 
secreted into the CSF. Some in vitro and in vivo studies by Schreiber et al. (1990), further 
supported this hypothesis. 
In contrast, a study where 125i-T4 covalentely bound to TTR was intravenously injected in 
rats showed that the serum T4 bound to TTR fraction is not transported into the CSF 
(Chanoine et al, 1992). The explanation is that given its high lipophylicity, thyroid 
hormones should be able to cross the membranes that constitute the blood-brain barrier 
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outside the choroid plexus without the need of any plasma transport protein. 
Studies done in ttr knock-out mice (ttr-) (Episkopou et al, 1993) revealed that TTR is not 
essential for thyroxine to reach the brain and other tissues (Palha et al, 1997). In addition, 
measurement of several parameters of thyroid hormone function indicate that these mice are 
euthyroid despite strongly reduced total T4 plasma levels (Palha et al, 1994). No other 
protein was found to replace TTR in the transport of T4 in the CSF, and T4 levels were 
normal in the cortex, cerebellum and hippocampus while strongly reduced in the choroid 
plexus of the ttr- mice (Palha et al, 2000a). Autoradiographic analysis of thyroid hormone 
distribution revealed that TTR is not required for the normal hormone distribution (Palha et 
al, in press). 
Therefore, it was suggested that TTR might be a reservoir for T4 both in the plasma and in 
the choroid plexus and CSF, which might become important under conditions of increased 
hormone demand. 
1.3.2- Transport of vitamin A 
TTR is also responsible for retinol transport through binding to retinol-binding protein 
(RBP) (Kanai et al, 1968). RBP is a 21 kDa monomelic protein comprising 182 aa residues 
(Rask et al, 1979). The conformational structure of RBP bound to retinol was determined 
by x-ray crystallography (Newcomer et al, 1984). In most instances, RBP is transported in 
the bloodstream in the form of a saturated holo-RBP protein equimolarly attached to TTR 
(Goodman, 1984; Blaner, 1989). 
Although TTR has four binding sites for RBP (Van Jaarsveld et al, 1973; Kopelman et al, 
1976), under physiological conditions only one RBP molecule is bound to TTR due to the 
RBP limiting concentration. 
In vitro TTR is able to bind two RBP molecules and this interaction occurs with only one of 
the dimers (Monaco et al, 1995). The dissociation constants for the two RBP molecules are 
1.9 ± 1.0 x 10"7 M for the first RBP molecule and 3.5 x 10"5 M for the second one. Each of 
the RBP molecules contacts with one of the remaining monomers and blocks the other 
RBP-binding sites in the tetramer molecule (figure 4). 
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Figure 4- TTR complexed with RBP (PDB entry 1QAB; Naylor and Newcomer, 1999) 
1.3.3- Other functions of TTR 
TTR has been shown to interact with a variety of compounds. However, the relevance of 
these interactions, in most instances, is not known. These molecules include: noradrenaline 
oxidation products (de Vera et al 1988; Boomsma et al, 1991), pterins (Ernstrom et al, 
1995), chicken lutein (Martone and Herbert, 1993; Martone et al, 1993)), hemin and 
hemoglobin (Martone and Herbert, 1993; Martone et al, 1993), polyhalogenated 
compounds (Brouwer, 1989; Cheek et al, 1999) and retinoic acid (Smith et al, 1994). 
Other studies have shown that TTR can play a role in immunological processes by 
interfering with the secretion of interleukin I (Borish et al, 1992); a decapeptide 
corresponding to the first N-terminal aa residues of TTR has also been proposed to have 
thymic activity in thymectomized mice (Burton et al 1978; 1985; 1987). 
Other in vitro work suggested that TTR can form stable complexes with amyloid p-peptide 
(AP) (Schwarzman et al, 1994), and prevent Ap accumulation in cell culture experiments 
(Mazur-Kolecka et al, 1995) and in transgenic Caenorhabditis elegans (Linke, 1995). 
Studies on the interaction of TTR with Ap suggest that, in the CSF, TTR plays a key role in 
the modulation of Ap aggregation and prevents amyloid formation (Serot et al, 1997). In 
addition, TTR levels were reported to be significantly decreased in patients with 
Alzheimer's disease (Riisoen, 1988; Serot et al, 1997; Merched et al, 1998) and depression 
(Sullivan et al, 1999). These data raised the possibility that amyloid fibril formation could 
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be promoted in patients with late onset Alzheimer's disease by the lack of sufficient 
concentrations of TTR or by the presence of TTR variants. The absence of TTR mutations 
in patients with Alzheimer's disease argues against the latter hypothesis (Palha et al, 1996). 
TTR has also been found associated to lipoproteins: Tanaka et al (1995) reported the 
presence of TTR not only in isolated low density lipoproteins (LDL) but also in high 
density lipoproteins (HDL) from normal subjects and in Japanese patients with different TTR 
mutations associated with familial amyloidotic polyneuropathy (FAP) (namely TTR 
VaDOMet, Glu89Gln, His56Pro and Arg34Thr). TTR was shown to associate with the HDL 
fraction to the same extent both in normal individuals and FAP patients, whereas the LDL 
fraction from the FAP patients showed higher amounts of TTR than normal individuals. Very 
recently, it has been shown that TTR also associates with HDL via apolipoprotein AI (apoAI) 
(Sousa et al, 2000a). 
13.4- TTR metabolism 
The biological half-life of TTR is about 2-3 days in humans (Socolow et al, 1965; Vahlquist et 
al, 1973), 22-23 hours in monkeys (Vahlquist and Peterson, 1972) and 10-13 hours in rats 
(Peterson et al, 1974). The major sites of TTR degradation in the rat are liver (36-38%), 
followed by the muscle (12-15%) and skin (8-10%) (Makover et al, 1988). Tissues that are 
sites of 1-8% of body TTR degradation include the kidneys, adipose tissue, testes, and 
gastrointestinal tract. Less than 1% of total TTR degradation occurs in the other tissues 
examined. The mean fractional turnover of plasma TTR is 0.15/h, and that of the total body 
TTR 0.04/h. 
A second study (Makover et al, 1988) was conducted in order to investigate the degradation of 
choroid plexus-derived TTR. The estimated turnover of cerebrospinal fluid TTR was in the 
order of 0.33/h. The major sites of degradation of labeled TTR injected in CSF or in plasma 
were approximately the same; almost identical tissue sites and quantitative patterns of TTR 
degradation were observed. Thus, for both routes of injection of labeled TTR, the liver was the 
major site of TTR degradation, followed by the muscle and skin. No specific transfer of 
plasma TTR to the nervous system or degradation of plasma TTR in the nervous system was 
observed. 
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The normal physiology of TTR is not completely understood, in particular, its cellular uptake. 
Nevertheless, several observations suggest that TTR internalization is receptor-mediated, both 
in human hepatoma cells (HepG2) (Divino and Schussler, 1990a, b) and in chicken oocytes 
(Vieira et al, 1995). Recently, megalin, a receptor implicated in the renal re-uptake of plasma 
proteins carriers of lipophilic compounds, was shown to play a role in renal uptake of TTR 
(Sousa et al, 2000b). Binding/uptake experiments performed with immortalized rat yolk sac 
cells expressing high levels of megalin and with radiolabelled TTR, free and complexed with 
T4 or RBP, demonstrated that radiolabelled TTR (both free and T4 complexed) was rapidly 
taken up by the cells. This uptake was strongly inhibited by a polyclonal megalin antibody and 
by the receptor-associated protein (RAP). Furthermore, different TTR mutations presented 
different levels of cell association and degradation, suggesting that the structure of TTR is 
important for megalin recognition. The same work shows that urine from patients with Dent's 
disease, a renal tubular disorder that alters receptor mediated endocytic reabsorption of 
proteins, presented high amounts of excreted TTR. Morover, immunohistochemical analysis of 
kidney sections of megalin-deficient mice, were negative for TTR in intracellular vesicles in 
the proximal tubule cells. This data strongly indicates that TTR represents a novel megalin 
ligand of importance in thyroid hormone homeostasis. 
TTR internalization was further explored by studying TTR uptake using hepatomas and 
primary hepatocytes (Sousa and Saraiva, 2001). This work showed direct evidence for TTR 
internalization by a specific receptor, forming a -90 kDa complex. TTR internalization was 
inhibited by RBP (70% decrease) and T4 (20% decrease) and TTR mutants revealed 
differences in uptake, indicating again that the recognition by receptor is structure dependent. 
Internalization was also inhibited by lipoproteins and RAP, a ligand for all members of the 
low-density lipoprotein receptor family (LDLr). All together, these results suggest a common 
pathway for TTR and lipoprotein metabolism and the existence of a RAP-sensitive receptor for 
TTR internalization. 
1.4- Molecular variants of TTR 
Table 1 shows the TTR variants reported so far. Almost without exception, these mutations 
result from point mutations in the polypeptide chain. The exception is the case of a deletion 
of an aa residue. The majority of the TTR variants are amyloidogenic, mainly associated 
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with peripheral neuropathy but also with cardiomyopathy, carpal tunnel syndrome and 
vitreopathy. 
Table 1- Amyloidogenic TTR mutations 
Mutation Codon change Predominant 
Clinical Features 
Origin 
CyslOArg TGTCGT PN, AN, Eye Hungary 
Leu12Pro CTG CCG LM, PN. AN UK 
Asp18Glu GAT GAG PN. AN Columbia 
Asp18Gly GATGGT LM Hungary 
Val20lle GTC ATC Heart Germany 
Ser23Asn AGTAAT Heart Portugal 
Pro24Ser CCTTCT Heart, CTS, PN USA 
Val28Met GTGATG PN, AN Portugal 
Val30Met GTG ATG PN, AN, Eye several 
Val30Ala GTG GCG Heart. AN Germany 
Val30Leu GTG CTG PN.AN Japan 
VaBOGly GTG GGG LM, Eye France 
Phe33lle TTC ATC PN, Eye Poland 
Phe33Leu TTCCTC PN, AN Poland 
Phe33Val TTC GTC PN.AN UK 
Arg34Thr AGAACA PN, Heart Italy 
Lys35Asn AAGAAC PN, AN, Heart France 
Ala36Pro GCT CCT PN, Eye Greece 
Asp38Ala GATGCT PN, Heart Japan 
Glu42Gly GAG GGG PN.AN Japan 
Glu42Asp GAG GAT Heart France 
Phe44Ser TTTTCT PN, AN, Heart Ireland 
Ala45Asp GCC GAC Heart Italy 
Ala45Ser GCC UCC Heart Sweden 
Ala45Thr GCC ACC Heart Italy 
Gly47Arg GGG CGG PN, AN Japan 
Gly47Ala GGG GCG Heart, PN, AN Italy 
Gly47Val GGG GTG PN, AN, Heart Sri Lanka 
Gly47Glu GGG GAG PN Germany 
Thr49Ala ACC GCC Heart. PN Italy 
Thr49lle ACC ATC PN, Heart Japan 
SerSOArg AGTAGG PN.AN Japan 
SerSOIIe AGTATT Heart, PN, AN Japan 
Glu51Gly GAG GGG Heart USA 
Set52Pro TCT CCT PN, AN, Heart UK 
Gly53Glu GGAGAA LM, Heart France 
Glu54Gly GAG GGG PN.AN UK 
Glu54Lys GAGGAA PN, AN, Heart Japan 
Leu55Arg CTG CGG LM, PN Germany 
Leu55Pro CTG CCG PN, Heart, AN Taiwan 
His56Arg CAT CGT Heart USA 
Leu58His CTC CAC CTS, Heart Germany 
Leu58Arg CTC CGC CTS. AN, Eye Japan 
Thr59Lys ACAAAA Heart, PN Italy 
ThrSOAIa ACT GCT Heart, CTS Ireland 
Glu61lys GAGAAG PN Japan 
Phe64Leu TTTCTT PN, CTS, Heart Italy 
Phe64Ser TTTTCT LM, PN, Eye Italy 
lle68Leu ATATTA Heart Germany 
Tyr69His TAC CAC Eye Scotland 
Lys70Asn AAAAAC CTS, PN, Eye Germany 
Val71Ala GTG GCG PN, Eye 
lle73Val ATA GTA PN.AN Bangladesh 
Ser77Phe TCTTTT PN France 
Tyr78Phe TAC TTC CPS, Heart Italy 
Ser77Tyr TCT TAT PN Germany 
lle64Ser ATCAGC Heart, CTS, Eye Switzerland 
lle84Asn ATCAAC Eye, Heart Italy 
He84Thr ATC ACC Heart, PN, AN Germany 
Glu89Gln GAGCAG PN, Heart Italy 
Glu89Lys GAGAAG PN, Heart USA 
Ala91Ser GCATCA PN, CTS, Heart 
Ala97Gly GCC GGC Heart, PN Japan 
Ala97Ser GCC TCC PN, Heart France 
lle107Val ATTGTT Heart, CTS, PN Germany 
lle107Met ATT ATG PN, Heart Germany 
Ala109Ser GCC TCC PN 
Leu111Met CTG ATG Heart Denmark 
Ser112lle AGC ATC PN. Heart Italy 
Tyii14Cys TAC TGC PN, AN, Eye Japan 
Tyr114His TAC CAC CTS 
Tyr116Ser TAT TCT PN, CTS 
Ala120Ser GCT TCT Heart, PN, AN 
Val122lle GTC ATC Heart 
DelVal122 GTC loss Heart, PN, CTS Equador/Spain 
Val122Ala GTC GCC Heart, Eye, PN UK 
AN - autonomic neuropathy; CTS - carpal tunnel syndrome; Eye - vitreous deposition 
PN - peripheral neuropathy; LM - leptomeningeal amyloid; Heart - cardiomyopathy 
(Taken from database www.ibmc.up.pt). 
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Several TTR mutations without pathogenic consequences have also been described and are 
presented in table 2. Additionally, several different compound hétérozygotes, carriers of two 
different TTR mutations have been reported (table 2). 
Table 2- Non-amyloidogenic TTR mutations and compound hétérozygotes. 
* Refers to mutant allele frequency 
** Silent mutation 
*** Mutations on the same allele 
(Taken from database www.ibmc.up.pt) 
Mutation Codon change Frequency* 
Gly6Ser GGTAGT 33/558 
Met13lle ATG ATC nd 
Asp74His GAC CAC nd 
His90Asn CATAAT 16/12,400 
Gly101Ser GGCAGC nd 
Pro102Arg CCC CGC 1/8,000 
Arg104Cys CGC TGC nd 
Arg104His CGC CAC nd 
Ala108AJa- GCC GCT nd 
Ala109Thr GCC ACC 1/10,000 
Ala109Val GCC GTC nd 
Thr119Met ACG ATG 35/10,000 
Pro125Ser CCC TCC nd 
Compound hétérozygotes 
Gly6SerA/al30Met 7/160 
Gly6Ser Phe33lle*** nd 
Gly6Sor/Ala4SAsp nd 
Gly6Ser/Ser77Tyr nd 
Gly6Ser/Tyr114Cys nd 
Gly6Ser/Thr119Met nd 
Gly6Ser/Val122/Ala nd 
His90AsnA/al30Met nd 
His90Asn Glu42Gly~* nd 
His90Asn/Tnr119Met nd 
Arg104HisA/al30Met nd 
Thr119MetA/al30Met nd 
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2- Amyloidosis and amyloid 
The term amyloidosis comprises a large group of pathologies mainly characterized by the 
deposition of fibrillar proteins- amyloid - leading to cell damage, organ dysfunction and 
death. 
Amyloid disorders are usually divided into two categories depending on the distribution of 
the amyloid deposits: localized and systemic amyloidosis. 
2.1- Amyloid diseases 
In localized amyloidosis, amyloid is restricted to a single tissue or organ, usually in the 
surroundings of the cells responsible for the synthesis of the precursor protein; in systemic 
amyloidosis, the amyloidogenic proteins are usually derived from circulating precursors that 
are either in excess, abnormal or both. Table 3 depicts the most common forms of 
amyloidosis. 
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Tabel 3- Amyloidosis in humans 
Amyloid Protein precursor Amyloidosis Syndrome and/ or involved 
protein tissues 
A(3 AP protein precursor L Alzheimer's disease 
(ApPP) Aging Familial (prototype Dutch) 
APrPsc Prion protein L Spongiform encephalopathies 
ACal (Pro)calcitonin L C-cell thyroid hormones 
AIAPP Islet amyloid polypeptide L Islets of Langerhans 
Insulinomas 
AANF Atrial natriuretic factor L Cardiac atria 
APro Prolactin L Aging pituitary 
Prolactinomas 
AIns Insulin L Iatrogenic 
ALac Lactoferrin L Cornea 
AMed Lactadherin L Senile aortic 
AKer Kerato-epithelin L Cornea 
AL Immunoglobulin light chain S,L Primary 
Myeloma-associated 
AH Immunoglobulin heavy S,L Primary 
chain Myeloma-associated 
ATTR Tranthyretin S Familial 
Senile systemic 
AA (Apo) serum AA S Secondary, reactive 
AP2M P2-microglobulin S Chronic hemodialysis 
AApoAI Apolipoprotein AI S Familial 
AApoAII Apolipoprotein All S Familial 
AGel Gelsolin S Familial (prototype Finnish) 
ALys Lysozyme S Familial 
AFib Fibrinogen a-chain S Familial 
ACys Cystatin C s Familial (prototype Iceland) 
ABri BRI gene product s Familial dementia, British 
... 
L- Localized; S- Systemic 
Adapted from Westermark et al, 1999. 
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General Introduction 
2.1.1.1- p-peptide amyloidosis (AP) 
Alzheimer's disease (AD) (acquired and familial) is the most common form of amyloidoisis 
and the major cause of dementia, affecting more than 5% of the population over the age of 
65 years (Katzman, 1986; Ghiso et al, 1994). AD in is mainly characterized by three 
different pathological changes: 
- Intraneuronal deposits (neurofibrillar tangle, NFT) formed from the microtubule-
associated protein tau 
- Neuritic or senile plaques 
- Cerebrovascular amyloidosis that affects small and medium vessels of the 
leptomeninges and cerebral cortex. 
NFT deposits are localized mainly in pyramidal neurons of the neocortex, hippocampus, 
amygdala, and basal nuclei (Selkoe et al, 1983). Neuritic or senile plaques are spherical 
lesions of variable size (10-200 um) found in the cerebral cortex, especially in the 
associative areas of neocortex and limbic structures. A mature plaque is formed typically of 
a central amyloid core, dystrophic neuritis and glial cells (Merz et al, 1983). 
The major component of the amyloid deposits is a peptide, the amyloid p-peptide (AP). In 
neuritic plaques of AD patients this peptide is 42-43 aa residues long whereas in vascular 
amyloid it is 39-40 aa residues long (Glenner and Wong, 1984; Masters et al, 1985). 
The Ap peptide is derived from the larger precursor protein (APP) as a normal cleavage 
product (Esch et al, 1990; Haass et al, 1992). APP is a transmembrane glycoprotein with a 
receptor-like structure composed of a large extracellular region (a cysteine-rich domain, an 
acidic fragment, and two putative Asn-glycosylation sites), a transmembrane domain and a 
C-terminus intracellular segment. 
Fibrillization of Ap appears to initiate a cascade of events producing neuronal death and 
resulting in the cognitive and behavioral decline characteristic of AD (Yankner, 1996). 
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2.1.1.2- Other localized amyloidosis 
Several other common types of localized amyloidosis have been described, including 
amyloidosis restricted to certain tumors of endocrine glands. In medulary carcinoma of the 
thyroid, amyloid fibrils are composed of procalcitonin (Hill et al, 1973; Sletten et al, 
1976), whereas in patients with islet cell tumors associated with diabetes mellitus type II, 
the amyloid subunit deposited is termed islet amyloid polypeptide or amylin (Westermark et 
al, 1987; Johnson et al, 1989). 
Human amylin is a 3904 Da peptide hormone produced in the islet p-cells of the pancreas 
and usually co-secreted with insulin (Cooper, 1994). It has been proposed that amylin 
regulates glucose metabolism (Cooper, 1994; Young et al, 1995). Amylin appears to be 
also involved in insulin resistance (Leighton and Cooper, 1988) and to play a role in the 
initiation and progression of diabetes type II (Cooper et al, 1994; Verchere et al, 1996). 
Synthetic amylin has a high tendency to aggregate producing amyloid-like fibrils; these 
fibrils present a polymorphic structure with a defined 5 nm protofilament, which can 
assemble into ribbon-like or into coiled fibrils (Goldsbury et al, 1997) and grow 
bidirectionally (Goldsbury et al, 1999). 
Transmissible spongiforme encephalopathies in human (or prion diseases) are characterized 
by neuronal spongiform degeneration, astrocytic gliosis and parenchymal amyloid 
deposition in the form of amyloid plaques (Ghiso et al, 1994) 
Atrial amyloidosis is a form of senile cardiac amyloidosis restricted to the atria (Johansson 
et al, 1987); in this condition, a 3 kDa fragment, cc-atrial natriuretic peptide (AANP), is the 
main constituent of the amyloid deposits. It is derived from a larger precursor molecule (14 
kDa) and has potent natriuretic and diuretic effects. 
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2.1.2- Systemic amyloidosis 
2.1.2.1- Non hereditary amyloidosis 
In humans, the most frequent forms of non hereditary systemic amyloidosis are amyloid A 
associated amyloidosis (AA) and light and heavy immnunoglobulin chains associated 
amyloidosis (AL and AH, respectively). 
2.1.2.1.1- AA amyloidosis 
AA, secondary or reactive amyloidosis, is a rare complication of common chronic 
infections, inflammatory disorders and certain neoplasms. The major constituent in AA 
amyloidosis is the protein AA (8.5 kDa), a 76 aa residue N-terminal fragment derived by 
proteolysis from serum amyloid A (SAA). SAA is a 12.5 kDa apolipoprotein synthesized in 
the liver that circulates as a high-density fraction (Levin et al, 1972; Rosenthal et al, 1976; 
Benditt and Erikssen, 1977). 
AA is also the amyloid protein found in familial Mediterranean fever (FMF), an autosomal 
recessive disorder. In addition, AA is the main fibril constituent in experimentally induced 
and spontaneous amyloidosis in a number of animals (Ghiso et al, 1994). The best studied 
AA animal model is the mouse, where amyloidosis can be induced with a variety of 
antigenic and inflammatory stimuli (Erikssen et al, 1976; Skinner et al, 1977; Benson et 
al, 1985;DiBartolae/a/., 1985). 
AA fibrils in situ appear as straight rods approximately 10 nm wide and composed of a core 
covered by a sheet of 4.5-5 nm in width made up of heparan sulphate proteoglycan. HSPG. 
AA protein filaments are found associated in the outer surface of the fibrillar structure 
(Inouee/tf/., 1998). 
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2.1.2.1.2- AL amyloidosis 
AL amyloidosis is associated with amyloid deposits of a monoclonal B-cell-derived 
population that synthesizes amyloidogenic immunoglobulin light chains. No common 
structural motifs were found among the amyloidogenic light chains. However, comparison 
between the sequences available, demonstrated the existence of critical aminoacid positions 
possibly involved in amyloidogenesis (Stevens et al, 1995). Although all light chains can 
originate amyloidosis, X light chains are involved in disease two or three times more 
frequently than K chains (Isobe and Osserman, 1974). 
AL patients present amyloid deposits primarily distributed in the heart, skin, gastrointestinal 
tract, tongue, peripheral nerves and ligaments. Kidney, liver, spleen, and adrenal can also be 
affected (Kyle and Bayrd, 1975; Wright and Calkins, 1981; Kyle and Greipp, 1983; 
Browning et al, 1985; Janssen et al, 1986). 
The amyloid subunit for AL was the first amyloid protein biochemically characterized 
(Glenner et al, 1971). In almost all cases of AL amyloidosis, fibrils are composed of either 
N-terminal fragments of L-chain and intact L-chain (5-23 kDa) (Osserman et al, 1987; 
Feiner, 1988; Finn and Gorevic, 1990; Castano and Frangione, 1988). 
2.1.2.1.3- (^-microglobulin related amyloidosis 
p2-microglobulin related amyloidosis constitutes a systemic form of disease with a 
preference for bone and synovium and appears in patients undergoing long-term 
hemodialysis. p2-microglobulin accumulates in the plasma and undergoes extracellular 
amyloid deposition. Clinical features include carpal tunnel syndrome (Bardin et al, 1985; 
Huaux et al, 1985; Walts et al, 1985), erosive arthropathy (Huaux et al, 1985), lytic bone 
lesions, and pathologic fractures (Bardin et al, 1985; Huaux et al, 1985). Usually, after 5-6 
years of hemodialysis the disease appears and after 20 years 80-100% of the patients are 
affected (Ghiso et al, 1994). 
p2-microglobulin constitutes the light chain of the major histocompatibility complex of type 
I (MHCI) and the related amyloid fibrils consist of full-length p2-microglobulin associated 
with fragments of various lengths (Linke, 1993). Like other amyloidogenic proteins, p2-
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microglobulin forms amyloid-like fibrils in vitro (Stoppini et al, 1997). Fibrils extracted 
from the femoral head of a patient under chronic hemodialysis for 11 years, revealed pV 
microglobulin that was able to refold acquiring a tertiary structure identical to the native 
form (Bellotti et al, 1998). These results suggest the possibility of refolding fibrillar 
proteins into globular proteins as a therapeutical goal. Renal transplantation showed, in 
some cases, to improve patient conditions leading to the reduction of the amyloid deposits 
(Nelson et al, 1991). In other cases, amyloid deposits persisted even 11 years after renal 
transplantation (Bardin et al, 1995). 
2.1.2.2- Hereditary amyloidosis 
The most common forms of this type of amyloidosis are related to six different proteins: 
TTR, apolipoprotein AI, apolipoprotein All, lysozyme, gelsolin, cystatin C and fibrinogen. 
TTR is associated with the most prevalent type of hereditary systemic amyloidosis. The 
pathologic conditions include familial amyloidotic polyneuropathy (FAP) and familial 
amyloidotic cardiomyopathy (FAC). A non hereditary condition is also related to TTR, 
systemic senile amyloidosis (SSA), and affects about 25% of people over 80 years of age. 
In SAA the deposits occur in the heart and are composed of wild-type TTR. 
2.1.2.2.1- ApoAI and ApoAII 
ApolipoproteinAI (apoAI) is a 28 kDa major apolipoprotein component of HDL and several 
amyloidogenic variants have been reported. Most of them result from point mutations in the 
gene (Nichols et al, 1990; Soutar et al, 1992; Vigushin et al, 1994; Booth et al, 1995; Asl et 
al, 1999; Hamidi et al, 1999). Two variants involve deletions from the gene in exon 4 that 
produce a variant protein with either a deletion and insertion of two aa residues (Booth et al, 
1996) or a deletion of three aa residues (Persey et al, 1998). The amyloid protein fraction 
was shown to be the amino terminal portion and fragments present variable lengths. 
The mechanism behind apoAI deposition is not known and unlike other amyloid protein 
precursors, apoAI is not recognized as having p structure. The first mutation reported, 
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Gly26Arg, (Nichols et al, 1988) is characterized by lower limb polyneuropathy, peptic 
ulcers, and nephrotic syndrome. LeuóOArg (Soutar et al, 1992) and Trp50Arg (Booth et al, 
1995) have also renal involvement; and in the deletion variants (Booth et al, 1996; Persey et 
al, 1998), patients have both renal and cardiac amyloidosis. It was hypothesized that the 
electrostatic alteration caused by the extra positive charge could be responsible for 
amyloidogenecity. However, in 1999 a new mutation, Leu90Pro, was described (Asl et al, 
1999) arguing against the theory first raised as no change in charge is produced. This 
mutation results in cutaneous amyloid deposition and restrictive cardiomyopathy. 
The deposition of N-terminal fragments of apoAI into amyloid was thougth to be caused by 
a local distortion caused by the mutation. As a result, it would affect lipid-apoAI 
interactions and/or expose sites for proteolytic cleavage and favoring the transition of a-
helix into |3-sheet. This hypothesis was contested by the discovery of an apoAI mutation 
located at the C-terminus of the protein, Argl73Pro (Hamidi et al, 1999). Nevertheless, 
clinically this variant is associated with cardiac and cutaneous amyloidosis. Furthermore, 
the deposited fragments correspond to the N-terminal part of the protein. Recently, a new 
mutation at the C-terminal of apoAI was described (Leul74Ser) (Obici et al, 1999). 
Interesting data arrived from the three-dimensional structure of free-lipid apoAI mutant, 
indicating that position 174 of one chain is located near position 93 of an adjacent chain; a 
new model was suggested proposing that the amino acid substitution at position 174 is 
permissive for a proteolytic cleavage at the N-terminal of Val93, releasing N-terminal 
fragments of the protein that, in turn, deposit as amyloid. 
Very recently, a new C-terminal amyloidogenic variant of apoAI, Leul78His, was reported 
(Sousa et al, 2000c), associated with cardiac and larynx amyloidosis and skin lesions with 
onset on the fourth decade. ApoAI and TTR co-localized in amyloid deposits and the 
amyloid deposits revealed both full-length and N-terminal fragments of ApoAI and normal 
TTR. Previous studies demonstrated that TTR is associated to HDL in plasma through 
apoAI (Sousa et al, 2000a) and thus, TTR and apoAI interaction seems to be relevant not 
only in physiological conditions but also in amyloidosis. 
In ApoAII amyloidosis, the protein suffers an extension at the C-terminus and it is thought 
that the added peptide is the direct cause of fibrillogenesis (Benson et al, 2001). Although 
no direct evidences are available, it has been suggested that alterations in binding to HDL 
particles may be related to this amyloidosis. The patients present renal glomerular amyloid 
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deposition that causes death. Other organs, including adrenal glands, liver and spleen are 
also involved (Weiss and Page, 1973). 
2.1.2.2.2- Other hereditary amyloidosis 
Gelsolin is an actin-modulating protein that severs actin filaments, nucleates actin filament 
growth and caps barbed actin filaments ends (Stossel et al, 1985). Gelsolin is associated 
with the Finnish type amyloidosis, an autosomal dominant form of systemic amyloidosis 
characterized by lattice corneal dystrophy, cranial neuropathy, and intermittent proteinuria 
(Meretoja, 1969). Amyloid deposits are found in kidney, muscle, nerves and cornea and 
fibrils are composed of gelsolin fragments (Haltia et al, 1990; Maury et al, 1990). The 
amyloidotic fraction starts at position 173 of the protein and contains one amino substitution 
at position 187 (Tyrl87Asn). The same phenotype has also been described in Danish and 
Czech kindreds, but with the Tyrl87 substituted by aspartic acid (de la Chapelle et al, 
1992). 
In cystatin C related amyloidosis (ACys) amyloid deposition of a cystacin C fragment 
occurs in cerebral cortex and leptomeninges, walls of small arteries and arterioles, lymph 
nodes, spleen, adrenal gland, ovary, testis, appendix, peripheral nerves and skin (Benedikz 
et al, 1990). The cystatin C fragment (12 kDa) contains one substitution at position 68 and 
misses 10 aa residues at the N-terminus (Barret et al, 1984; Brzin et al, 1984). 
In 1993, amyloid fibrils from a transplanted kidney of a patient with hereditary renal 
amyloidosis were found to contain a fragment of fibrinogen Aot-chain with a substitution of 
Leu for Arg at position 554 (Benson et al, 1993). 
Two additional mutations in the fibrinogen Aa-chain were shown to be related to the 
disease. One of the mutations is a nucleotide deletion resulting in a frame shift and early 
termination of the fibrinogen Aa-chain after aa residue 547 (Uemichi et al, 1996). 
Lysozyme is associated with autosomal dominant hereditary non-neuropathic amyloidosis, 
caused by nucleotide base changes. The mutations occur in highly conserved residues as in 
the case of Ile56Thr and Asp67His (Pepys et al, 1993) and the amyloid fibrils consist 
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exclusively of the variant protein (Booth et al, 1997; Pepys et al, 1993). Very recently, a 
new lysozyme mutation has been identified, Trp64Arg (Valleix et al, 2002), associated 
with prominent nephropathy. Lyso2yme is an ubiquitous bacteriolytic enzyme present in 
external secretions and in polymorphs and macrophages, but its physiological role is not 
clear. 
2.1.2.2.3- Familial Amyloidotic Polyneuropathy (FAP) 
Familial amyloidotic polyneuropathy (FAP) is related to a peculiar form of hereditary 
autosomal dominant polyneuropathy. Corino de Andrade first described the disease in 1952 
(Andrade, 1952) in the Portuguese population mainly from the northern part of the country. 
Characterized by systemic deposition of amyloid and with a special involvement of the 
peripheral nerves, the age of onset of the disease is usually between 20 and 35 years of age, 
with a fast progression to death within 10 to 15 years. 
Clinically, FAP is characterized by early impairment of temperature and pain sensation in 
the feet, and autonomic dysfunction leading to paresis, malabsorption and emaciation. 
Painless injury to the feet complicated by ulcers, celulitis, osteomyelitis and Charcots joints 
may also occur (Reilly et al, 1993). Motor involvement occurs with disease development 
causing wasting and weakness and there is a progressive loss of reflexes. Upper limbs 
involvement may occur years after lower limb manifestations, progressing in a similar way. 
The amyloid deposits (figure 5) can occur in any part of the peripheral nervous system, 
including the nerve trunks, plexus and sensory and autonomic ganglia. In the peripheral 
nerves, they affect the epineurium, perineurium and especially the endoneurium. In the 
endoneurium, deposits are usually closely opposed to Schwann cells or collagen fibrils. 
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Figure 5- Amyloid fibrils from a FAP nerve section. 
Scale bar = 100 run (kindly provided by Rui Fernandes, Amyloid Unit, IBMC) 
The other organ frequently involved in FAP, is the heart. Clinically, the cardiomyopathy 
may present as an arrhythmia, heart block or heat failure. Electrocardiographic 
abnormalities with Q-wave and T-wave repolarization changes and various conduction 
disturbances are some of the clinical features. Echocardiography shows a restrictive 
cardiomypathy with thickened interventricular septum and ventricular walls (Staunder, 
1991), although changes consistent with a hypertrophic cardiomyopathy have also been 
described (Fonseca et al, 1991). 
In FAP the amyloid deposits are widely distributed and other clinical features additional to 
the main ones already described can occur: nephropathy and more rarely pulmonary (Diaz 
Lobato et al, 1991) and bone involvement (Allard et al, 1991). 
The first report relating immunologically TTR as the main protein in FAP fibrils was in 
1978 by Costa and colleagues. Six years latter, in 1984, Saraiva et al identified a VaBOMet 
mutation in the protein isolated from Portuguese FAP patients. This variant was shown to 
be a biochemical marker for FAP (Saraiva et al, 1985) that resulted from a point mutation 
in the exon 2 of the TTR gene (Maeda et al, 1986). 
Since the identification of the VaBOMet variant, many others aa substitutions were 
identified in the TTR protein (table 1, page 11); these variants are associated with different 
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clinical phenotypes and a considerable number of non pathogenic TTR mutations have been 
identified (table 2, page 12). 
For a long time it was thought that all the patients carrying the TTR VaBO Met mutation 
were Portuguese in origin and had a common founder. However, haplotype studies have 
shown at least three different haplotypes associated with this mutation (Yoshioka et al, 
1989; Almeida et al, 1995). 
2.1.2.2.3.1- Phenotypic diversity in TTR related amyloidosis 
The VaBOMet mutation is the most common among FAP patients of Portuguese origin 
(Saraiva et al, 1984) but it has also been identified in patients of different origins: Sweden 
(Dwulet and Benson, 1984), Japan (Nakazato et al, 1984), Cyprus (Holt et al, 1989), 
Greece (Holt et al, 1989), France (Bhatia et al, 1993) and England (Bhatia et al, 1993). 
Within these populations, there is some heterogeneity in FAP, both in age of onset and 
clinical presentation. Portuguese and Japanese Val30Met-related-FAP populations have a 
close median age of onset, 33.5 and 43.2, respectively (Sousa et al, 1995; Ikegawa et al, 
1991), although cases of late onset in TTR VaBOMet related FAP have been observed in 
Portuguese patients (Saraiva et al, 1986; Sequeiros and Saraiva, 1987). For the Swedish 
kindred the average onset is at 56.7 years of age (Sousa et al, 1995). Swedish patients also 
differ from Portuguese patients by presenting frequent vitreous opacities. An intermediate 
age of onset is found in Maiorca, at 49 years of age (Munar-Qués and et al, 1990). 
Compounds heterozygous individuals carrying the VaBOMet and the Thrl 19Met mutations 
present a late onset and a more benign clinical course of the disease (Coelho et al, 1993). In 
vitro studies showed an increased T4 binding affinity for TTR Thrl 19Met (Almeida et al, 
1997) and although there is no relationship between T4 binding properties and 
amyloidogenecity, it is acceptable that both are related with structural alterations induced by 
the mutation. While TTR VaBOMet is the most frequent and widespread variant, TTR 
Leu55Pro (Jacobson et al, 1992) and TTR Leul2Pro (Brett et al, 1999) are the most severe 
mutations. 
Some TTR variants are associated predominantly with cardiomyopathy and absence of 
neuropathy. Familial cardiac amyloidosis (FAC) is related mainly to two TTR variants: 
TTR Vall22Ile and TTR LeulllMet. TTR Vall22Ile is the most common amyloidogenic 
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mutation producing FAC primarily in individuals of African descent (Jacobson, 1992). TTR 
Leul 1 lMet has the earliest age of onset, around 40 years, with death occurring within 1-3 
years (Ranlov et al, 1992). 
2.2- Amyloid - unifying features 
The designation amyloid was introduced in 1854 by Virchow when studying cerebral 
samples with abnormal macroscopic appearance and describing a substance that stained 
blue pale with iodine, and violet after the addition of sulfuric acid. At the time, the tinctorial 
properties of amyloid were attributed to the presence of starch and thus, the name amyloid 
derives from the Latin amylum and the Greek amylon. A few years later, the presence of 
protein in the amyloid mass was demonstrated, shifting the study of amyloid first as a 
protein and later as a class of such. 
Amyloid deposits show special tinctorial properties that for a long time were the only form 
diagnosis available. These include apple-green birefringence under polarized light after 
staining with Congo red (figure 6); staining with thioflavin S and thioflavine T, producing a 
yellow-green fluorescence (Vassar and Culling, 1959; Bennhold H., 1922); thioflavine T 
has also been shown to interact with amyloid in suspension producing a specific fluorescent 
signal with a new excitation maximum at 450 nm (LeVine III H, 1993, 1995). 
' S É * 
Figure 6 - Amyloid deposit stained with Congo red and viewed under polarized light (from Sousa 
et al, 2001a). 
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A century later after Friedreich and Kekule studies, electron microscopy observations 
revealed that the amyloid material was fibrillar (Cohen and Calkins, 1959). Methods to 
isolate and purify these deposits were developed and the capability to solubilize the fibrils 
(Pras et al, 1868; Kaplan et al, 1999) made possible the characterization of the protein 
constituents; in 1971 the first amyloid-related protein was sequenced and characterized 
(Glenner et al, 1971), an immunoglobulin light chain. Since then, over 16 biochemically 
distinct amyloid-related proteins were identified. 
2.2.1- The amyloid fibrils 
Regardless the protein precursor involved in the amyloid disease, the properties associated 
to this condition are common to all forms. In addition to the tinctorial characteristics 
referred above, general structural features unify amyloid fibrils. Ultrastructurally, they 
appear as bundles of straight or coiled fibrils, non-branched, 7-10 nm wide and variable in 
length (Blanden et al, 1966; Shirahama and Cohen, 1967; Glenner, 1980); in most cases 
they seem to be helically twisted. Amyloid fibrils present a high content in (3-pleated sheet 
as demonstrated by x-ray diffraction analysis (Eanes and Glenner, 1968; Bonar et al, 1969) 
and extensive antiparallel p-sheet strands with their axes running perpendicularly to the axis 
of the growing fibril (cross-|3 pattern), (figure 7) (Glenner, 1980 and 1981; Lansbury, 1992). 
Figure 7 - Diagram of the antiparallel cross-0 pattern present in amyloid fibrils. (Adapted from 
Spencer et al, 1991). 
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2.2.2- Other components in amyloid deposits 
Amyloid deposits are not entirely composed of the amyloid precursor protein. Several 
components have been found associated with all amyloid fibrils. These include: serum 
amyloid P component (SAP), sulphonated glycosaminoglycans (GAGs), apoliproteins E 
and J, al-antichymiotrypsin, several basement membrane components such as fibronectin, 
laminin and collagen type IV, complement proteins, and metal ions. 
In vivo amyloid formation may suffer the influence of other factors in addition to the 
fibrillar protein. Several components have been identified; some, implicated in amyloid 
inhibition acting as molecular chaperones (Wisniewski and Frangione, 1992); others 
inducing fibril formation or preventing amyloid degradation under normal conditions. 
Serum amyloid protein (SAP), a decameric plasma glycoprotein, is found associated to all 
types of amyloid deposits (Coe et al, 1981; Prelli et al, 1985; Inoue and Kisilevsky, 2001) 
to which and it binds in a calcium-dependent manner. SAP contributes to amyloidogenesis, 
probably by stabilizing amyloid fibrils and retarding their clearance (Pepys, 2001). One 
possible way of contributing to persistence of amyloid in vivo is by protecting fibrils from 
proteolysis (Tennent et al, 1997), as SAP is itself very resistant to proteolysis. 
Other extracellular matrix components (ECM) including glycosaminoglycans (GAGs) and 
proteoglycans (PGs) have been demonstrated to be significant components of all amyloid 
deposits thus far analyzed. Their role is not clear and contradictory results have been 
reported. 
Laminin, a major basement membrane glycoprotein, was found to interact with Apl-40 
peptide by blocking fibril formation and even inducing depolymerization of preformed 
fibrils (Morgan and Inestrosa, 2001); aggregation of the Dutch Apl-40 variant, a peptide 
with a higher capacity to aggregate, was also inhibited by laminin (Bronfman et al, 1998). 
Other studies reported a very high in vitro affinity between laminin and Alzheimer's 
amyloid precursors (AAPs), suggesting that very specific interactions normally occur 
between AAPs and the ECM (Narindrasorasak et al, 1991,1995). 
It is thought that laminin interacts with Zn2+ and that the formed complex contributes to 
basement membrane cross-linking, which in turn is important for its assembly (Ancsin and 
Kisilevsky, 1996). Laminin contains 42 cysteine-rich repeats of which 12 contain nested 
zinc finger consensus sequences. The effect of several ions on laminin binding activity was 
evaluated and found that Zn2+ was the most effective at enhancing laminin-entactin and 
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laminin-collagen IV binding. Furthermore, apoSAA (the serum precursor of AA amyloid) 
also binds laminin, involving a single class of binding sites. The nature of this interaction is 
ionic and enhanced by Zn2+ (Ancsin and Kisilevsky, 1997), and probably mediated through 
Cys-rich zinc finger-like sequences. Further investigations, localized the laminin binding 
site on apoSAA (Ancsin and Kisilevsky, 1999) and the authors postulated that laminin 
facilitates AA amyloidosis by arresting apoAA. Collagen type IV also binds apoSAA but 
with lower affinity than laminin (Ancsin and Kisilevsky, 1997). 
Interaction of A(3 with glycosaminoglycans significantly enhances fibril formation (Castillo 
et al, 1997; Mclaurin et al, 1999). The sulphate moiety of PG was proposed as being 
critical in this interaction. This hypothesis was confirmed when removal of all sulphates 
from heparin led to a complete loss in the Ap fibrillogenesis. 
Significant amounts of GAGs were detected in close association with purified myocardial 
amyloid fibrils (Magnus et al, 1991). The GAGs were identified as 50% chondroitin 
sulphate, 33% heparin/ heparan sulphate and 17% hyaluronan. It is also suggested that the 
proportion of different GAGs in the amyloid deposits may depend both on the organ or 
tissues affected and the type of fibrils. TTR was also shown to interact with perlecan in 
vitro (Smeland et al, 1997). It is clear that basement membrane and its constituents play a 
role in amyloidogenesis. Whether they enhance or inhibit fibrillogenesis is not clear. 
Apolipoprotein E (Strittmatter et al, 1993; Corder et al, 1993; Wisniewski et al, 1993) and 
apolipoprotein J (Ghiso et al, 1993) have been shown to bind soluble Ap. 
Immunoprecipitation with anti-ApoJ (Ghiso et al, 1993) sequesters soluble Ap from CSF, 
indicating that a complex is formed between them; al-antichymotrypsin has been shown to 
influence fibril formation by Ap synthetic peptides (Fraser et al, 1993). 
2.2.3- Amyloid ligands 
Dyes as Congo red and thioflavin T are usually employed to identify ex vivo amyloid. For 
diagnostic purposes, these amyloid markers imply invasive methods, such as biopsy, to 
provide the sample to be analyzed. Conventional non-invasive diagnostic techniques, such 
as clinical evaluation, joint ultrasonography or X-ray, computed tomography or magnetic 
resonance imaging findings, as well as conventional bone scans, when available, suffer 
from relative non-specificity and/ or low sensitivity. In this regard, sensitive imaging 
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techniques have been developed in order to evaluate amyloid load and/ or treatment 
evolution. 
In 1986, Baltz and colleagues (Baltz et al, 1986) showed for the first time that the 
circulating SAP is the precursor of the amyloid P component in systemic amyloidosis. At 
the same time, this work provided a mean for selective targeting of diagnostic tracers and/ 
or effector agents to amyloid deposits in vivo. Labeled 123I-SAP was shown to specifically 
bind amyloid deposits producing highly specific, high resolution scintigraphic images of 
amyloid in mice with experimentally induced amyloid A protein (Hawkins et al, 1988a). 
Due to its ability to bind all known types of amyloid fibrils, SAP was further used to 
develop a new general diagnostic method for in vivo imaging of amyloid deposits (Hawkins 
et al, 1988b; Hawkins, 1994). SAP was able to specifically bind AL, AA and (32-
microglobulin amyloid deposits. However, once localized to amyloid deposits, the 123I-SAP 
persisted for long periods in contrast to its normal rapid degradation. Moreover, only a 
small part of the total injected dose became localized in the amyloid deposits (Hawkins et 
al, 1988b; Baltz et al, 1986), suggesting that SAP affinity might be reduced for certain 
organs. In fact, when used to evaluate amyloid deposition in patients with P2-microglobulin-
related amyloidosis, radiolabeled SAP failed to accumulate in some of the frequently 
involved sites, such as hips or shoulders (Floege et al, 2000). 
Small molecules such as (/ra«5,/ra«5)-l-bromo-2,5-bis-(3-hydroxycarbonyl-4-
hydroxy)styrylbenzene (BSB) (Skovronsky et al, 2000), a Congo red derivative, have been 
developed, especially directed to detection of amyloid in Alzheimer's disease. BSB 
sensitively labels senile plaques (SPs) in AD brain sections and is able to permeate living 
cells in culture, binding specifically to intracellular Ap aggregates. In living transgenic 
mouse models of AD amyloidosis, BSB labels SPs composed of human Ap and crosses the 
blood brain barrier (BBB), labeling numerous AD-like SPs throughout the brain of the 
transgenic mice after i.v. injection. BSB was also shown to bind diverse beta-pleated sheet 
structures in postmortem human neurodegenerative disease brains, including extracellular 
Ap protein and intracellular lesions composed of abnormal tau and synuclein proteins 
(Schmidt et al, 2001). These results suggest that radioiodinated BSB derivatives might be 
useful imaging agents to monitor different amyloids in vivo. X-34, another Congo red 
derivative, has also been proposed as an amyloid marker not only for Alzheimer's disease 
but for amyloidosis in general since it also binds AL and TTR amyloid (Link et al, 2001; 
Styren et al, 2000). Chrysamine G (CG) is a lipophilic Congo red derivative; it appears to 
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bind amyloid in the same way as Congo red- through a bidentate attachment spanning 
several amyloid peptide chains- and crosses the BBB. Furthermore, CG appears to have low 
toxicity (Klunk et al, 1994) and binding of 14C-CG correlated well with the number of SPs 
and neurofibrillar tangles (Klunk et al, 1995) in mice models for AD. CG labeled with 
99mTc (99mTc-MAMA-CG) was found to bind specifically to A|3 deposits (Dezutter et al, 
1999) and to amyloid in chickens with spontaneous joint amyloidoisis (Dezutter et al, 
2001a). This tracer agent was further tested in amyloid deposits types AA, Ay and AK, 
suggesting it can be applicable for diagnostic purposes in clinical amyloidosis (Dezutter et 
al, 2001b). 
Lipophilic thioflavin derivatives (Mathis et al, 2002; Klunk et al, 2001) have also been 
described to bind amyloid deposits. These molecules are also capable of entering the brain 
and are proposed as promising candidates for in vivo amyloid imaging in Alzheimer's 
disease. 
The antiprotease aprotinin, usually employed as a cortical renal tracer, was evaluated for the 
imaging of amyloid associated with AL deposition (Aprile et al, 1995). Aprotinin labeled 
with technetium-99m (TcA) was shown to accumulate in organs known to have amyloid 
deposition, prompting this anti-serine protease as a low-cost available radiopharmaceutical 
for imaging in AL type amyloidosis. 
3- Amyloid formation pathway 
The mechanism that leads to amyloid formation is still poorly understood. It is believed that 
several factors take part in the process that culminates in fibril formation. A prominent 
agent is the amyloidogenic potential of the protein that can be enhanced or diminished by 
the presence of mutations; other intervening component is the presence of tissue and/or 
circulating factors that can contribute to the deposition of amyloid and may determine the 
specificity of localization; other factors, like environment and genetic background, have 
been proposed and could account for the differences in onset between individuals carrying 
the same mutation. 
The large number of proteins associated to amyloidotic diseases together with their 
unrelated primary structure and lack of consensus sequences, suggest the presence of other 
particularities that may contribute to their tendency to self-aggregate. In this regard, the 
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high content in p­sheet structure, present in most amyloidogenic proteins, has been 
implicated as favoring fibril formation. This assumption is deduced from the cross­P pattern 
present in all amyloid fibrils and thus, proteins rich in p­sheet would be more prone to fibril 
formation. However, some proteins associated with amyloid disorders present 
predominantly oc­helix in their secondary structure. It is the case of lysozyme that in its 
native form presents only a small amount of p­structure (Artymiuk and Blake, 1981) and of 
the prion protein; however, modifications, particularly changes in the p­content, lead to 
amyloid formation. 
In vitro fibril formation has been a powerful tool in studying of mechanism that leads to 
amyloid formation. Theories for the events occurring in vivo have been proposed based on 
the knowledge of the in vitro results. Virtually all types of fibrils are produced in vitro from 
their normal precursors, suggesting that the amyloidogenic potential is determinant. 
Moreover, morphologically, synthetic fibrils (figure 8) are similar to those formed in vivo, 
suggesting a predominant role of the amyloidogenic potential of proteins in amyloid 
disorders. 
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Figure 8 ­ TTR fibrils formed in vitro. Scale bar = 100 nm (Amyloid unit, IBMC, Porto). 
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3.1- Hypotheses for amyloid formation 
Different hypothesis have been raised to explain amyloid formation concerning the protein 
amyloidogenic potential. We next described some of the proposed theories. 
3.1.1- Partial unfolding of globular proteins and partial folding of disordered proteins-
the conformational hypothesis 
Proteins like TTR, lysozyme and light-chain variable domain (VL) adopt globular folds in 
their soluble states (Kelly, 1998,1996). It is now currently accepted that these proteins must 
undergo destabilization into a partially unfolded state, in order to self-assemble into fibrils. 
Mutations seem to induce the structural conformations that favor the destabilization. In the 
case of TTR, the occurring mutations would favor the formation and/ or exposure of new 
structural motifs in the TTR molecule that would culminate with tetramer dissociation and 
formation of partially unfolded intermediates. TTR VaBOMet crystal structure shows a 
higher spacing between DAGH and CBEF sheets in the monomer together with a 
movement of strand A exposing residue 10 to solvent (Terry et al, 1993). For another 
variant, TTR Vall22Ile, an increase in the length of the hydrogen bonds between dimers 
was reported (Damas et al, 1996). Furthermore, the FG loop also differs in all 
amyloidogenic TTR variants while it is conserved in WT and non-amyloidogenic TTRs. 
The structural differences are thought to destabilize the tetrameric structure, the proposed 
initiation step in the amyloidogenic cascade. 
Contrary to globular proteins, many amyloidogenic polypeptides consist primarily of 
random-coiled structure in their native states. Ap and IAPP are examples. These proteins 
can, however, adopt a partially structured conformation that is stabilized by oligomerization 
(Ratnaswamy et al, 1999). Kayed et al, (1999) demonstrated that IAPP fibril formation 
involves a transient formation of a conformer with the characteristics of a molten globule, 
containing substantially more a-helix and P-sheet than the native state. When the fibrils are 
formed, the a-helix content decreases whereas the P-sheet contents increases even further. 
A similar process was observed for Ap with a transient increase in a-helix during the 
conversion of largely unfolded low molecular Ap to amyloid fibrils enriched in p-sheet 
(Walsh et al, 1999). 
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3.1.2- Amyloid formation may require proteolysis- proteolytic hypothesis 
Proteolysis has been viewed as an important event in most types of amyloidosis. Some 
amyloidogenic proteins are released from precursors by proteolysis. For example, Ap is 
derived from the amyloid precursor protein by a combination of (3- and y- secretases 
cleavages (Teplow, 1998; Selkoe, 1999). Additional fibrillogenic fragments were identified 
in the recent past: the 34-residue Abri peptide, derived from a putative transmembrane 
precursor and found in plaques of British dementia (Vidal et al, 1999; Lansbury and Kosik, 
2000); the 50-residue medin peptide, derived from lactadherin and associated with aortic 
medial amyloid (Hággqvist et al, 1999); an N-terminally cleaved fragment of lithostathine 
found in fibrillar aggregates of AD and chronic calcifying pancreatitis (Cerini et al, 1999). 
TTR peptides in addition to the intact protein, have been found in amyloid fibrils from SSA 
and some FAP patients, raising the hypothesis that proteolysis could trigger fibril formation 
by releasing amyloidogenic fragments (Saraiva and Costa, 1991). The fragments released 
result from cleavages that vary according to the TTR variant involved: in SSA fibrils, the 
fragments result from cleavage at positions 46, 49 and 52 (Cornwell III, 1988); TTR 
VaBOMet (Wahlquist et al, 1991), TTR Vall22Ile (Gorevic et al, 1989) and TTR Phe33Ile 
(Pras et al, 1983; Nakazato et al, 1984) fragments result from cleavage at position 49; TTR 
Leul 1 lMet carriers showed amyloid fibrils containing TTR molecules cleaved at positions 
46,49 and 59 (Nordlie et al, 1990; Hermansen et al, 1995). 
Several works were conducted in order to assess the capacity of TTR peptides to form 
amyloid fibrils. Most of the synthetic peptides that retain the ability to self-aggregate into 
fibrils represent p-strands in the tertiary structure of TTR and formed fibrils with the 
characteristic cross P-sheet arrangement (Gustavsson et al, 1991). Nuclear magnetic 
ressonance (NMR) and circular dichroism (CD) studies using these peptides revealed that 
they are predominately comprised of random-coil structures but may also include a low 
percentage of turn or helical elements. The peptides displayed no predisposition to 
exclusively form P-strands structures in solution as supposed from the P-sheet based fibrils 
they form (Jarvis et al, 1994). 
However, in other samples of VaBOMet TTR fibrils, no fragments are found (Saraiva et al, 
1984; Tawara et al, 1983) and thus, the role of proteolysis in TTR amyloidosis is still 
unclear and evidences suggest that the release of peptides is not essential. 
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3.1.3- Nucleation and seeding 
Several studies report that amyloid formation seems to occur via a nucleation dependent 
oligomerization (Harper and Lansbury, 1997; Lansbury, 1997) in which an ordered nucleus 
is formed after a lag phase. After nucleation, growth of the fibril occurs rapidly and follows 
an accumulation time course sigmoidal in shape (Kisilevsky, 2000). The development of 
animal models with accelerated AA amyloid and prion deposition are examples of fibril 
formation upon the supply of a template, usually employing isolated AA fibrils as amyloid 
enhancing factor (AEF) (Axelrad and Kisikevsky, 1980; Kisilevsky and Boudreau, 1983) 
and prions (Prusiner and Scott, 1997), respectively. Moreover, this nucleation event may be 
created using as nucleus heterologous fibrils. It is the case of in vivo murine AA 
amyloidosis, where fibrils derived from A0 (Ganowiak et al, 1994), TTR fragments (Johan 
et al, 1998), IAPP or amylin (Johan et al, 1998), and even modified silk fibrils (Kisilevsky 
et al, 1999) may replace AEF. 
TTR associated amyloidosis is thought to obey to this nucleation event. Although 
proteolysis is not absolutely necessary for TTR related fibril formation, the fragments 
originated in some cases, may provide a nidus for further and faster polymerization. 
3.2 - Intermediate species in TTR amyloidogenesis 
From the native form of the precursor to the mature fibril, several species appear as 
intermediates in the path that ends with the TTR mature fibril. 
3.2.1- Monomelic intermediates 
Fibril formation in vitro opened the possibility to study the process by which a native 
soluble protein loses its normal fold and aggregates into fibrils, paving the way for better 
understanding the mechanism that culminates in amyloid formation and to the design of 
drugs that interfere with such process. In 1991, Gustavsson and colleagues (Gustavsson et 
al, 1991) first described the production of TTR amyloid-like fibrils when dissolving the 
protein in a 10% acetic acid solution, pH 2.3. Colon and Kelly (1992) further studied this 
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theme and showed that the rate of fibril formation is pH dependent with higher rates at pHs 
between 3.6-4.0 (Colon and Kelly, 1992). The accurate identification of the TTR 
denaturated intermediate was complicated by the fact that fibril formation occurs over a pH 
range that is close to the pH where a TTR tetramer to monomer transition is operating. The 
results were consistent with either a rearranged tetrameric or monomelic TTR denaturation 
intermediate. This work also hypothesized the lysosomal intervention in amyloid formation, 
supported by the range of pHs found to induce higher rates of fibril formation. However, in 
vivo, TTR amyloid deposits are extracellular arguing against this view. 
Further work in 1996 by Lai et al, suggested that tetrameric TTR dissociates to a monomer 
in a process that is dependent on both pH and concentration. The acid denaturation pathway 
of TTR involves the formation of several different intermediates having variable quaternary, 
tertiary and secondary structures. Moreover, the authors stated the dissociation of the TTR 
tetramer into monomers with a defined yet, non-native tertiary structure. The dissociation 
would involve rearrangement in the C-strand-loop-D-strand region in such a way that a 
monomelic (3-sheet sandwich was afforded having the A, B, F, and H strands exposed 
allowing the self-assembly into amyloid. 
Even though the use of low pH has been useful to study amyloid formation, physiological 
conditions were required to better understand the process that takes place in vivo. Others 
approaches under physiological conditions were performed. Quintas et al., (1997) reported 
that TTR dissociates to a monomelic species at pH 7.0 and nearly physiological ionic 
strengths; the tetramer dissociation is apparently irreversible and the monomer is non-native 
(Quintas et al, 1999). This monomelic species does not behave like a molten globule and 
leads to the formation of partially unfolded monomelic species and high molecular mass 
soluble aggregates (Quintas et al, 1999). Based on aging experiments of tetrameric TTR, 
under physiological conditions, and protein unfolding experiments of the non-native 
monomelic forms, it has been shown that tetramer dissociation and partial unfolding of the 
monomer precedes amyloid fibril formation (Quintas et al, 2001). 
3.2.2- Dimeric intermediates 
The structure of Val30Met reveals a movement of strand A exposing CyslO to the solvent. 
This lead Terry et al. (1993) to consider that amyloidogenic fibrils could form after the 
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association of TTR molecules through disulphide bridges. However, this theory does not fit 
with the formation of fibrils by a TTR CyslOArg variant. 
Redondo et al, (2000a) addressed the question of whether dimers are able to form amyloid 
fibrils; mutant dimmers covalently linked through disulphide bonds were unable to 
polymerize into amyloid while disruption of the S-S bridges by a reducing agent, lead to 
amyloid formation. These data implied the need of a monomeric entity prior to TTR fibril 
assembly. 
In a recent work by Olofsson et al (2001), the substitution of two aa in the hydrophobic 
core of TTR lead to a mutant very prone to form amyloid. Prior to fibril formation, a stable 
dimeric species was detected at low temperature. However, a small population of monomers 
was also observed. The data is in good agreement with the findings by Serag et al (2001) 
that suggest that the native dimeric interactions are preserved within the amyloid fibril. The 
conclusions arrive from the ability of forming fibrils starting with cross-linked engineered 
TTR mutants with extra cysteins. 
3.2.3- Tetrameric intermediates 
In spite of the evidences supporting the involvement of monomeric species during TTR 
fibril assembly, several authors have questioned the monomer as the building block. Besides 
the dimeric block, a tetrameric structure has also been submitted for discussion. 
Ferrâo-Gonçalves et al, (2000) proposed a hypothesis based on in vitro experiments under 
high pressure in which an altered tetramer could be responsible for TTR aggregation. 
However, the work did not present morphological evidence for fibril formation. This 
hypothesis may apply to very early events on fibril formation as the authors report the 
presence of a small population of monomers after treatment at high pressure. Moreover, the 
work was performed with TTR WT and did not include an equal treatment for TTR 
amyloidogenic variants. 
Recently, the structure of the TTR synthetic variant, Gly53Ser, Glu54Asp, Leu55Ser, was 
resolved and an altered tetramer was suggested as the building block of TTR fibrils 
(Eneqvist et al, 2000). This mutant, generated according to a predicted mutational hot spot 
region in the short D strand of the molecule (Serpell et al, 1996), polymerizes at 
physiological conditions, originating high molecular weight aggregates with amyloid 
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characteristics (Goldsteins et al, 1997). The crystal structure of this variant reveals a shift 
in the strand D that affects the positions of residues Ser-50-Glu-63, the p-slip, and the 
Leu58 is positioned at the site normally occupied by Leu55. New packing interactions 
include the BC loop, DE loop, FG loop and the area normally involved in complex 
formation with RBP. The proposed model does not imply tetramer dissociation into 
monomers for fibril formation. However, it should be noted that this is a non-natural TTR 
variant. 
3.3- Structural amyloidogenic determinants in TTR 
Two naturally occurring TTR mutations revealed to be very important in the study of the 
TTR aggregation pathway giving information on the structural determinants of 
intermediates: TTR Leu55Pro and Tyr78Phe. 
3.3.1 - The Leu55Pro and the Tyr78Phe TTR variants 
TTR Leu55Pro variant is associated with the one of the most aggressive forms of TTR-
related amyloidosis, characterized by an early age of onset, between 15 to 20 years of age. 
The disease progresses very rapidly to death in 5 to 10 years (Jacobson et al, 1992; 
Yamamoto et al, 1994). Besides neuropathy, this variant is also associated with 
cardiomyopathy and vitreous opacities. 
Biochemical studies reported lower tetramer stability towards acid denaturation for this 
variant when compared to the WT counterpart (McCutchen et al, 1993; Lashuel et al, 
1998). Furthermore, TTR Leu55Pro was shown to form protofilaments in vitro at 
physiological pH (Lashuel et al, 1999), indicating that this variant may represent an 
intermediate, involved in the events occurring in vivo. Thyroxine binding studies, used to 
assess structural modifications of TTR variants, showed a very low binding affinity for TTR 
Leu55Pro/TTR WT heterozygotic serum and inability to bind homozygotic recombinant 
protein (Almeida et al, 1996). 
To learn more about structure/ pathogenesis relationship in TTR variants, X-ray studies 
using recombinant TTR Leu55Pro were performed and results compared with the TTR WT 
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structure. Crystallographic works on other amyloidogenic variants, TTR VaBOMet 
(Hamilton et al, 1993; Terry et al, 1993), TTR Vall22Ile (Damas et al, 1996), and TTR 
Ile84Ser (Hamilton et al, 1996), revealed an overall structural homology with the WT 
protein. However, the crystal of TTR Leu55Pro showed the presence of eight monomers in 
the unit cell (Sebastião et al, 1998) in contrast to the WT crystal that crystallizes with a 
dimer in the asymmetric unit (Blake et al, 1978). In the mutant monomer, due to the 
disruption of hydrogen bonds between strands D and A, residues 54-56 are part of a long 
surface loop that connects strands C and E and thus, the TTR Leu55Pro monomer is 
organized in seven strands and one a-helix (figure 9), instead of the normal 8 strands that 
constitute the WT monomer. This loop is involved in the crystallographic packing observed 
in the crystal structure and contacts between CE loops are believed to be determinant in 
amyloid formation. Another element involved in the overall force in the assembly of units is 
the hydrogen bonding between the AB loop and the a-helix of the nearest neighbor. 
Figure 9- Representation of the TTR Leu55Pro monomer visualizing the long loop CE formed 
upon the disruption of H-bonds between strands D and A (PDB entry 5TTR; Sebastião et al, 1998). 
The topology presented by this mutant is similar to the classic p-barrel. Furthermore, the 
crystal packing shows several channels running parallel to each other, suggesting a tubular 
structure and the authors proposed that this variant can constitute an intermediate structure 
for TTR amyloid formation (figure 10) (Sebastião et al, 1998). 
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Figure 10- TTR Leu55Pro crystal packing: several channels running parallel to each other, 
suggesting a tubular structure similar to the TTR amyloid fibril structure (Sebastião et al, 1998). 
The same authors re-enforce this view by showing that TTR Leu55Pro used for 
crystallization binds ThT, indicating the presence of an amyloid-like oligomeric structure 
(Sebastião et al, 2000). Thus, changes in the D strand together with the contacts of the AB 
loop and the oc-helix are pivotal in amyloid formation. Experiments performed with 
synthetic TTR mutants with a triple substitution or a triple deletion in the D strand (TTR 53, 
54, 55) showed a high potential for amyloid formation even at physiological pH (Serpell et 
al, 1996; Goldsteins et al, 1997). Binding studies performed with an antibody raised 
against this mutant, demonstrated that the antibody displayed affinity to ex vivo TTR fibrils 
and TTR mutants with an amyloidogenic fold but not to TTR WT or mutants with the WT 
fold (Goldsteins et al, 1999). Interestingly, in the TTR Leu55Pro crystal, the region 
corresponding to the D strand forms the outer part of the asymmetric units that assembles 
into the tubular structure (Sebastião et al, 1998). 
The data gathered so far on the described TTR variant, TTR Leu55Pro, clearly promotes 
this mutant to a high level in the study of amyloid formation. 
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Given the known crystallographic structure of TTR Leu55Pro (Sebastião et al, 1998), and 
with the purpose of destabilizing the AB loop and thus the tetrameric fold, a TTR mutant 
with a Tyr residue at position 78 was generated (Redondo et al, 2000b). 
The resulting protein presents a soluble tetrameric form as shown by resistance to 
dissociation on native and SDS-PAGE electrophoretic studies and elution patterns on 
HPLC; the protein also retains the ability to bind T4 indicating a functional tetrameric 
folding. Interestingly, this variant is very prone to amyloid formation as observed by 
thioflavine T binding after acidification. Furthermore, the mutated protein is recognized by 
the monoclonal antibody known to react only with highly amyloidogenic mutant proteins 
and with amyloid fibrils and with similar binding properties as synthetic fibrils, as measured 
by surface plasmon resonance (SPR) spectroscopy. The authors propose that this variant 
may represent an early event in in vitro amyloidogenesis (Redondo et al, 2000b). TTR 
Tyr78Phe was later observed in an Italian patient with TTR-related amyloidosis (Anesi et 
al, 2001). The patient presented weight loss, chronic diarrhea, exertional dyspnea and distal 
muscle fatigue with walking difficulty. Physical examination revealed marked macroglossia 
with teeth indentation, peripheral edema and hepatomegaly. Echocardiography showed 
restrictive cardiomyopathy with a thickened interventricular septum of 14 mm and a 
conserved ejection fraction. Furthermore, bilateral carpal tunnel syndrome had been treated 
surgically 10 years earlier. 
4- Proposed models for TTR amyloid 
The question about the basic units that form an amyloid fibril is yet not answered. The 
problem is even more complicated for TTR related amyloid fibrils as the amyloidogenic 
protein involved presents itself as a tetramer. So far, we have discussed the intermediates 
that might be involved in the amyloidogenic pathway, apparently complex and difficult to 
unravel. Most of the times, authors propose the intermediate species as the building blocks. 
Altered dimers and/or tetramers of TTR may be captured when studying amyloid formation; 
that does not necessarily signify they are the building blocks of the fibrils but rather provide 
insights into the steps of fibril formation. Analyzing and resolving the structure of pre-
formed fibrils is probably a better way to answer the question so many times asked. We 
next describe the available models based on the study of ex vivo fibrils from FAP patients. 
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4.1- Fibrils examined with high-resolution electron microscopy 
Ultrastructure analysis of FAP TTR VaBOMet fibrils from sural nerve biopsies was done by 
transmission electron microscopy (TEM) and immunolabelling. The FAP amyloid fibril 
seems to be formed by a core composed of a tight helix of 3 irai wide double tracks 
containing pentosomes (subunits of amyloid P component) at its center. Other type of 
double tracks 4.5-5 nm wide are observed made up of heparan sulphate proteoglycan 
(HSPG). Based on the observations a model was proposed (Inoue et al, 1998) (figure 11), 
in which TTR appears as filaments 0.5-1 nm wide at the periphery of the core. The 
dimensions of the TTR filaments made the authors suggest that the TTR basic unit in the 
FAP fibrils is a modified monomer. 
TTR FAP amyloid fibril 
(cutout model) 
Contents of 
'amorphous' material 
Figure 11- Schematic drawing of the formation of FAP amyloid fibrils (Inoue et al, 1998). 
4.2- Fibril analysis by reconstruction image 
Reconstruction of TEM images was done on amyloid material obtained from the vitreous 
humor of patients homozygous for the TTR VaBOMet mutation (figure 12). 
Analysis showed that fibrils are about 130 Â in diameter and 4-fold symmetry with four 
protofilaments, each measuring 40 to 50 A across, arranged around a central hollow core 
(Serpell et al, 1995). This study did not allow determining the nature of the TTR 
component that makes up the protofilaments. 
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Figure 12- Isolated cross-section images used to study the structure and dimensions of the TTR 
amyloid fibril (from Serpell et al, 1995). 
4.3-X-ray fibril diffraction of ex: vivo fibrils 
Two main models have been proposed based on X-ray fiber diffraction studies. Although 
the source of FAP fibrils is the same in both cases, the results obtained are distinct. 
4.3.1- Monomers are the building blocks of protofilaments 
Based on X-ray diffraction studies on TTR amyloid fibrils isolated from biopsies of vitreous 
humor, a model was proposed in which the unit structure is similar to a monomer. The fibril 
is composed of a pair of P-sheets consisting of four hydrogen-bonded P-chains per sheet, 
with the P-chains oriented approximately perpendicular to the fibril axis (rnouye et ah, 
1998). The altered monomers are stacked axially with a 29 Á- period, constituting the 
protofilament (figure 13). Furthermore, the dimensions of the fiber and the constituent 
protofilament are found to be 110-130 Á and 40-50 Á, respectively. The protofilaments 
within the fiber are not tightly packed, suggesting that components other than the full-length 
42 
General Introduction 
TTR may fill the space between them. This probably accounts for the difference in size seen 
in the in vitro amyloid-like fibrils (60-100 Â) (Colon and Kelly, 1992; Gustavsson et al, 
1997). 
When analyzing FAP fibrils, TTR fragments in addition to full-length TTR also appear to 
contribute to the fibrils (Westermak et al, 1990; Cornwell III et al, 1988). SDS-PAGE 
studies on vitreous FAP fibrils also show smaller bands apart from those corresponding to 
the monomer and dimer (Thylén et al, 1993). One of these bands corresponds to a peptide 
starting at Thr49 and the other to a mixture of peptides starting at positions 1 and 3. The fact 
that the 29 Â-period lengths along the meridian are greater than the size measured for Hi-
bonded P-chains, suggests that shorter TTR fragments may fill the space in between (Inouye 
et al, 1998). 
p r o t o f i l a m e n t s 
23Â 
29Â 
Figure 13- Schematic representation of the 
protofilament assembly for TTR amyloid (Inouye 
etal, 1998). 
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4.3.2- Monomers or dimers are the building blocks 
The other model suggests that amyloid fibrils consist of p-sheets extended in regular helical 
twists along the length of the fibril (Blake and Serpell, 1996). The polypeptide chains are 
hydrogen bonded together along the entire length of the fibril, contributing to the great 
stability of this structure. The suggested protofilament is composed of four p sheets related 
by a single helix axis coincident with the fibril axis. As in the previous model, the proposed 
structure for the FAP fibril requires a TTR building block structurally different from the 
native tetramer. However, the building block is not completely defined and the authors 
suggest it can be either a monomer or a dimer with reorganized or truncated (3 sheets. 
Moreover, amyloid formation would require significant structural change in precursor 
proteins, which contrasts with the previous model (figure 14). 
Figure 14- Model of the amyloid protofilament. 
(a) core structure of the amyloid protofilament 
viewed perpendicularly (top) and along (bellow) 
the filament axis, (b) an isolated P sheet; the 
strands in the four component sheets are parallel 
to one another. (From Blake and Serpell, 1996). 
44 
General Introduction 
5- Animal models for FAP 
Although in vitro studies have contributed to the knowledge of the amyloid formation 
mechanism, they tend to simplify the process and disregard a number of factors thought to 
play a role in pathogenesis. In order to acquire insights into amyloidogenesis occurring in 
vivo, several transgenic mice carrying the human TTR VaDOMet gene were generated as 
models to study FAP. The homology between mouse and human TTR sequences is 
considerably high with only 25 out of 127 aa residues of the mature protein being replaced 
by different ones in the mouse. Almost all these substitutions (24 out of 25) are located in 
the outer surface of the protein, implying that the regions corresponding to functional 
domains of both proteins are highly conserved between the two species. Furthermore, the 
sequences of the 5'-flanking region are highly conserved and the homology from the 
putative TATA box to -189 region is 85% (Wakasugi et al, 1986). 
Microinjection of foreign DNA into the pronuclei of single cell ova and the subsequent 
implantation into pseudopregnant females has been the strategy used to produce transgenic 
animals. 
5.1- Transgenic mice with inducible heterologous promoters 
The first report of an FAP mice model occurred in 1986 by Sasaki and colleagues (Sasaki et 
al, 1986). A DNA fragment containing the mouse metallothionein-I (MT) promoter fused 
to the structural gene coding for the human TTR VaBOMet variant was microinjected into 
fertilized mouse eggs. Human TTR was inducible and secreted into serum but at low levels 
(2.5- 12 fig/ ml). In these animals TTR mRNA was present in the liver, kidney, intestine, 
spleen, brain, heart and testis. The testis showed constitutive mRNA synthesis, while all 
other tissues were zinc-inducible (Sasaki et al, 1989). No amyloid deposition was observed 
(Sasaki etal, 1989). 
Shimada et al (1989) reported the breeding of transgenic mice for TTR VaBOMet in the 
background C57B1/6J. The structural portion of human ttr Met30 gene was associated to 
the mouse MT2 promoter (MT2-TTRMet30). In these animals TTR levels in serum were 
10-60 u.g/ml and amyloid deposits were found in the mucosa of small intestine after 6 
months; after 12 months, the deposits extended to 10% of renal glomeruli, heart and thyroid 
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but no deposition was found in the brain, bone marrow, spleen, liver, lymph node, choroids 
plexus or peripheral nerves (Yi et al, 1991; Araki et al, 1994). The MT2-TTRMet30 gene 
was expressed in various tissues as liver, brain, heart, skeletal muscle, kidney and lung. 
However, mRNA expression was not found in the small intestine suggesting that the 
deposited human TTR in this organ originates from the serum. 
5.2- Transgenic mice using homologous promoter regions 
In 1987, Yamamura et al. (1987) produced transgenic mice using the entire human ttr 
Met30 structural gene with 600 bp of upstream sequence including the native promoter (0.6-
TTRMet30). TTR mRNA was detected in liver and yolk sac but not in other tissues 
including brain. These animals showed low levels of human TTR mRNA being about one-
tenth of those of mouse endogenous TTR mRNA. Analyses of serum TTR suggested that 
the human TTR was coupled with mouse TTR forming heterotetramers. Congo red staining 
indicated no amyloid deposition until 12-15 months of age (Shimada et al, 1989). 
A distant enhancer element was identified in the mouse ttr gene (Costa et al, 1990) 
probably missing in the 0.6 kb sequence used to generate the transgenic mice above 
described. In cultured human hepathocytes, the mouse ttr gene expression is increased about 
10 fold in the presence of the distant enhancer element. Thus, another DNA fragment 
containing about 6 kb of the upstream region and the entire human mutant ttr Met30 gene 
was used to produce transgenic animals (6-TTRMet30) (Yokoi et al, 1996). The resulting 
mice have serum levels of human TTR varying from 0 to 170 ug/ml. Six months after birth, 
amyloid deposition starts in the gastrointestinal tract, cardiovascular system and kidneys 
and extends to other organs and tissues with advancing age (Nagata et al, 1995; Takaoka et 
al, 1997). 
The 6-TTRMet30 transgenic mice also form hybrid TTR tetramers and this was one of the 
explanations raised for the lower and slower degree of amyloid deposition in transgenic 
mice. In 1993 the ttr knockout mice (ttr-) became available (Episkopou et al, 1993) and 
crossed with the 6-TTRMet30 mice, generating animals lacking the endogenous ttr gene but 
carrying the human TTRVal30Met mutant (Maeda et al, 1996; Yokoi et al, 1996). 
Although the animals presented higher levels of circulating human TTR Val30Met than 
FAP patients, amyloid deposition was similar to the one observed for the 6-TTRMet 
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transgenics. Therefore, the presence of the mouse endogenous protein was not the factor 
leading to delayed amyloid deposition. 
Transgenic animals carrying mutations other than the TTR VaBOMet have been generated: 
TTR Leu55Pro (Teng et al, 1995) and TTR Ile84Ser (Waits et al, 1995). Surprisingly, no 
amyloid deposits were found in these animals. As TTRLeu55Pro is a very amyloidogenic 
mutation a new attempt to generate mice expressing this variant was performed (Sousa et 
al, submitted). The transgene was expressed under the control of sheep metallothionein 
promotor and all the generated lines had the liver as the major site of TTR synthesis 
although other organs such as the intestine were shown to express the protein. Average 
plasma levels of TTR after one week of induction with ZnSC>4 were approximately 150 
ug/ml. As for other transgenic animals, the formation of heterotetramers between mouse 
TTR and human TTR Leu55Pro was observed. Detection of mutant TTR-immunoreactive 
material occurred in several organs, particularly in the gastrointestinal tract starting at age of 
3 months. Congo red staining was negative for this material. 
To study the process of age-related fibrillogenesis, a feature of senile cardiac amyloidosis, 
transgenic mice overexpressing human wild-type TTR have been produced. Eighty-four 
percent of C57BI/6xDBA/2 mice older than 18 months developed TTR deposits primarily 
in the heart and kidney. In most animals, the deposits are non fibrillar and non congophilic 
(Teng et al, 2001), however, 20% of the animals older than 18 months have TTR cardiac 
amyloid deposits identical to the lesions seen in SSA. Extraction of amyloid and 
nonamyloid deposits showed intact human TTR monomers with no evidence of proteolysis 
or deposition of murine TTR. This work first raised the hypothesis that the non-congophic 
material is either a pre-amyloid state or an alternate form of tissue deposition; the finding 
that older animals develop congophic amyloid deposits, suggests that non amyloid deposits 
occur prior to fibril formation. 
The failure of many of the transgenic generated to develop amyloid raises the question of 
suitability of mice as animal models for FAP, especially because so far, no amyloid 
deposition in the peripheral nerve has been reported. 
Table 4 summarizes the main transgenic mouse lines carrying human ttr sequences. 
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General Introduction 
6- Therapeutical strategies in FAP 
The knowledge acquired over time regarding not only the identification of the 
amyloidogenic proteins, their synthesis, metabolism and degradation but also the pathway 
for fibril formation with several intermediates involved, made several therapeutical 
strategies possible. 
6.1- Liver transplantation 
As TTR is mainly produced by the liver, strategies aiming at removing or reducing the 
amyloidogenic precursor pool, require liver transplantation (first strategy). This 
therapeutical approach abolishes the major site of synthesis of mutant TTR and replaces it 
with the normal protein. The first liver transplantation for an FAP patient occurred in 1990 
in Sweden. The procedure is now used all over the world. 
Liver transplantation seems to be the only method of slowing down the disease (Lewis et 
al, 1994). Holmgren et al, (1993) reported that amyloid deposits regressed after 1-2 years 
of transplantation. Stangou et al, (1999) referred to liver transplantation as producing 
improvements in autonomic function, gut symptoms, nutritional state, and general well 
being. However, improvements are not always observed as recently reported for the 
progression of cardiomyopathy after liver transplantation in patients with FAP (Olofsson et 
al, 2002). Moreover, the peripheral neuropathy seems to recover very slowly and this 
therapy is associated with considerable risks for the patients. Thus, other strategies aiming 
at reducing the amyloid deposits are necessary. They can be divided into three main 
categories: (II) tetrameric stabilizers; (III) fibril inhibitors and (IV) fibril disrupters (figure 
15). 
Fibril inhibitors 
Native 
tetramer A Modified 
Tetrameric monomers Fibril 
Stabilizers Disrupters 
(H) (IV) 
Fibrils 
Figure 15- Amyloid fibril assembly (possible pathway). For each step the proposed strategy is 
indicated. 
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6.2- Preventing the formation of the amyloidogenic intermediate 
The tetrameric nature of TTR implies that in FAP therapy the first step of the 
amyloidogenic cascade to be inhibited is protein dissociation (second strategy). The 
potential use of small molecules that bind in the TTR channel, stabilizing the native fold of 
the protein has been explored; molecules such as flufenamic acid and similar compounds 
inhibit the conformational changes leading to amyloid formation as assessed by its ability to 
inhibit the denaturation occurring at acidic pH (Peterson et al, 1998; Baures et al, 1998, 
1999; Oza et al, 1999; Klabunde et al, 2000). Crystallographic studies indicate that 
flufenamic acid mediates intersubunit hydrophobic interactions and intersubunit hydrogen 
bonds that stabilize the normal tetrameric fold of TTR. The side chains of Serll7 and 
Thrll9 rearrange to facilitate additional hydrogen bonding between the subunits of the 
tetramer. However, these compounds have not proved yet to be active against amyloid 
formation in vivo. Their use may be compromised by the presence of other proteins with 
higher binding affinity towards such molecules. 
A different approach proposed was the intake of antioxidants to avoid oxidative stress. In 
this way, TTR monomers and tetramers would maintain the reduced state providing an 
increased stability to TTR molecule as assessed by isoelectric focusing (Altland and Winter, 
1996). Further studies showed that oxidation of CyslO (the only cysteine residue in TTR) 
by sulfite, produces more stable tetramer (Altland and Winter, 1999). The stabilizing effect 
of sulfite was further investigated in vitro and in vivo and showed to also increase the ratio 
tetramer/monomer (Altland and Winter, 1999). Facing these results, sulfite was proposed as 
a potential drug to delay the onset and progression of TTR related amyloidosis. However, in 
vitro studies by Kishikawa et al, (1999), demonstrated that sulfonated TTR has an 
enhanced amyloidogenicity when compared to reduced or free TTR. Although different 
methodologies have been used, the different conclusions obtained from these experiments 
demonstrate the need for a full characterization and comprehension of the amyloid pathway 
in order to correctly interpret the results obtained. 
6.3- Preventing fibril elongation 
Inhibiting the formation of amyloidogenic intermediates from the soluble counterpart is 
expected to be a more specific reaction as amyloidogenic precursors are not structurally 
related and thus, molecules that inhibit TTR dissociation probably do not produce the same 
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effect in other amyloidogenic proteins. In contrast, drugs that inhibit elongation or disrupt a 
certain type of amyloid are most likely to have the same activity towards others amyloid 
types. 
It is accepted that amyloid fibrils result from the assembly of intermediate species with 
amyloidogenic potential. In the case of FAP, an altered monomer seems to be in the base of 
such process. Therefore, one of the possible therapies in the treatment of amyloid diseases is 
to block the interaction and association of such structures into amyloid fibrils (third 
strategy). 
This particular point of intervention has not been properly addressed due to the difficulty in 
identifying the species in question. In addition, amyloid formation seems to undergo a 
nucleation event with a rapid initial stage. Hence, the study of a single stage in the 
amyloidogenic cascade, such as fibril elongation, is most of the times difficult if not 
impossible. Moreover, studies aiming at studying and finding molecules capable of 
preventing TTR tetramer dissociation (second strategy) have been performed under acidic 
pH; under these conditions the dissociation process is very rapid and thus, it is possible that 
the results obtained also concern fibril elongation. In this view, experiments under 
physiological conditions that mimic the events occurring in vivo are necessary to 
conveniently distinguish intermediate formation from elongation. Such discrimination will 
allow testing the potential use of different drugs. 
For example, in Alzheimer's disease, a considerable effort has been made in the search of 
therapeutic drugs inhibiting polymerization. Molecules of structurally diverse types such as 
cyclodextrins (Camilleri et al, 1994), hemin (Howlett et al, 1997) and benzofurans 
(Howlett et al, 1999a) are able to prevent the formation of a biologically active form of Ap. 
Carbazole-type compounds were also investigated as inhibitors of Alzheimer p-amyloid 
fibril formation; a number of common structural features seemed to be associated with their 
inhibitory properties (Howlett et al, 1999b). Rifampicins were shown to inhibit in vitro Ap 
aggregation and to prevent its toxic effects in cultured rat PC 12 cells (Tomiyama et al, 
1994); hexadecyl-N-piperidinium bromide was reported to specifically inhibit AP(l-40) 
aggregation in vitro but not TTR or LAPP (Wood et al, 1996). Finally, antibodies have also 
been investigated and shown to reduce pathology in a mouse model of Alzheimer's disease 
(Bard etal, 2000). 
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6.4- Disaggregation of amyloid fibrils 
Therapeutic strategies can also aim at dissolving/disrupting mature amyloid fibrils (fourth 
strategy). 4'-deoxy-4'-iododoxorubicin (I-DOX) is an example of a drug fitting in this 
category. Recently, I-DOX has been proven useful as a tool for disrupting TTR amyloid 
fibrils (Palha et al, 2000b); it strongly interacts with TTR amyloid fibrils and is able of 
disrupting the characteristic fibrillar structure of amyloid into amorphous material. 
I-DOX has been previously shown to induce amyloid resorption in patients with AL 
amyloidosis (Gianni et al, 1995); nevertheless, in clinical trials not all AL patients 
responded to treatment (Merlini et al, 1999; Gertz et al, 2002). The activity of this drug 
was also tested against prion disease producing the delay of the clinical signs and the 
extension of survival time in an animal model (Tagliavini et al, 1997). In vitro experiments 
demonstrated that I-DOX interacts with different types of amyloid fibrils besides TTR and 
AL, including insulin, p2-microglobulin, Ap (Merlini et al, 1995) suggesting that the drug 
recognizes a motif common to all amyloid fibrils. Modeling studies using TTR Leu55Pro 
crystals, which represent an amyloid-like oligomer, indicated that the I-DOX iodine atom is 
trapped in a pocket located between the two p-sheets of the TTR monomer and with the 
aromatic-moiety long axis nearly perpendicular to the direction of the P-sheets (Sebastião et 
al, 2000). I-DOX cardiotoxicity is, however, a drawback for its use and efforts are under 
way to design non toxic analogues. 
Other compounds have been tested and shown to possess a disrupter activity. In vitro, 
anthracyclines were shown to affect AP fibril formation leading to the disassembly of pre-
formed fibrils (Forlorn* et al, 2001; Howlett et al, 1999b). In addition, Ap aggregation was 
also inhibited. Tetracyclines contain an extended hydrophobic core formed by aromatic 
moieties, allowing interactions with lipophilic residues of Ap. Tetracycline and its 
derivatives also contain a variety of polar substiruents that can form hydrogen bonds with 
specific residues of Ap (Forloni et al, 2001). It is conceivable that some of these motifs are 
still exposed in Ap fibrils and common to all type of fibrils, constituting the basis of these 
drug activity. Supporting this hypothesis is the work describing the ability of tetracyclines 
to prevent and reverse the prion protein (Tagliavini et al, 2000), indicating that the anti-
amyloidogenic capacity of tetracyclines is not exclusive of Ap. 
Suggestions that hydrophobic interactions mediated by the C-terminal portion of AP are 
important for fibril stability lead to the hypothesis that small hydrophobic compounds might 
be able to interfere with the stability of the fibrils. In this view, nitrophenols were tested and 
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shown to disaggregate previously formed AP fibrils (De Felice et al, 2001). In addition, 
they were also able to prevent A(3 aggregation. 
7- Concluding remarks 
The process leading to TTR amyloid formation is not fully understood and although a 
common mechanism is thought to underline all types of amyloid, it is expected that some 
differences occur between them. In spite of the possibility of generating TTR fibrils in vitro, 
their particular morphological features, kinetics and species present have not been subjected 
to an exhaustive study. Furthermore, the building blocks making up TTR fibrils remain to 
be elucidated. In FAP, TTR mature fibrils have been described as the causative agent of 
disease but the toxicity of amyloidogenic species generated throughout the different stages 
of amyloid formation is unknown. 
Among the key therapeutic steps, inhibiting tetramer denaturation/ intermediates formation 
and fibril elongation are presented as decisive concerning FAP treatment. However, the 
identification of drugs affecting these stages has been limited by the characterization of the 
structural determinants in TTR amyloidogenic species. TTR Leu55Pro crystal suggests that 
this natural mutant is an amyloidogenic intermediate presenting a tubular structure that 
might be similar to the TTR amyloid fibril structure. Another naturally occurring variant, 
TTR Tyr78Phe, was also shown to possess amyloid-like properties. The subsequent 
characterization of these two mutants concerning the formation of amyloid-like fibrils will 
be of great importance on the investigation of drugs affecting the amyloidogenic cascade. In 
addition, disaggregation of amyloid fibrils is also a possibility in FAP treatment. 
The present study addresses some of these unsolved questions. 
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Research Project 
Objectives 
Ohiectives 
1- Objectives 
The present project aimed at investigating aspects concerning amyloid structure and the 
mechanism of TTR amyloid formation, particularly the basic units that constitute the related 
fibrils and the characterization of the stages occurring from the native protein to the mature 
fibrils, and respective intermediary species. Another major proposal was the search for 
drugs affecting the amyloidogenic cascade. 
The delineated experiments had the following goals: 
A. Characterize the binding properties of a new amyloid fibril ligand (aprotinin). 
B. Characterize the assembly progression of TTR Leu55Pro fibrils formed under 
physiological conditions and determine the building blocks of TTR fibrils. 
C. Search for TTR amyloid fibrils disrupters and assess the toxicity of different TTR 
species. 
D. Characterize the early events in the amyloidogenic cascade and search for compounds 
inhibiting them. Develop a method for detecting TTR subtle conformational alterations 
during denaturation and aggregation. 
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Chapter I 
Aprotinin binding to amyloid fibrils 
Binding of aprptipin to amvloid fibrils 
Aprotinin binding to amyloid fibrils 
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Summary 
Different low molecular weight ligands have been used to identify amyloid deposits. 
Among these markers, the dyes Thioflavin T and Congo red interact specifically with the P-
sheet structure arranged in a cross-P conformation, which is characteristic of amyloid. 
However, the molecular details of this interaction remain unknown. When labeled with 
Technetium-99m, the proteinase inhibitor aprotinin has been shown to represent a very 
important radiopharmaceutical agent for in vivo imaging of extra-abdominal deposition of 
amyloid in amyloidosis of the immunoglobulin type. However, no information is available 
whether aprotinin binds other types of amyloid fibrils and on the nature and characteristics 
of the interaction. The present work shows aprotinin binding to insulin, transthyretin, p-
amyloid peptide and immunoglobulin synthetic amyloid fibrils by a specific dot blot ligand 
binding assay. Aprotinin did not bind amorphous precipitates and/or the soluble fibril 
precursors. A Ka of 2.9 uM"1 for the binding of aprotinin to insulin amyloid fibrils was 
determined by Scatchard analysis. In competition experiments, analogues such as an 
aprotinin variant, a spermadhesin and the soybean trypsin inhibitor were tested and results 
suggest that both aprotinin and the spermadhesin interact with amyloid fibrils through 
pairing of P-sheets of the ligands with exposed structures of the same type at the surface of 
amyloid deposits. An electrostatic component may also be involved in the binding of 
aprotinin to amyloid fibrils since important differences in binding constants are observed 
when substitutions Lys 15Val, Argl7Leu, Met52Glu are introduced in aprotinin and P-sheet 
containing acidic proteins, like the soybean trypsin inhibitor (STI), are unable to bind 
amyloid fibrils. We also tested binding of short peptides derived from aprotinin (APR1 and 
APR2) to different types of synthetic amyloid fibrils and showed specific binding to insulin, 
TTR Leu55Pro and AP amyloid fibrils; no binding was observed with the soluble 
counterpart or amorphous precipitates. On competition assays, the two peptides were shown 
to bind insulin fibrils with similar strengths and a Ka of 1.7 uM"1 was determined for APR2 
by Scatchard analysis. Together with aprotinin, these peptides can contribute to the 
development of future peptide radiopharmaceuticals for diagnosis of amyloidosis. 
Keywords: aprotinin, transthyretin, amyloid fibrils, spermadhesin 
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Introduction 
The term amyloidosis designates a group of clinically and biochemically diverse diseases 
mainly characterized by the extracellular deposition of insoluble fibrilar protein, leading to 
organ dysfunction and cell death. All the deposits bind the dye Congo red resulting in a very 
characteristic positive green birefringence when viewed under polarized light and yellow-
green fluorescence upon staining with Thioflavin S. Thioflavin T (Th T) interacts 
specifically with amyloid fibrils generating a characteristic fluorescent signal. The 
ultrastructural morphology of amyloid deposits is characteristically fibrilar, with 
unbranched appearance, consisting of a number of filaments aggregated side-by-side, 
forming fibers 75-100Â in diameter and with variable length. There is a predominant (Î-
pleated sheet structure and extensive antiparallel strands with their axes arranged 
perpendicular to the longitudinal axes of the fiber. Efforts are being developed to 
understand the detailed molecular organization of amyloid fibrils (for a review see Teplow 
etal, 1998). 
Antiproteases, together with several other elements, are known to be present in certain types 
of amyloid deposits (Campistol et al, 1992). Recently, the serine proteinase inhibitor 
aprotinin (a.k.a. bovine basic pancreatic trypsin inhibitor (BPTI), Trasylol®) has been 
successfully used for in vivo imaging of extra-abdominal light chain type amyloid (AL) 
(Aprile et al, 1995) allowing ascertainment of organ involvement with no need for biopsy 
procedures. This low molecular weight polypeptide (6,500Da) is composed of 58 amino 
acid residues arranged in a single chain and is selectively and stably accumulated in the 
kidney, being for that reason usually employed as a cortical renal tracer (Bianchi et al, 
1984). No information is available on the significance of antiprotease accumulation in 
amyloid deposits, whether aprotinin binds other types of amyloid and if so, what is the 
nature of this interaction. The purpose of the present study was to characterize binding of 
aprotinin and aprotinin peptides to synthetic amyloid fibrils, contributing to the 
comprehension of the nature of the amyloid-aprotinin/peptide interaction and to establish a 
sensitive binding assay for amyloid detection in vitro. For this purpose we used synthetic 
insulin fibrils, which are easily obtained and widely used in in vitro studies, synthetic fibrils 
from two transthyretin (TTR) mutants (TTR Val30Met and Leu55Pro), A0(l-42) fibrils and 
fibrils derived from a Bence Jones protein (BJP). 
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Experimental procedures 
Isolation and purification of TTR 
Mutant TTR VaBOMet and Leu55Pro proteins were produced in an E. coil expression system, 
isolated and purified as described elsewhere (Furuya et al, 1991). 
Preparation of amyloid fibrils 
Mutant TTR VaBOMet (2mg/ml) was incubated with 0.05M sodium acetate/0.1M KC1 pH 3.6 
for 48 hours at 25°C to form amyloid fibrils (Colon and Kelly, 1992). 
Bovine insulin (Sigma) dissolved at 10mg/ml in 0.5% acetic acid, pH 2 (with HC1) was 
incubated at 85°C for about 2 hours and then alternately frozen at -80°C and heated at 50°C to 
form amyloid fibrils (Bourke and Rougvie, 1972). After 5 freeze/thaw cycles, the fibrils were 
sedimented by centrifugation at 15,000g for 30 minutes in a microfuge and the pellet 
resuspended in water. 
Mutant TTR Leu55Pro protein was dialysed against water and concentrated to 5 mg/ml. 
After centrifugation at 15,000g for 30 minutes at 4°C this preparation produced a pellet, 
which was resuspended in PBS and incubated at 37°C overnight to produce amyloid fibrils. 
Ap-peptide amyloid fibrils were prepared by dissolving Ap\l-42) (Sigma) in 50% acetonitrile, 
0,1% trifluoroacetic acid and water at 1 mg/ml. Immediately after dissolution the preparation 
was lyophilized. After lyophilization, A(3(l-42) was dissolved in PBS at 0.5mg/ml and 
incubated at 37°C for 3 days. 
One Bence Jones protein (A.-BJP ZIM) (Eulitz et al, 1987) was digested with pepsin 
(Boehringer Mannheim) in 0.1 M sodium acetate buffer pH 3.5 to produce amyloid fibrils. The 
enzyme to protein ratio used was 1:1000 and the digestion was conducted at 37°C for 10 hours. 
The fibrils were sedimented by centrifugation at 15,000g at 4°C for 30 minutes. 
All types of amyloid fibrils were tested for Th T fluorescence: Excitation spectra were 
recorded on a Jasco FP-770 spectrofluorometer at 25°C with 30uM Th T (Fluka) in 50mM 
Glycine-NaOH buffer, pH 9.0 in 1ml assay volume. Preparations showing the characteristic 
novel excitation maxima at 450nm upon Th T binding were used in binding experiments. 
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Aprotinin-peptide synthesis 
Aprotinin peptides were synthesized by Q-BIOgene yielding 95% pure peptide. The peptides, 
APR1 and APR2, comprised aa residues 16-37 with a few modifications. 
Labeling with 12sIodine and with Biotin 
Aprotinin (bovine lung, Sigma) and aprotinin peptides (APR1 and APR2) were radiolabeled 
with 125I (Amersham) by the iodogen method, following the instructions of the supplier, which 
gave specific radioactivities of -48,000 and -25,000 cpm/ng protein, respectively. Aprotinin 
was biotinylated by incubating 2mg aprotinin with 1.5mg biotinyl-s-aminocaproic acid N-
hydroxysuccinimide (Pierce) in 2ml sodium phosphate buffer, pH 7.4, for 2 hours at 4°C with 
constant stirring, followed by exhaustive dialysis (Bilingsley et al, 1985). APR2 peptide was 
biotinylated by incubating 0.5 mg of peptide with 20 u.g of biotinyl-8-aminocaproic acid N-
hydroxysuccinimide (Pierce) in 2ml sodium phosphate buffer, pH7.4, for 2 hours at 4°C 
with constant stirring. The biotinylated peptide was purified in a Bio- Gel P2 column with 
PBS (BioRad). 
Dot Blot assay for aprotinin and APR2 binding 
Soluble protein, fibrils and trichloroacetic acid (TCA) precipitates of insulin and TTR 
VaBOMet, AP(l-42) and fibrils derived from Â.-BJP ZIM were immobilized onto a 
nitrocellulose membrane (Hybond™-C pure, Amersham). The membrane was then blocked 
with 5% powdered milk at room temperature for 1 hour, washed with phosphate buffered 
saline-Tween 20 solution (PBST) and incubated with 500,000 cpm ^^I-aprotinin. Finally, the 
membrane was washed with PBST and processed for autoradiography. Alternatively, the 
samples were immobilized onto the nitrocellulose membrane, blocked and then incubated with 
biotinylated aprotinin for 1 hour at 37°C. Bound aprotinin was visualized by streptavidin-
biotinylated horseradish peroxidase complexes (Amersham). 
Other soluble proteins tested included: p2-microglobulin (human urine, Calbiochem) and four 
different BJPs (Eulitz et al, 1987; Eulitz et al, 1982). 
To study APR2 ability to bind other types of amyloid fibrils, soluble protein, fibrils and 
trichloroacetic acid precipitates of insulin, Ap\l-42), and TTR Pro55 were tested following the 
procedures described above. 
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Reduction and alkvlation of aprotinin 
2mg of lyophilised wild type aprotinin were dissolved in 10ml 0.1 M Tris/HCl pH 8.0, 5% 
(v/v) 2-mercaptoethanol and incubated at room temperature, in the dark. After 16h, 5% 
(v/v) 4-vinylpyridine was added and the incubation proceeded for 45 minutes. The sample 
was then loaded onto a reverse-phase HPLC column (Bio-Sil 318-10, 250x4.6mm, BioRad) 
and eluted with a 15 minutes linear gradient from 15 to 60% (v/v) acetonitrile in 0.1% (v/v) 
trifluoroacetic acid at a flow rate of lml/min. The degree of S-pyridylethylation of the 
eluted fractions was determined by MALDI-MS analysis. The fractions containing fully 
modified aprotinin were dried and used for further experiments. 
Amyloid fibril - Aprotinin/APR competition binding assay 
64ug of insulin of fibrils were incubated with lOOul of cold aprotinin or APR solutions of 
variable concentrations ranging from 0 to 75uM containing a constant amount of labeled 125I-
aprotinin or APR (~50,000 cpm) in a final volume of 400ul. This mixture was incubated for 1 
hour at 37°C and then applied onto a 0.2|jm pore cellulose acetate membrane filter (Schleicher 
& Schuell) using a manifold system (Gibco BRL) under vacuum to separate fibril-
aprotinin/APR complex from free aprotinin or APR. The filter was washed 3 times with PBST 
and counted. Bound aprotinin or APR was expressed as a percentage of the total amount 
added. Each sample was tested in triplicate and each binding assay was performed at least 
twice. The binding data was analyzed using the GraphPad Prism computer version (version 
2.01). The equilibrium constant was determined by Scatchard analysis. In the case of aprotinin, 
competitive assays were also performed in the presence of Congo Red, Thioflavin T 
(concentrations ranging from 0 to 150|xM), soybean trypsin inhibitor (Type I-S, Sigma), 
aprotinin variant Lysl5Val, Argl7Leu, Met52Glu, sperrnadhesin PSP-II (Calvete et al, 1995; 
Varela et al, 1997), Lysozyme (chicken egg white, Sigma), cytochrome C (bovine heart, 
Sigma) and histones (calf thymus, Sigma) at concentrations ranging from 0 to 75uM. 
Protein concentration 
Protein concentrations were determined spectrophotometrically at 280 nm, using an extinction 
coefficient of 7.76 x 104M"1cm"1 based on a 55 kDa molecular weight for TTR (Van Jaarsveld 
et al, 1973), 5480 M'W"1 for aprotinin (wild-type and variant Lysl5Val, Argl7Leu, 
Met52Glu), 3400 M'W"1 for soybean trypsin inhibitor (type-I, Sigma) and 14890 M'W"1 for 
sperrnadhesin PSP-II. The extinction coefficients used for aprotinin, soybean trypsin inhibitor 
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and PSP-II were calculated with the program PeptideSort from the Wisconsin Package 
(version 9.0 Genetics Computer group (GCG), Madison, Wisconsin). Thioflavin and Congo 
red (Aldrich) concentrations were determined spectrophotometrically at 411nm using an 
extinction coefficient of 2.2 x 104 IVT'cm"1 and at 488nm using an extinction coefficient of 595 
g"1dm3cm"1 (as referred to in Merck Index), respectively. 
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Results 
Dot blot assay for binding of aprotinin to amvloid fibrils: 
In order to investigate the binding of aprotinin to different amyloid fibrils, a dot blot binding 
assay was set up. For that purpose, variable amounts of protein fibrils were immobilized on 
a nitrocellulose membrane, and as negative controls the soluble proteins and the same 
amount of protein precipitated with trichloroacetic acid (TCA) were used. 
Four different proteins were assayed: insulin, TTR VaBOMet, Ap-(l-42) and one BJP (k-
BJP ZIM). Figure 1 documents specific binding of aprotinin to amyloid fibrils: insulin (top 
row, a to d), TTR Val30Met (middle row), À-BJP ZIM and AP(l-42) in the bottom row. No 
binding was observed with all the four soluble proteins or amorphous materials. 
Other soluble proteins with high P-sheet content were also used as negative controls: human 
p2-microglobulin and four different BJP (K-BJP MEV, X-BJP ZIM, X-BJP HEN and K-BJP 
GRI) and they showed no binding to aprotinin (data not shown). 
Identical results were obtained when using biotinylated aprotinin (data not shown). 
Insulin 
TTR Val30Met 
A,-BJP ZIM/ 
Ap(l-42) ^r 
125 
Figure 1- Dot blot binding assay using I-aprotinin. 
Top row- insulin fibrils (100, 50, 25, lOug from a to d, respectively), lOOug of soluble (e) 
and TCA precipitated (f) insulin. Middle Row- TTR VaBOMet fibrils (100, 50, 25, lOug 
from a to d, respectively), lOOug of soluble (e) and TCA precipitated (f) TTR VaBOMet. 
Bottom Row- lOOug of amyloid fibrils derived from À-BJP ZIM. (a), lOOug of Ap(l-42) 
fibrils (b). 
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Characterization of Aprotinin binding 
Specific binding of aprotinin 
Aprotinin has three disulfide bonds, which are determinant for the maintenance of its three-
dimensional structure (Fritz et al, 1983). To further substantiate the specificity of aprotinin 
binding to amyloid fibrils, the capacity of fully reduced aprotinin to bind synthetic insulin 
fibrils was tested. Insulin fibrils (64ug) were incubated for 1 hour at 37°C with 50,000 cpm 
125I-aprotinin in the presence of increasing concentrations (0-75uM) of cold aprotinin or 
cold fully reduced and S-pyridylethylated aprotinin and then processed as described in 
material and methods. Specific binding of aprotinin to insulin fibrils was observed as cold 
aprotinin completely abolished binding of the radioligand (figure 2A). Reduced and S-
pyridylethylated aprotinin failed to bind insulin fibrils (data not shown). 
Competitive binding with Th T and Congo red 
Competitive assays using increasing concentrations (0-150jiM) of Th T or Congo red and 
i25I-aprotinin as the displaceable radioligand were also performed. No competition was 
observed between the dyes and aprotinin, indicating they bind differently to amyloid fibrils 
(data not shown). 
Characterization of the binding site of aprotinin 
In order to investigate whether aprotinin binding to amyloid fibrils involved the binding 
loop of the inhibitor, a competitive binding assay was performed in the presence of Soybean 
trypsin inhibitor (STI). No competition for binding was observed (data not shown). 
To further characterize the aprotinin-amyloid fibril interaction, an aprotinin variant 
(Lysl5Val, Argl7Leu, Met52Glu) and a spermadhesin (PSP-II) were also tested for their 
ability to bind amyloid fibrils. The results obtained for the competition assays were plotted 
against increasing concentrations of cold aprotinin, aprotinin variant or PSP-II, as 
competitor. The results are shown in figure 2A and each curve represents the mean values 
obtained for 3 replicates. Both aprotinin variant and PSP-II bind insulin fibrils in a saturable 
manner, but with a lower potency than aprotinin (IC5o = 10820.0nM, 690.0nM and 
391.2nM, respectively). Figure 2B represents the Scatchard analysis for aprotinin and a Ka 
value of 2.9 ± 0.37UM"1 was determinated for the fibril-aprotinin interaction. 
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Figure 2- Aprotinin binding to insulin fibrils. 
(A) competition curves. The symbols are: (■) aprotinin; (A) aprotinin variant Lys 15Val, Argl7Leu, 
Met52Glu; (D) spermadhesin PSP-II. (B) Scatchard analysis for aprotinin. A Ka value of 2.9 ± 
0.37(iM_1 was determined. 
64 
Binding of aprotinin to amvloid fibrils 
The aprotinin peptides APR1 and APR2 were tested for insulin fibrils binding. On 
competition assays, APR1 and APR2 were shown to bind insulin fibrils with similar 
strengths (figure 3). 
M 
■o s 
Si 
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Figure 3- Binding of APR1 and APR2 to insulin fibrils. Competition assay. 
(■) APR1 
(A)APR2 
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We determined the affinity constant for APR2 binding to insulin fibrils and found a Ka 
1.7 uM"1 (figure 4A and B). 
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Figure 4- APR2 binding to insulin fibrils. 
(A) Competition curve. (B) Scatchard analysis: a Ka value of 1.7 uM"1 was determined. 
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A dot blot assay using either 125I- or biotinylated APR2 showed specificity for amyloid 
since no binding was observed for soluble precursors or for amorphous precipitates of both 
insulin and TTR. Additionally, APR2 also bound p-peptide (1-42) fibrils- Figure 5A and 
5B. 
lOOng 50 25 10 
Insulin fibrils 
Soluble insulin 
TTR Leu55Pro fibrils 
Soluble TTR Leu55Pro 
100ng 50 25 10 
Insulin fibrils 
Soluble insulin 
Insulin TCA precipitate ■> 
TTR Leu55Pro fibrils 
P-peptide (1-42) 
Figure 5- Dot blot binding assay using APR2. 
(A)- Dot blot using 125I-APR2. (B) Dot blot using biotinylated APR2. Specific binding of APR2 to 
insulin, TTR Leu55Pro and Ap fibrils was observed; No binding was detected to soluble insulin, 
TTR Leu55Pro and insulin TCA precipitates. 
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Discussion 
The process by which certain soluble proteins aggregate to form amyloid fibrilar structures 
is at present the subject of intense research. Amyloid fibrils can be produced in vitro from 
different protein precursors indicating that they have an intrinsic amyloidogenic potential. 
Ex vivo amyloid fibrils have other proteins associated, such as particular basement 
membrane components. These common components might recognize structural features 
shared by different amyloid proteins. In this context, molecular studies on the interaction of 
amyloid fibrils with different ligands are important to reveal commonalities among amyloid 
structures and subunit assembly pathways. 
Here we reported aprotinin binding to insulin, TTR, AP(l-42) and immunoglobulin 
synthetic fibrils and investigated biochemical and structural features of the aprotinin-
amyloid interaction. Due to its size and availability for clinical use, aprotinin constitutes an 
ideal tracer for amyloid imaging purposes. Our results showed that aprotinin is very specific 
for the four types of amyloid fibrils tested since no interaction with soluble or TCA 
precipitates of amyloid precursor proteins were observed. 
Aprotinin interacted more strongly with amyloid fibrils formed from insulin than from TTR 
(data not shown). The same trend is observed for the relative interaction between Thioflavin 
T and insulin and TTR fibrils (LeVine, 1995). This may be the result of structural 
differences in fibrils from different precursors, most likely a different accessibility of the 
structures recognized by aprotinin and thioflavin or small differences in the aminoacid 
sequence present in the binding region of the amyloid proteins. Alternatively, it may be the 
result of different ratios fibrils/amorphous precipitates present in the sample. In fact, it is 
known that the efficiency of fibril formation in vitro is much higher for insulin (with almost 
100% yield) than for TTR, making insulin fibrils an optimal tool to test amyloid binding 
reagents. 
The specific binding to amyloid deposits displayed by aprotinin has been previously 
observed for certain organic dyes such as Thioflavin and Congo red. These compounds are 
proposed to interact with the (3-sheet structure characteristic of amyloid. However, 
Thioflavin T and Congo red did not compete with aprotinin for binding to amyloid fibrils. 
This suggests that the interactions amyloid-aprotinin and amyloid-organic dyes are 
essentially different in nature. 
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Soybean trypsin inhibitor (STI) is, like aprotinin, a proteinaceous inhibitor of serine 
proteinases. Both inhibitors display canonical proteinase-binding loops, and they do inhibit 
similar proteinases. Competition binding assays with STI and aprotinin revealed no 
competition for binding to amyloid fibrils. This rules out the possibility that the rather 
strong binding of aprotinin to amyloid deposits occurs through the proteinase binding loop 
of the inhibitor and/or is an interaction of the proteinase: inhibitor type. 
As aprotinin has a strong basic character (pl=9.1), while TTR, insulin, AP-peptide and 
immunoglobulins (and presumably also their fibrils) are acidic, the interaction we observed 
could be simply electrostatic. To rule out this possibility, the interaction of several proteins, 
both basic and acidic, with amyloid fibrils was tested. We observed that the aprotinin 
mutant Lys 15Val, Argl7Leu, Met52Glu displays a lower affinity towards amyloid fibrils 
than the wild-type molecule. Since this mutant is a proteinase inhibitor as active as the wild-
type molecule, albeit of a different specificity, we assume that its three-dimensional 
structure is unchanged. However, as a result of the triple mutation the electrostatic potential 
at the surface of the protein is certainly altered, resulting in a less basic molecule (pl=8.2). 
Other basic proteins were tested for fibrils binding, with varying results. STI (pl=4.7) did 
not bind at all, while PSP-II (pl=8.9; IC50=690nM), hen egg while lysozyme (pl=9.2; 
IC5o=2580.5nM), horse heart cytochrome C (pl=10.4; IC5o=905.7nM) and bovine histone 
(pl=ll-12; IC5o=601.8nM) did. It must be noted that all the basic proteins tested bound 
amyloid fibrils with different affinities that do not correlate directly with their basicity. 
Thus, PSP-II, the most acidic protein in the experiment, binds more strongly than the hen 
egg white lysozyme and horse heart cytochrome C; on the other hand, the highly basic 
bovine histones are only slighter better amyloid fibrils ligands than PSP-II, despite having a 
2 to 3 full units higher pi. In our opinion, this completely rules out the hypothesis of pure 
electrostatic binding in the amyloid-aprotinin complex, suggesting other type of forces 
involved in the interaction. 
In aprotinin, a central anti-parallel two-stranded p-sheet and a C-terminal a-helix form the 
core of the molecule to which the proteinase-binding loop is attached. The central p-sheet 
constitutes the most prominent secondary structure element of aprotinin (figure 3). Upon 
reduction and modification of the three disulfide bonds of aprotinin with 4-vinylpyridine the 
inhibitor fails to bind to amyloid deposits. This is mostly likely due to the alteration of the 
three-dimensional structure of aprotinin induced by reduction and S-pyridylethylation. 
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Analysis of X-ray diffraction patterns from amyloid fibrils reveals a cross-P conformation 
and it has been suggested that interactions between p-sheets of adjacent molecules are 
involved in amyloid formation (Blake and Serpell, 1996; Sebastião et al, 1998; Inoue et al, 
1998; Lansbury et al, 1995) (see figure 3). Based on the above observations, we propose a 
similar mechanism for the interaction of aprotinin with amyloid fibrils, through pairing of 
P-sheets of the ligands with exposed structures of the same type at the surface of amyloid 
deposits. This is supported by the fact that the proteins found to bind more efficiently to 
amyloid fibrils (aprotinin and PSP-II) are those that possess secondary P-structure, while in 
egg hen white lysozyme, horse heart cytochrome C and bovine histones are completely 
devoid of these. 
Figure 3- Schematic representation of 
the three-dimensional structure of 
aprotinin (PBD entry 5PT1), porcine 
spermadhesin II (PSP-II; PDB entry 
1SPP), and transthyretin (TTR; PDB 
entry 2PAB). The secondary structure 
elements are shown. The location of the 
aprotinin residues mutated in the 
variant used is also indicated. Figure 
produced with SETOR (Evans, 1993). 
The aprotinin peptides tested were also shown to bind amyloid fibrils derived from insulin, 
TTR Leu55Pro and P-peptide. The peptides bound insulin fibrils with similar strengths and 
- Aprotinin 
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with the same magnitude as aprotinin. Although we cannot predict the structure of these 
peptides, we have calculated the theoretical pi (mtp://us.expasv.org/tools/pi tool.html) 
resulting in 9.31 for APR1 and 9.99 for APR2. Therefore, the electrostatic effect is still 
present and probably partially responsible for the binding to amyloid fibrils. 
In summary, binding of aprotinin and related structures to amyloid is proposed to have two 
major components, namely interactions between p-structure elements of both fibrils and 
ligands and an electrostatic effect. The first component is suggested by the observed 
impairment of aprotinin binding upon disruption of its three-dimensional structure and by 
the significantly weaker binding of exclusively a-helical proteins. Important differences in 
binding constants when substitutions Lysl5Val, Argl7Leu, Met52Glu are introduced in 
aprotinin, a general binding observed for basic proteins, and the inability of P-sheet 
containing acidic proteins (e.g. STI) to bind amyloid fibrils, are in favor of an electrostatic 
component in the mechanism of binding. Molecular modeling and crystallographic studies, 
together with site-directed mutagenesis of amyloidogenic proteins are underway in order to 
fully characterize the interaction of this proteinase inhibitor with amyloid fibrils. 
Acknowledgments 
We thank Paul Moreira for excellent technical assistance in the preparation of recombinant 
TTR VaBOMet. Aprotinin variant Lysl5Val, ArgHLeu, Met52Glu was a generous gift of 
Dr. Ernies Auerswald (LMU, Munich, Germany), PSP-ÏÏ and BJPs were kindly provided by 
Dr. Juan J. Calvete (Instituto de Biomedicina, C.S.I.C., Valencia, Spain) and Dr. Reinhold P. 
Linke (Max-Planck-Institut fur Biochemie, Martinsried, Germany), respectively. This work 
was supported in part by a grant (SAU/1290/95) and PhD scholarships (BD/15725/98 to I. 
C. and BD/9782/96 to P. J. B. P.) from Fundação para a Ciência e a Tecnologia, Portugal. P. 
J. B. P. is a Programa Gulbenkian de Doutoramento em Biologia e Medicina fellow. 
71 
Chapter I I 
Transthyretin f ibriI logenesis entails the assembly of 
monomers: a molecular model for in vitro assembled 
transthyretin amyloid-like fibrils 
Dynamics of transthyretin fibril assembly 
Transthyretin fibrillogenesis entails the assembly of monomers: A molecular model for 
in vitro assembled transthyretin amyloid-like fibrils 
Cardoso, I.1'2, Goldsbury, C, S.3, Mûller, S. A.3, Olivieri, V.3, Wirtz, S.3, 
Damas, A. M.2'4, Aebi, U.3, and Saraiva M. J. ' 
1 Amyloid and 4 Molecular Structure Units, Institute for Molecular and Cell Biology, 
Institute for Biomedical Sciences of Abel Salazar, Porto University, Porto, Portugal and 
M. E. Mueller Institute for Structural Biology, Biozentrum, University of Basel, Switzerland 
Running title: Dynamics of transthyretin fibril assembly 
Correspondence to: M. J. Saraiva, Amyloid Unit, IBMC, Rua do Campo Alegre, 823, P-
4150-180 Porto, Portugal. Fax: +351 22 609 9157, Tel: +351 22 607 4900, E-mail: 
mi saraiv(S>,ibmc.up.pt 
72 
Dynamics of transthyretin fibril assembly 
Abstract 
Extracellular accumulation of transthyretin (TTR) variants in the form of fibrillar amyloid 
deposits is the pathological hallmark of Familial Amyloidotic Polyneuropathy (FAP). The 
TTR Leu55Pro variant occurs in the most aggressive forms of this disease. Inhibition of 
TTR wild-type (WT) and particularly TTR Leu55Pro fibril formation is of interest as a 
potential therapeutic strategy and requires a thorough understanding of the fibril assembly 
mechanism. To this end, we report on the in vitro assembly properties as observed by 
transmission electron microscopy (TEM), atomic force microscopy (AFM) and quantitative 
scanning transmission electron microscopy (STEM) for both TTR WT fibrils produced by 
acidification, and TTR Leu55Pro fibrils assembled at physiological pH. The morphological 
features and dimensions of TTR WT and TTR Leu55Pro fibrils were similar, with up to 300 
run long, 8 nm wide fibrils being the most prominent species in both cases. Other species 
were also evident; 4 - 5 nm wide fibrils, 9 - 10 nm wide fibrils and oligomers of various 
sizes. STEM mass-per-length (MPL) measurements revealed discrete fibril types with 
masses of 9.5 and 14.0 ± 1.4 kDa/nm for TTR WT fibrils and 13.7, 18.5 and 23.2 ± 1.5 
kDa/nm for TTR Leu55Pro fibrils. These MPL values are consistent with a model in which 
fibrillar TTR structures are composed of 2, 3, 4 or 5 elementary protofilaments, with each 
protofilament being a vertical stack of structurally modified TTR monomers assembled with 
the 2.9 nm axial monomer-monomer spacing indicated by X-ray fibre diffraction data. Ex 
vivo TTR amyloid fibrils were also examined. From their morphological appearance 
compared to these, the in vitro assembled TTR WT and Leu55Pro fibrils examined may 
represent immature fibrillar species. The in vitro system operating at physiological pH for 
TTR Leu55Pro and the model presented for the molecular arrangement of TTR monomers 
within fibrils may, therefore, describe early fibril assembly events in vivo. 
Keywords: AFM, atomic force microscopy/ amyloid fibrils/ TEM, transmission electron 
microscopy/ TTR, transthyretin/ STEM, scanning transmission electron microscopy 
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Introduction 
Familial amyloidotic polyneuropathy (FAP) is an autosomal dominant disorder 
characterised by the extracellular deposition of fibrillar protein (amyloid) with special 
involvement of the peripheral nerve. The major protein component of the amyloid deposits 
in FAP is a transthyretin (TTR) variant. To date, about 80 different TTR mutations related 
to amyloid deposition, and 10 non-pathogenic mutations have been described (Saraiva, 
2001). TTR is a 55-kDa tetrameric serum protein involved in the transport of thyroid 
hormones and vitamin A. Each 14-kDa monomer within the functional tetramer contains a 
small helical segment and two beta-sheets composed of the strands DAGH and CBEF 
(Blake et al, 1978). The most pathogenic FAP variant known, Leu55Pro, causes a very 
aggressive form of the disease (Jacobson et al, 1992). Biochemical studies indicate lower 
tetramer stability for this variant compared to the wild-type (WT), as measured by a lower 
activation barrier for tetramer dissociation (Lashuel et al, 1998). The recent finding that 
TTR Leu55Pro crystallises with different packing contacts compared to TTR WT is in 
agreement with this observation; while the unit cell of TTR WT crystals contains a single 
TTR dimer (Blake et al, 1978), the unit cell of TTR Leu55Pro crystals contains eight 
monomers (Sebastião et al, 1998). The dissociation of tetramers into monomers is thought 
to mediate TTR fibril formation (Lashuel et al, 1998). Indeed, the fact that TTR Leu55Pro 
crystals are able to bind thioflavin-T, an amyloid binding dye, suggests that they may 
already have fibril-like properties (Sebastião et al, 2000). The leucine substitution at 
residue 55 disrupts the hydrogen bonds between beta-sheet strands D and A, exposing new 
surfaces which are involved in aggregation. The consequent ready formation of fibrils by 
TTR Leu55Pro in vitro under physiological conditions makes this variant an important tool 
in the study of amyloidogenesis and fibril structure. 
As revealed by electron microscopy, amyloid deposits generally consist of straight or coiled 
fibrils, 7.5 to 10 nm in width and up to several microns in length. The morphology of ex 
vivo TTR fibrils appears to depend on the tissue localization as well as to some degree on 
the extraction technique employed and the presence of other non-TTR components. The 
deposits are characterised by certain tinctorial properties such as a green birefringence under 
polarised light after staining with Congo red, and by a "cross-beta" X-ray fibre diffraction 
pattern (Eanes and Glenner, 1968). Although the cross-beta model has long been accepted 
as the consensus structure for all forms of amyloid, the details of the molecular subunit 
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packing for each respective form are still not fully understood. Early electron microscopy 
investigations of isolated amyloid revealed the existence of a hierarchical assembly system 
(Shirahama and Cohen, 1967). Accordingly, elementary sub-fibres associate to form higher 
order fibrils. These sub-fibres and fibrils have been given a variety of names in the 
literature: "filament", "fibril", "sub-protofibril", "protofibril", "protofilament". For 
simplicity, we reduce to two terms and herein define the smallest sub-fibres of TTR "fibrils" 
as "elementary protofilaments". In combination with Eanes and Glenner's cross-beta 
structural model, this concept of an amyloid protofilament first proposed by Shirahama and 
Cohen, has led to recent attempts at molecular modelling of amyloid fibrils (Blake and 
Serpell, 1996; Lazo and Downing, 1998; Chaney et al, 1998; Malinchik et al, 1998; Inouye 
étal, 1998). 
There are conflicting molecular definitions of the elementary protofilament in the TTR 
literature. X-ray fibre diffraction studies of vitreous FAP TTR (VaBOMet variant) amyloid 
fibrils using synchrotron radiation, have lead to two interpretations of the structure both 
consistent with the cross-beta model. According to Blake and Serpell (Blake and Serpell, 
1996) the protofilament core is a continuous beta-sheet helix composed of four parallel, 
twisted beta-sheets resulting in an elemantary protofilament 5 to 6 nm wide with a helical 
repeat of 11.5 nm. Considerable structural reorganization of the TTR molecule from its 
native tetrameric state must occur to form this protofilament "building block" that is not 
only either monomelic or dimeric but also has an altered beta-sheet structure. Four of the 
elementary protofilaments are considered to associate around a central hollow core to form 
the four-fold symmetric fibrils observed by electron microscopy (Serpell et al, 1995). An 
alternative interpretation of the same data has been proposed by Inouye et al (1998). In this 
model, each TTR protofilament is composed of a single chain of axially aligned TTR 
monomers. Although there are also four protofilaments in the mature TTR fibril in this 
scenario each protofilament contains just two twisted beta-sheets. Other models suggest the 
formation of TTR amyloid fibrils from different building blocks: The beta-slip concept 
proposes a tetrameric subunit that is distorted but intact (Eneqvist et al, 2000) and Serag et 
al (2001) suggest that TTR amyloid fibrils assemble from dimeric subunits or a multiple of 
such, rather than from rearranged monomers. These models are conflicting. The precise 
nature of the building block (tetrameric, dimeric or monomelic) and its arrangement within 
the architecture of the fibril remain to be defined. 
The mechanism that leads to TTR amyloid fibril formation is also poorly understood. In 
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most cases the assembly process has been studied under acidic rather than physiological 
conditions. Kelly and co-workers have suggested that in vivo fibril formation takes place at 
a low pH like that found in the lysosome (McCutchen et al, 1993). They report that in vitro 
the variant Leu55Pro forms "protofilaments" at physiological pH but not mature fibrils 
(Lashuel et al, 1999) and consider the TTR WT fibrils produced by acidification to be 
mature. Thus, the universal definition of the elementary TTR protofilament and how it 
relates to mature fibrils remains unclear. We seek to clarify these issues and present an 
ultrastructural characterization of m vitro assembled TTR WT and TTR Leu55Pro fibrils. 
In the detailed electron microscopy study outlined in this report, including mass-per-length 
(MPL) measurements of in vitro assembled TTR fibrils, we clearly show these to be 
polymorphic, and propose that they are composed of 2, 3, 4 and 5 elementary 
protofilaments. Furthermore, consistent with our data and that of others (Inouye et al, 1998; 
Quintas et al, 2001) we propose that each protofilament contains two twisted beta-sheets 
and is a single vertical stack of structurally modified TTR monomers. 
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Materials and Methods 
Isolation and purification of TTR 
TTR WT and mutant TTR Leu55Pro proteins were produced in an E. coli expression system 
(Furuya et al, 1991), isolated and purified as previously described (Almeida et al, 1997). 
Briefly, after growing the bacteria, the protein was isolated and purified by preparative gel 
electrophoresis after ion exchange chromatography. Protein concentration was determined 
using the Lowry method (Lowry et al, 1951 ). 
Preparation of amyloid fibrils 
To initiate amyloid fibril formation, TTR WT (2 mg/ml) was incubated in 0.05 M sodium 
acetate pH 3.6, for 72 hours at room temperature (Colon and Kelly, 1992). The sample was 
then centrifuged at 15,000 g for 30 minutes at 4°C and the pellet obtained was washed and 
re-suspended in MilliQ water and incubated at 37°C. 
TTR Leu55Pro was dialysed against water pH ~ 7.0 and concentrated to 5 mg/ml. At this 
point the preparation was centrifuged at 15,000 g for 30 minutes at 4°C. The pellet was then 
washed and re-suspended in phosphate buffer pH 7.4 (PBS) at 2 mg/ml and incubated at 
37°C. 
At given time points, the samples were visualised for the presence of amyloid fibrils by 
TEM and/or AFM. The fibril concentrations were assessed by the Lowry method (Lowry et 
al, 1951). 
Native TTR amyloid vitreous fibrils were obtained from a FAP patient expressing the TTR 
VaDOMet mutant, who had been subjected to vitreoctomy. The sample was negatively 
stained for TEM observation. 
A peripheral nerve biopsy obtained from a FAP TTR VaBOMet patient was fixed in 2.5% 
glutaraldehyde for 3 hours at room temperature, rinsed in PBS and postfixed with 1% 
osmium tetroxide for 1.5 hours at 4 °C. The specimen was then cut into 3-mm3 fragments, 
which were subsequently dehydrated in a graded series of ethanol/water mixtures (70% to 
100 % ethanol) and embedded in Epon. Polymerisation was carried out at 50°C overnight. 
Transmission electron microscopy (TEM) 
For visualization by TEM aliquots of the recombinant protein samples were diluted (1:50) 
with water (TTR WT) or PBS buffer (TTR Leu55Pro) and immediately adsorbed to glow-
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discharged carbon-coated collodion film supported on 200-mesh copper grids. The vitreous 
sample was used without dilution. For negative staining, the grids were then washed with 
deionised water and stained with 0.75% uranyl formate. For metal shadowing, freeze-dried 
specimens were first uni-directionally shadowed with tungsten at an elevation angle of 25° 
and then uniformly coated with a thin layer of carbon evaporated from above using a 
Balzers machine (BAF 301). In both cases the grids were visualised at a defined orientation 
relative to the electron beam in order to determine the direction of fibril coiling. A Hitachi 
7000, lOOkV was employed. Measurements of the fibril widths and lengths were made from 
enlarged prints of the electron micrographs using a magnifying glass with a built-in 
calibrated ruler. 
Ultra-thin (450 nm) sections of the peripheral nerve fragments were collected on carbon 
coated nickel grids (Agar) and the indirect immunogold technique was applied. Once on the 
grids, the Epon sections were exposed to a saturated aqueous solution of sodium 
metaperiodate for 1 hour. Next, they were floated on the surface of a drop of 1% bovine 
serum albumin (BSA, Sigma) in PBS followed by diluted (1:50, 1% BSA in PBS) rabbit 
anti-human transthyretin antibody (Dako) for 1 hour at room temperature. The grids were 
washed in PBS and exposed to goat anti-rabbit immunoglobulins (1:15, 1% BSA in PBS) 
that had been coupled to 5-nm gold particles (Amersham). They were washed again in PBS 
and Tris-HCl buffer, pH 7.6 and counterstained with uranyl acetate for 4 minutes followed 
by lead citrate for 15 seconds. The grids were examined in a JEOL 100 CX II electron 
microscope operated at an acceleration voltage of 60 KV. 
Atomic force microscopy (AFM) 
All AFM images were recorded in liquid. A diluted aliquot (50 ul, 1:500 dilution in water 
for TTR WT and PBS for TTR Leu55Pro fibrils) of the TTR fibril preparation was adsorbed 
to a freshly cleaved mica substrate for 15 minutes. The substrate was then rinsed with the 
sample buffer (but not dried) and transferred to the fluid cell of the AFM (Nanoscope HI 
multimode AFM equipped with a J- or E- scanner, Digital Instruments). Imaging was 
carried out in water (TTR WT) or PBS buffer (TTR Leu55Pro). Tapping mode images (512 
x 512 pixels) were obtained using 100 um oxide sharpened cantilevers with a nominal 
spring constant of 0.38 N/m (Digital Instruments). A scan speed of 2 Hz, drive amplitude of 
160-200 mV and resonant frequency of 8.7-9.5 Hz were employed. The scan sizes ranged 
between 0.5um and 5.0 um. 
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Scanning transmission electron microscopy (STEM) 
In the dedicated scanning transmission electron microscope a small electron beam is raster 
scanned over the specimen. The electrons elastically scattered from each point (pixel) of the 
scan are collected by an annular dark-field detector capable of single electron counting. In a 
calibrated instrument, knowledge of the incident electron dose and the collection efficiency 
allows the mass irradiated to be calculated. A Vaccuum Generators HB5 STEM interfaced 
to a modular computer system (Tietz Video and Image Processing systems) and calibrated to 
measure the mass of protein samples (Engel, 1978; Mûller et al, 1992) was employed in the 
present experiments. The microscope was operated at an acceleration voltage of 80 kV. 
For mass measurement, 7-ul aliquots of the TTR WT and TTR Leu55Pro samples were 
diluted with water and PBS, respectively, and adsorbed for 1 min to glow discharged, thin 
(approximately 3 nm) carbon films which spanned a thick fenestrated carbon layer covering 
200-mesh/inch, gold plated copper grids. The grids were then blotted, washed with 5 drops 
of water to remove buffer salts and freeze-dried at -80°C and 5xl0"8 Torr, overnight in the 
microscope. Isolated tobacco mosaic virus particles (kindly provided by Dr. Ruben Diaz-
Avalos, Institute of Molecular Biophysics, Florida State University, USA) adsorbed in the 
same way to a separate grid, washed on 5 drops of 0.01 M ammonium acetate and air-dried, 
served as an instrument control for each experiment. 
Low dose, 512x512 pixel, digital dark-field images were recorded from the unstained 
samples at a nominal magnification of 200 OOOx. The images were evaluated using the 
program package IMPSYS as outlined by Mueller et al (Mûller et al, 1992). Accordingly, 
fibril segments suitable for mass-per-length (MPL) measurement were selected in square 
boxes, tracked and their length calculated. The total scattering within an integration box 
matched to their width was then calculated, the background scattering of the carbon support 
film subtracted and the average MPL determined. The corresponding mass profile was 
displayed for each fibril stretch and the width at half maximum height of the mass profile 
(termed the full width half maximum, FWHM) assessed. The accuracy of the FWHM 
measurement was limited by the pixel size at the magnification used, ~ 0.9 nm. 
In addition, beam induced mass-loss was experimentally determined for the TTR Leu55Pro 
sample by repeatedly scanning the same region and monitoring the change in fibril MPL 
(Mûller et al, 1992). The relationship obtained, y = 100 - 0.01613 x, where y is the residual 
mass percent and x the incident electron dose in electrons/nm2, was assumed to hold for all 
samples. The recording doses were 356 ± 24 electrons/nm2 and 369 ± 24 electrons/nm2 for 
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the two TTR WT samples and 353 ± 32 electrons/nm2 for the TTR Leu55Pro sample. In 
each case, making the correction increased the MPL values by almost 6%. The resulting 
absolute values were displayed in histograms and described by Gauss curves. 
Finally an error assessment was made considering both the standard error (SE) of each MPL 
measurement and the 5% uncertainty in the STEM calibration (CU). The SE was estimated 
for each peak according to the equation, SE = SD/(Vn), where n is the number of segments 
included in the peak and SD is the standard deviation of the results. The SE and CU were 
combined by calculating the square root of the sum of the squares. 
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Results 
Assembly of TTR WT fibrils 
Solutions of recombinant TTR WT were prepared at acidic pH and incubated at 37 °C for 11 
weeks. Fibrils readily formed during this time. Their assembly dynamics and structure was 
studied by withdrawing aliquots of the solution at various stages and examining them by 
negative stain transmission electron microscopy (TEM) (Figures 1A-C). The protein 
remained non-fibrillar in control experiments made at physiological pH; even after 4 weeks 
incubation at 37° only very small recombinant TTR WT oligomers (probably tetramers) 
were observed on the microscopy grids (Figure ID). 
The fibrillar structures formed at acidic pH were polymorphic (Figures 1A, B and C). 
Prominent among them were 8 nm wide fibrils, which lengthened with time becoming up to 
300 nm long (arrow, Figure 1A; white arrow, Figure IE). At least three other structures 
were also present during the first 6 weeks: 9-10 nm wide fibrils (arrowhead, Figure IB; 
black arrow, Figure IE); 4 - 5 nm wide fibrils (arrow, Figure IB; white arrowhead, Figure 
IE); and oligomers with diameters of approximately 5 or 8 nm (arrowheads, Figure 1A, 
black arrowheads Figure IE). As shown in Figure IF, occasionally the lateral association 
and coiling together of 4 - 5 nm wide fibrils was observed. Freeze-drying followed by 
unidirectional metal shadowing and TEM (Figure 1G), and atomic force microscopy (AFM) 
(FigurelH), both revealed small subsets of 8 nm wide fibrils twisted in a left-handed sense 
with an axial substructure of 17 nm. A longer twist appeared in figure IF, which probably 
does not represent an end point of fibril coiling. After approximately 6 weeks incubation, 
the fibrils started to aggregate by lateral association forming bundles (Figure 1 C). This was 
frequently accompanied by additional intertwining giving rise to tangles. Fibril bundles had 
widths of up to 20 nm; length measurements were not possible due to their tangled nature. 
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Figure 1- Assembly of TTR WT fibrils produced by acidification. 
(A-C) Negative stain TEM images documenting the polymorphism observed over an 11-week period of TTR 
WT fibril assembly at acidic pH and 37°C: 8 nm wide fibril (arrow, panel A), oligomers approximately 5 or 8 
nm wide (arrowheads, panel A), a 4 nm wide fibril (arrow, panel B) and a thicker fibril 9 - 10 nm wide 
(arrowhead, panel B). (D) TTR WT after incubation at physiological pH and 37°C for 4 weeks. Scale bar (A-
D) = 100 nm. (E) Image showing the different species present in the acidified TTR WT fibril sample at higher 
magnification: Oligomers of different size (black arrowheads), an 8 nm wide fibril (white arrow), a 4 nm 
wide fibril (white arrowhead) and a thicker fibril 9-10 nm wide (black arrow). (F) Two 4 - 5 nm wide fibrils 
present after approximately 7 weeks incubation, associating laterally and coiling together. The end-point of 
fibril coiling has probably not yet been attained. (G) TEM image of a TTR WT fibril formed after 6 weeks 
incubation, which has been freeze-dried and unidirectional shadowed with tungsten. A 17-nm left-handed axial 
substructure is clearly visible. (H) Tapping mode AFM image of the TTR WT fibrils formed after 6 weeks 
incubation. The fibrils were adsorbed to a mica surface and imaged in water. Again a 17-nm left-handed axial 
substructure is clearly visible. Scale bar (E- H) = 50 nm. 
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Assembly of TTR Leu55Pro fibrils 
An analogous morphological study was carried out at physiological pH for the TTR 
Leu55Pro variant. Figure 2 is representative of the assembly progression occurring over 11-
weeks. The morphological development was similar to that followed by the TTR WT 
preparation on acidification, starting with abundant short fibrils and oligomers (Figure 2A 
and B) and evolving to longer fibrils (Figure 2C, D and E). Although there was substantially 
more tangling, after 11 weeks incubation the assembly of new fibrils appeared to have 
reached a steady state (compare Figures 2D, E and F). Eight nanometer wide fibrils were 
again the most prominent species throughout (Figure 2B and C, arrow), interestingly, at 
equivalent time points the relative abundance of the various fibril species was different in 
the TTR Leu55Pro and TTR WT preparations. In particular, 4 - 5 nm wide fibrils were 
rarely detected on the TTR Leu55Pro grids. Furthermore, after extended incubation periods 
the TTR Leu55Pro fibrils produced at physiological pH (Figure 2F) appeared to undergo a 
lower degree of bundling than the TTR WT fibrils formed by acidification (Figure 1C). 
As revealed by unidirectional metal shadowing (Figures 2G and H, arrow), like TTR WT 
fibrils TTR Leu55Pro fibrils also occasionally exhibited a 17 nm axial sub-structure with a 
left-handed twist. TTR Leu55Pro fibrils adsorbed to mica and imaged in buffer solution by 
AFM had similar lengths to those imaged by TEM, but were slightly wider (Figure 2 I). This 
apparent width difference may be explained by the dependence of the width measured by 
AFM on the size and shape of the scanning tip used for imaging, which in this case did not 
allow the visualization of any axial substructure. 
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Figure 2- Assembly of TTR Leu55Pro fibrils produced at physiological pH. 
(A - F) Negative stain TEM images documenting the polymorphism observed over an 11-week 
period of TTR Leu55Pro fibril assembly at physiological pH and 37°C: 8 nm wide fibril (arrow, 
panels B and C), oligomers approximately 5 or 8 nm wide (panel B), a 4 nm wide fibril 
(arrowhead, panel B). Scale bar (A- F) = 100 nm. (G, H) TEM image of a TTR Leu55Pro 
preparation after freeze-drying and unidirectional metal (tungsten) shadowing. A left-handed 
substructure can be distinguished on some fibrils (arrow). Scale bar (G, H) = 50 nm. (I) Tapping 
mode AFM image of TTR Leu55Pro fibrils after 6 weeks incubation. The fibrils were adsorbed to a 
mica surface and imaged in PBS buffer. No substructure was resolved. Scale bar (I) = 100 nm. 
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A more detailed analysis of the in vitro fibril growth rate was made since TTR Leu55Pro is 
of particular interest, occurring in the most aggressive forms of FAP, and it is possible to 
follow the assembly at physiological pH. The frequency distribution of TTR Leu55Pro fibril 
length is shown in Figure 3. The measurements were made at the time points examined by 
TEM in Figure 2A-E; 100 fibrils were measured in each case. The average fibril length 
versus incubation time is plotted in Figure 3F. This graph illustrates that TTR Leu55Pro 
fibril growth was sigmoidal in character and that the fastest rate of fibril growth occurred 
between 11 and 18 days corresponding to an elongation rate of 9.2 nm/day. Unfortunately 
the need for acidification prohibited the same experiment for TTR WT. 
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Figure 3- Fibril elongation. 
Frequency distribution of fibril length (graphs A-E) and growth rate (F) of TTR Leu55Pro fibrils 
followed over a 32-day period. The fastest rate occurred between days 11 and 18 corresponding to 
an elongation of 9.2 nm/day. 
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Mass-per-length analysis 
To estimate the arrangement of TTR molecules within the fibrils, their mass-per-length 
(MPL) was measured by quantitative scanning transmission electron microscopy (STEM). 
For this purpose, TTR WT fibrils formed under acidic conditions and TTR Leu55Pro fibrils 
formed under physiological conditions, were incubated for approximately 6 weeks at 37°C, 
adsorbed to thin carbon films, freeze-dried and imaged. As in negative stain TEM, tangling 
of the assembled fibrils to form clusters was frequently observed on the STEM images of 
both variants. The resulting overcrowding meant that these regions, which usually included 
fibrils of various widths (Figure 4A, bottom left), could not be employed for MPL 
measurement. Accordingly, for each variant over 300 fibril segments of various lengths 
were selected on well-separated individual fibrils or where these extended from tangles, and 
analysed. After correction for beam induced mass-loss (see Materials and Methods), 
corresponding data sets were pooled, displayed in histograms and fitted with Gauss curves. 
Typical images of the freeze-dried, unstained TTR WT fibrils analysed are shown in Figure 
4A. Comparison of their MPLs (indicated for the regions marked by square boxes; units, 
kDa/nm) documents the sample heterogeneity. This heterogeneity was quantitatively 
assessed by pooling the MPL data from 358 TTR WT segments (Figure 4B). The peaks at 
9.5 and 14.0 ±1.4 kDa/nm (number of segments, n ~ 195 and 125, respectively; Figure 4B) 
indicate the presence of two major fibril types. In addition, there are two very minor fibril 
populations with average MPLs of 19.9 ± 1.4 kDa/nm (n = 23) and 25.8 ± 1.3 kDa/nm (n = 
11). As detailed in Table 1A the overall uncertainty in the major peak positions was < 1 
kDa/nm. An estimate of the fibril widths was obtained from the corresponding mass 
profiles. The full-width-half-maximum (FWHM; see Materials and Methods) values 
documented the absence of the 4 - 5 nm wide fibrils detected by negative stain TEM at 
earlier time points (data not shown). Interestingly, fibrils giving rise to the 9.5 and 14.0 
kDa/nm peaks had very similar FWHM values (~7 nm). As the FWHM is an underestimate 
of the actual width, these fibrils probably correspond to the 8 nm wide fibrils that 
predominated at most of the time points examined by TEM. 
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Figure 4- MPL analysis of TTR WT and TTR Leu55Pro fibrils after approximately 6 weeks 
incubation at 37°C. 
STEM dark-field images of unstained TTR WT fibrils produced by acidification (A) and TTR 
Leu55Pro fibrils formed at physiological pH (C). The absolute MPLs of the segments are cited in 
white (units: kDa/nm). Scale bar = 100 nm. 
Histogram for the TTR WT samples (B) displaying the absolute MPL values of 358 fibril segments 
with an average length of 35.1 ± 7.7 nm and for the TTR Leu55Pro samples (D) displaying the 
absolute MPL values of 441 fibril segments with an average length of 30.03 ± 9.54 nm. 
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Representative images recorded from freeze-dried, unstained Leu55Pro fibril samples are 
shown in Figure 4C. Again, comparison of the MPL values (evaluated for the regions 
marked by square boxes; units, kDa/nm) documents considerable sample heterogeneity, 
which was in this case quantitatively assessed by pooling the MPL data from 441 fibril 
segments (Figure 4D). As shown in Figure 4D, three major species were present in the TTR 
Leu55Pro samples. These had MPLs of 13.7,18.5 and 23.2 ± 1.9 kDa/nm (n ~ 250, 105 and 
65, respectively). The few remaining segments had MPLs in the range of 30.1 ± 1.9 kDa/nm 
(n ~ 19). The MPL peak at 9.5 kDa/nm found for the TTR WT fibrils was not present on the 
TTR Leu55Pro histogram instead there were two additional, well defined peaks at higher 
mass, implying that this variant forms a larger percentage of higher-order structures than 
TTR WT after 6 weeks of incubation. The overall uncertainty in the peak positions is 
detailed in Table IB and was < 1 kDa/nm for the two lowest peaks. The fibrils giving rise to 
the peaks at 13.7 and 18.5 kDa/nm had very similar FWHMs (6 to 7 nm in both cases) while 
the FWHM of those with a MPL of 23.2 kDa/nm was somewhat larger (8 to 9 nm). Again, 
as documented by the FWHM values, 4 - 5 nm wide fibrils were absent from these samples. 
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Table 1 Error assessment for the MPL measurements 
A. TTRWT 
Peak Standard 
deviation 
approx. n 
9.5 1.4 195 
14.0 1.4 125 
19.9 1.4 23 
25.8 1.3 11 
Standard 
error 
0.1 
0.1 
0.3 
0.4 
The smallest segment evaluated was only 14.9 nm long while the longest segment evaluated was 46.9 nm long; 
their mass-per-length values were weighted equally in the histograms. 
5% Calibration 
uncertainty 
0.5 
0.7 
1.0 
1.3 
Overall 
uncertainty 
0.5 
0.7 
1.0 
1.4 
B. TTR Leu55Pro 
Peak Standard approx. n Standard 
deviation error 
13.7 1.9 250 0.1 
18.5 1.9 105 0.2 
23.6 1.9 65 0.2 
30.1 1.9 19 0.4 
5% Calibration 
uncertainty 
0.7 
0.9 
1.2 
1.5 
Overall 
uncertainty 
0.7 
0.9 
1.2 
1.6 
The three smallest segments evaluated were only 8.1±0.1nm long while the two longest segments evaluated 
were 46.9±0.4nm long; their mass-per-length values were weighted equally in the histograms. 
The STEM data confirm and quantitatively characterize the fibril polymorphism observed 
by TEM and AFM. Within experimental uncertainties, the increment between the MPL 
peaks is the same for both isoforms (4.5 - 4.8 kDa/nm; average value, 4.7 ±0.1 kDa/nm). 
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FAP ex vivo fibrils - a comparison 
The data presented so far refers exclusively to in vitro TTR fibril assembly from 
recombinant TTR. For a structural comparison, we also analysed TTR VaBOMet ex vivo 
fibrils from two different sources, the vitreous of the eye and the peripheral nerve. Negative 
staining of the vitreous ex vivo preparation is presented in Figures 5 A and 5B. The fibrils 
were several microns long, 15 - 20 nm wide (Figure 5A) and exhibited longitudinal stripes 
implying the presence of multiple strands; in support of the latter, a few fibril fragments 
appeared to be a bundle of 8 nm wide strands associated laterally (Figure 5B, arrow). A 
transverse banding pattern that had an approximate repeat of 20-25 nm, but was not always 
periodically spaced along the fibril axis, was also distinguishable (Figure 5A). These 
features are identical to those reported for TTR fibrils isolated from the vitreous and 
analysed by image reconstruction from electron micrographs by Serpell et al. (Serpell et al, 
1995). 
Finally, we examined in situ TTR VaBOMet amyloid deposits found in a biopsy of the 
peripheral nerve of a FAP patient. Figure 5C shows the result of ultrastructural immunogold 
labelling for TTR. Interestingly, these fibrils, seen in cross section, were much narrower (7-
10 nm wide) than the fibrils extracted from the vitreous (15-20 nm wide) even though the 
same mutant was present. This suggests that polymorphism of TTR fibrillar assemblies also 
occurs in vivo. 
Figure 5- TTR ex-vivo fibrils analysed by TEM. 
(A and B) TEM images of a negatively stained ex vivo vitreous sample, that was obtained from a FAP TTR 
VaBOMet patient. The fibrils were several microns long and exhibited longitudinal striations implying the 
presence of multiple strands (panel A). A transverse banding with an approximate repeat of 20-25 nm could 
also be distinguished. However, this was not always periodically spaced along the fibril axis. A fragmented 
fibril suggests the presence of a bundle of laterally associated 8 nm wide strands (arrow, panel B). (C) Cross-
section of a peripheral nerve biopsy from a FAP TTR Val30Met patient after labelling with anti-TTR. The 
fibrils are much narrower (7 - 10 nm wide) than those extracted from the vitreous of the eye (panels A and B) 
even though the same mutant was analysed. Scale bar for (A-C) = 100 nm. 
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Discussion 
Mutations in the TTR protein cause FAP, a hereditary amyloidosis disease affecting 
predominantly and at high frequency, populations in northern Portugal, northern Sweden 
and Japan. The TTR Leu55Pro variant gives rise to a very aggressive form of FAP disease 
and the recombinant protein has a correspondingly high fibril forming capacity in vitro. 
Accordingly, strategies to inhibit TTR amyloid fibril formation would be promising as 
therapeutic interventions. Their development requires an understanding of the mechanism of 
fibril assembly and the molecular arrangement of the elementary subunits. Since fewer 
parameters are involved in in vitro systems, allowing the conditions to be precisely 
controlled, we used recombinant TTR, to investigate the assembly of TTR amyloid-like 
fibrils. Our major goals were to define the elementary protofilament subunits and their 
arrangement within the fibrils and to compare the in vitro assembled structures with ex vivo 
TTR fibrils derived from diseased organs. 
In the early stages of polymerisation (Figures 1A and 2A) recombinant TTR WT and TTR 
Leu55Pro samples contained abundant oligomers 5 or 8 nm in diameter. Fewer oligomers 
were observed at latter time points, suggesting that they are used up on fibril formation. The 
assembled TTR fibrils were polymorphic. In TTR WT samples, the most predominant 
fibrils had widths of 8 nm, lengths of up to 300 nm and sometimes exhibited a 17 nm axial 
sub-structure. Fibrils with widths o f 9 - 1 0 n m o r 4 - 5 n m were also observed. Given their 
small dimensions, the 4 - 5 nm wide fibrils probably represent single elementary 
protofilaments. All these species were also present in TTR Leu55Pro samples but both 
negative stain microscopy and STEM mass measurements indicated that the assembly 
kinetics were faster for this variant, particularly since the 4 -5 nm wide fibrils were only 
rarely observed. 
Mass measurement by STEM allowed the morphological polymorphism of both variants 
revealed by TEM and AFM (Figures 1 and 2) to be more precisely characterized. Within 
experimental uncertainties (Table 1), the increments between the major MPL peaks at 9.5 
and 14.0 kDa/nm for TTR WT and at 13.7, 18.5 and 23.2 kDa/nm for TTR Leu55Pro 
(Figure 4) are identical (4.5 - 4.8 kDa/nm; average value, 4.7 ± 0.1 kDa/nm), suggesting that 
this reflects the MPL of the elementary protofilament and that the protofilaments of both 
variants have the same architecture. Given the molecular weight of a TTR monomer (14 
kDa), a MPL of 4.8 kDa/nm would be expected for a vertical stack of monomers with the 
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monomer-monomer spacing of 2.9 nm predicted by X-ray fibre diffraction data (Inouye et 
al, 1998). Therefore, the MPL increment, 4.7 ±0.1 kDa/nm, supports the hypothesis that 
this is the architecture of the elementary protofilament and prompts the assembly model 
presented in Figure 6A. The 8 nm wide fibril, with a MPL of 9.5 kDa/nm, formed by two 
protofilaments strands with a left-handed twist has an axial crossover repeat of 17 nm, for 
both TTR WT and Leu55Pro, as assessed by unidirectional metal shadowing and AFM. 
Since each TTR monomer is 14 kDa, these results imply that a total of 6 monomers are 
present per crossover repeat with a twist of 30° between neighbouring monomers (figure 
6B). 
Here, the monomelic subunits are proposed to have a modified structure similar to that 
found in the TTR Leu55Pro crystal. Based on this model, in the case of TTR WT the major 
MPL peaks arise from fibrils containing 2 and 3 elementary protofilaments, and in the case 
of TTR Leu55Pro 3, 4 and 5 elementary protofilaments, respectively. Further, the two very 
minor TTR WT populations with higher MPLs represent fibrils containing 4 and 5 
elementary protofilaments. All of these higher order fibrils could either form by the lateral 
association of two or more elementary protofilaments or nucleate and elongate separately 
but maintain a common protofilament substructure. In either case intertwining of their 
elementary protofilaments would giving rise to the 17nm axial repeat occasionally observed. 
It should be noted that none of the MPL data are compatible with an elementary 
protofilament formed by the stacking of 55-kDa TTR tetramers with dimensions similar to 
those revealed by X-ray crystallography (Blake et al, 1978)(7.0x5.5x5.0 ran). In this case, 
higher MPL increments would be expected (minimum value 7.9 kDa/nm, maximum value 
11.0 kDa/nm depending on how the tetramers stack). 
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Figure 6- Structural model describing the observed in vitro TTR fibril assembly. 
(A) Structurally modified monomers (discs) stack vertically with the 2.9 nm monomer-monomer spacing 
indicated by X-ray diffraction data (Inouye et al, 1998). to form the smallest filamentous structure, a 4 - 5 nm 
wide elementary protofilament which has a MPL of 4.8 kDa/nm. (B) Fibrils with the distinct MPLs measured 
by STEM. The indicated intertwining of their elementary protofilaments would give rise to the 17nm axial 
repeat observed for some 8nm fibrils. These fibrils either form by the lateral association of 2, 3, 4 or more of 
elementary protofilaments or nucleate and elongate separately but maintain a common protofilament 
substructure. Intertwining of their elementary protofilaments may be a relatively rare event. The 9.5 kDa/nm 
fibril presenting the 17nm crossover repeat has a total of 6 monomers/crossover/strand with a twist of 30° 
between neighbouring monomers. This model is also proposed to describe the early stages of in vivo fibril 
formation, the immature fibril types considered being precursors of the much longer, rigid mature fibrils with 
distinct axial substructure that are isolated from in vivo sources. The structure of the monomer was taken from 
the database bank (PDB entry 5TTR). 
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Interestingly, the FWHM values corresponding to all of the major MPL peaks except that at 
23.2 kDa/nm (TTR Leu55Pro variant), were essentially equivalent (~7 nm; an underestimate 
of the width dependent on the mass profile shape), implying that all of these fibril types 
might have been classified as 8 nm wide fibrils by TEM. The peak at 23.2 kDa/nm arose 
from fibrils with somewhat larger FWHM values (8 to 10 nm). Thus, the 8-nm fibrils 
observed by negative stain TEM were probably heterogeneous comprising at least two 
morphologically distinct species for both the TTR WT and the TTR Leu55Pro samples. In 
addition as detailed above, the number of elementary protofilaments making up the major 
fibrillar species was different for TTR WT (2 and 3 protofilaments) compared to TTR 
Leu55Pro (3,4 and 5 protofilaments). 
In the TTR Leu55Pro variant crystal the three-dimensional structure of the monomers is 
changed compared to TTR WT by the disruption of beta-sheet strand D, which becomes a 
long loop connecting beta strands C and E. This variant packs into a tubular crystal formed 
by monomers with several channels running parallel to each other. Given the binding 
propensity of the crystals to the amyloid dye thioflavin T, the packing interactions occurring 
within them could be significant for amyloidogenesis (Sebastião et al, 1998). It is 
conceivable that the monomers of adjacent elementary protofilaments within TTR fibrils 
interact via their CE loops in a similar manner. Such lateral protofilament interactions might 
be highly favoured during the in vitro assembly of TTR Leu55Pro, which would explain 
both why single 4 - 5 nm wide protofilaments were only rarely seen and the formation of 
higher order fibrillar species at earlier time points than the WT (Figure 4). However, 
although fibril assembly was faster for TTR Leu55Pro, as illustrated by comparing Figures 
1C and 2F, after reaching a certain size the TTR WT fibrils showed a higher tendency to 
bundle. 
The work of Redondo et al. (Redondo et al, 2000a) is in agreement with the model outlined 
in Figure 6. The recombinant TTR variants they produced existed as tetramers, formed by 
the association of dimers that were stabilised by disulphide bridges between their 
monomers. These recombinant proteins were unable to form fibrils. However, amyloid-like 
fibrils assembled upon the release of monomelic units by reduction. Studies made on other 
specially engineered TTR variants not found in nature have led to alternative hypotheses. 
Eneqvist et al. (Eneqvist et al, 2000) suggest that conformational rearrangement but not 
tetramer dissociation is required for fibril formation. Similarly, Ferrão-Gonçalves et al. 
(Ferrão-Gonzales et al, 2000) suggest that an altered tetramer could be responsible for TTR 
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aggregation, although it should be noted that a detailed structural analysis of the fibrils was 
not made. This hypothesis may apply to very early events on fibril formation as the latter 
authors reported the presence of a small population of monomers after treatment at high 
pressure (Ferrão-Gonzales et al, 2000). 
The TTR WT and TTR Leu55Pro fibrils assembled during out in vitro experiments were 
relatively short (up to 300 nm in length), flexible and in most cases did not exhibit any clear 
axial substructure such as helical twisting, transverse banding or periodic coiling (Figures 1 
and 2). This suggests that they are probably immature fibril types and precursors of the 
much longer (several microns), rigid mature fibrils exhibiting distinct axial substructure, 
isolated from in vivo sources such as the vitreous of the eye or the peripheral nerve (Figure 
5). Consequently, our in vitro system may be detecting early events relevant to fibril 
assembly in vivo making it particularly interesting for therapeutic studies. The model 
presented in Figure 6 is accordingly proposed to also describe the early stages of in vivo 
fibril formation. 
We found distinct differences in the dimensions and morphology of the ex vivo fibrils 
obtained from two different sources. Although both fibril types reached lengths of several 
microns, the fibrils were 7 - 1 0 nm wide in the peripheral nerve and 15-20 nm wide in the 
vitreous. These observations indicate that after a certain stage amyloid formation may 
follow different pathways and involve different non-TTR components in the various organs. 
It also prompts the hypothesis that after this point the presence of such non-TTR 
components is essential for further assembly, and that it is these that control the formation 
of the organ-specific amyloid species. The two molecular models present in the literature for 
the structure of ex vivo vitreous amyloid (Blake and Serpell, 1996; Inouye et al, 1998) are 
conflicting in their definition of the elementary protofilament. One proposes a protofilament 
formed from a single vertical-stack of monomers i.e., two beta-sheets per building-block 
(Inouye et al, 1998), while the other proposes four beta-sheets related by a single helix axis 
arising from two monomers or a dimer as the repeating unit (Blake and Serpell, 1996). MPL 
measurements of the ex vivo vitreous amyloid samples after the removal of non-TTR 
components would allow these two X-ray models to be differentiated. 
To conclude, the in vitro systems examined have provided invaluable information, revealing 
the large degree of polymorphism that occurs during TTR amyloid fibril formation. The 
structural model proposed for the in vitro fibrils is based on the results of quantitative 
STEM and defines the elementary protofilament as a vertical stack of structurally modified 
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TTR monomers. Further experiments are now required to determine which of the ex vivo 
models is correct and to show exactly how the very short, flexible in vitro assembled fibrils 
are related to the long, rigid fibrils found in vivo. Accordingly, the role of non-TTR 
components must be elucidated. 
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T-DOX disrupts TTR Leu55Pro fibrils in vitro 
Abstract 
Familial Amyloidotic Polyneuropathy (FAP) is an autosomal dominant disorder 
characterized by extracellular deposition of fibrillar amyloid protein- transthyretin (TTR)-
with special involvement of the peripheral nerve. A large number of TTR variants are 
associated with this disease. TTR Leu55Pro is one of the most aggressive forms known and 
has the ability of forming fibrils in vitro under physiological conditions (PBS, pH 7.4). 
We studied by transmission electron microscopy (TEM) the effect of the drug 4'-iodo-4'-
Deoxydoxorubicin (I-DOX) on the in vitro assembly of TTR Leu55Pro fibrils, by following 
the fibril growth over a 15 day period. Our results showed that I-DOX at a concentration of 
IO"5 M/100 ug fibrils does not inhibit fibril formation up to 10 days since fibrils of 
approximately 7- 8 nm wide, identical to the fibrils present in the non-treated sample were 
observed. However, after 15 days of I-DOX treatment, only round particles approximately 
5- 6 nm wide, resembling soluble native TTR were observed. We also tested the ability of a 
series of compounds to interfere with amyloid fibril formation. These included ten I-DOX 
analogues, tetracyclines, and nitrophenols and found that they all act as fibril disrupters. The 
group of compounds tested showed fibril disruption activity to different extents and some of 
them resulted in the complete disaggregation of fibrils. 
In addition, the species generated upon I-DOX treatment are non-toxic, as revealed by the 
lack of significant caspase-3 activation on a Schwanoma cell line. This result suggests that 
I-DOX is a potential therapeutic drug in TTR related amyloidosis. 
Keywords: familial amyloidotic polyneuropathy, transthyretin, I-DOX, amyloid disruption, 
caspase-3. 
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Introduction 
Familial Amyloidotic Polyneuropathy (FAP) is an autosomal dominant disorder 
characterized by extracellular deposition of fibrillar amyloid protein with special 
involvement of the peripheral nerve (Coimbra and Andrade, 1971). The major component 
of the amyloid deposits in FAP is a variant transthyretin (TTR). To date, about 80 different 
TTR mutations related to amyloid deposition, and 10 non-pathogenic mutations have been 
described (Saraiva, 2001). 
TTR is a tetrameric serum protein composed of four identical 127-residue subunits (Blake 
and Swan, 1972). Each 14 kDa monomer within the functional tetramer contains two-beta-
sheets composed of strands DAGH and CBEF, as well as a small helical segment (Blake et 
al, 1978). TTR Leu55Pro is one of the most pathogenic FAP variants known (Jacobson et 
al, 1992) and has been implicated as the causative agent in early-onset FAP. X-ray studies 
on this mutant showed the disruption of hydrogen bonds between strands D and A leading 
to the formation of a long loop between strands C and E. It is believed that interactions 
between CE loops of neighboring monomers are very important in the amyloidogenic 
process. 
Amyloid fibrils are characterized by certain tinctorial properties such as birefringence under 
polarized light after staining with the dye Congo red and binding to thioflavin T (Th T). The 
fibrils are straight or coiled, non-branched, 7.5 to 10 nm in diameter and several microns in 
length. X-ray studies revealed a cross-P pattern with the (3-sheets running perpendicular to 
the axis of the growing fibril. Several other components are associated with amyloid 
deposits, including a non-fibrillar glycoprotein, the P component, and a variety of 
mucopolysacharides and other plasma and tissue proteins (Staunter et al, 1991). 
In vitro fibril formation has been a powerful tool in the study of the mechanism that leads to 
amyloid formation. Theories for the events occurring in vivo have been proposed based on 
in vitro results. In vitro screening of drugs that reverse or avoid the amyloidogenic process 
is necessary to prevent or treat the disease. Therefore, it is very important to elucidate the 
dynamics of amyloid fibril formation to prevent disease: different drugs may act on 
different species present at different stages on the amyloidogenic pathway, and this 
knowledge enables us to search for specific drugs for each step of the process. 
In this work we investigated the action at different time points of TTR fibril formation, of a 
class of compounds known to disrupt amyloid fibrils. The drugs tested included 4'- Deoxy-
4'- iododoxorubicin (I-DOX) (Gianni et al, 1995; Merlini et al, 1995; Palha et al, 2000b), 
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tetracycline dérivâtes (Howlett et al, 1999b; Forloni et al, 2001; Tagliavini et al, 2000) 
and nitrophenols (De Felice et al, 2001). 
Whether this drug produces toxic intermediate species has not been addressed. Specifically, 
we investigated the nature and toxicity of the intermediate species formed by the action of 
these drugs on TTR amyloid. 
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Materials and methods 
Isolation and purification of TTR 
TTR proteins were produced in an E. coll expression system (Furuya et al, 1991), isolated 
and purified as previously described (Almeida et al, 1997). Briefly, after growing the 
bacteria, the protein was isolated and purified by preparative gel electrophoresis after ion 
exchange chromatography. Protein concentration was determined using the Lowry method 
(Lowry e/a/., 1951). 
Preparation of amyloid fibrils 
TTR VaDOMet (2 mg/ml) was incubated in 0.05 M sodium acetate pH 3.6, for 72 hours at 
room temperature (Colon and Kelly, 1992). The sample was then centrifuged at 15,000 g 
for 30 minutes at 4°C; the pellet obtained was washed and re-suspended in MilliQ water and 
incubated at 37°C. 
TTR Leu55Pro was dialyzed against water pH ~ 7.0 and concentrated to 5 mg/ml. The 
preparation was centrifuged at 15,000 g for 30 minutes at 4°C and the pellet was then 
washed and re-suspended in phosphate buffered saline (PBS) or 0.9% NaCl, at 2 mg/ml and 
incubated at 37°C. 
Fibril concentrations were assessed by the Lowry method (Lowry et al, 1951 ). 
Filter assays 
To investigate whether I-DOX was able to dissolve amyloid fibrils, 100 ug of TTR 
synthetic fibrils (obtained by acidification) or soluble TTR were incubated with 10"5 M I-
DOX in 0.9% NaCl added freshly everyday for 7 days, at room temperature in the dark. 
The samples were applied to SPINE-X (Costar) centrifuge filter units, centrifuged, and 
washed with 0.9%NaCl. Protein concentration of the filtered material was determined 
using the Bio-Rad protein Assay (Bio-Rad) and albumin as standard. 
IDOX effect on TTR fibrils 
IDOX (kindly provided by Pharmacia and Upjohn) was dissolved in 0.9% NaCl and filtered 
through a 0.2 um filter (Schleicher & Schuell). IDOX concentration was determined 
spectrophotometrically at 478 nm, using an extinction coefficient of 13300 M"'cm"' based on a 
631 Da molecular weight. Stock solutions were prepared at approximately IO"3 M. 
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Aliquots of TTR Leu55Pro (100 ug), prepared as described above and resuspended in 0.9% 
NaCl or PBS, were incubated at 37°C in the dark alone or in the presence IDOX 10"5 M. The 
same amount of IDOX was added everyday for 15 days. In one aliquot IDOX was added only 
once in the first day. 
At given time points, the samples were visualized by TEM for the presence of amyloid 
fibrils. 
In a different set of experiments TTR Leu55Pro prepared as above and resuspended in 0.9% 
NaCL, was allowed to grow into fibrils for 10 days at 37°C and then I-DOX was added in 
concentrations ranging from 10^ to 10"7 M. After five more days at 37°C in the dark, the 
samples were analyzed by TEM. 
Transmission electron microscopy (TEM) 
For visualization by TEM, samples aliquots were diluted (1:50) with NaCl 0.15 M and 
immediately adsorbed to glow-discharged carbon-coated collodion film supported on 200-
mesh copper grids. For negative staining, the grids were washed with deionized water and 
stained with 1% uranyl acetate. The grids were visualized with a Zeiss microscope, operated 
at 60kV. Measurements of the fibril widths and lengths were made from enlarged prints of 
the electron micrographs using a magnifying glass with a built-in calibrated ruler. 
Screening for TTR fibril disrupters 
A series of compounds were tested for their ability to interfere with TTR amyloid fibril 
formation or to disrupt mature fibrils. These included: (i) I-DOX analogues (1-10), kindly 
provided by the MD Anderson Cancer Center (University of Texas, USA); (ii) the 
tetracycline derivatives rolitetracycline and doxycycline, a kind gift of the Department of 
Neuroscience, SmithKline Beecham-Pharmaceuticals, UK; (iii) and tetracycline, 2,4-
dinitrophenol (DNP) and 3-nitrophenol (NP) were purchased from Sigma. 
I-DOX analogues (1-10) were dissolved in methanol (Merck) at a concentration of 
approximately 10'3 M. 100 ug of fibrillar TTR Leu55Pro (2 mg/ml, 0.9% NaCl) were 
incubated with each one of the analogues at a concentration of 10"5 M added freshly everyday 
for 15 days. 
Tetracycline, rolitetracycline, doxycycline, DNP and NP were prepared in dimethylsulfoxide 
(DMSO) at 10 mg/ml. lOOug of fibrillar TTR Leu55Pro prepared as described (2 mg/ml, PBS) 
was incubated with a single dose of each of the compounds at 360 uM. 
102 
inOX disrupts TTR Leu55Pro fibrils in vitro 
Controls (TTR Leu55Pro alone and TTR Leu55Pro with equal amounts of methanol or 
DMSO) and compound-added aliquots were analyzed by TEM at different time points. 
Caspase-3 assay 
RN22 cells (rat Schwanoma cell line) were propagated in 25 cm2 flasks and maintained at 
37°C in a humidified atmosphere of 95% and 5% C02. Cells were grown in Dulbecco's 
minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
(Life Technologies). 
TTR Leu55Pro fibrillar material (500 ug) was treated with I-DOX added freshly everyday 
for 3 or 15 days (10"5 M I-DOX/100 ug fibrils). The sample was then centrifuged at 14,000 
rpm, washed 3 times with 0.9% NaCl to remove IDOX in excess and resuspended again in 
0.9% NaCl. Toxicity of I-DOX treated fibrils was evaluated by activation of caspase-3, 
measured using the CaspACE colorimetric 96 well plate assay system (Promega), following 
the manufacturer's instructions. Briefly, 80% confluent RN22 cells in DMEM in 1% FBS 
were exposed for 48 hrs to 2 uM TTR (either soluble, fibrillar TTR Leu55Pro alone or I-
DOX treated). Subsequently, each well was trypsinized and the cell pellet was lysed in 100 
ul hypotonic lysis buffer (Promega) by 5 cycles of freeze/ thawing. 40 ul of each cell lysate 
was used in duplicates for determination of caspase-3 activation. The remaining cell lysate 
was used to measure total cellular protein concentration using the BIO-RAD protein assay 
kit (Bio-Rad), using BSA as standard. Values shown are the mean of duplicates and the 
experiment was performed twice. 
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Results 
Effect of the drug I-DOX on the in vitro assembly of TTR Leu55Pro fibrils 
TTR Leu55Pro is a TTR variant associated with a very aggressive form of FAP disease and 
X-ray data on this mutant revealed important conformational changes suggesting this 
variant as a representative of amyloid precursors forms (Sebastião et al, 1998). This variant 
constitutes thus, an important tool to follow and study fibrillogenesis. 
We studied the effect of I-DOX (figure 1) on the in vitro assembly of TTR Leu55Pro fibrils 
by following the morphological properties over a 15 days period by EM, and comparing 
with the characteristics of the sample incubated in the absence of the drug. 
Figure 1- 4'-iodo-4'-deoxydoxorubicin (I-DOX) 
In the following described experiments both TTR Leu55Pro fibrils and I-DOX were 
prepared in 0.9% saline as the drug is not active in PBS (results not shown). 
I-DOX was co-incubated at 37°C with the TTR Leu55Pro preparation and after 6 days we 
observed fibrils identical to the ones in the non-treated sample (figure2). Up to 10 days it 
was still possible to observe fibrils in the treated sample (figure2). The continuous addition 
of the drug to the preparation up to 15 days lead to the disruption of the fibrillar material 
(figure 2, lower panel) into round particles, that resembled soluble protein. 
We next investigated whether these round particles, in fact, represented soluble protein. 
Specifically, incubating synthetic mature fibrils TTR fibrils with I-DOX for periods up to 7 
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days, we checked for the presence of soluble TTR after filtration. While soluble TTR (in 
the absence or presence of I-DOX) was completely filtered, TTR fibrils or amorphous 
precipitate (resultant from I-DOX treatment) were completely retained (not filtered) when 
applied on SPIN-X centrifuge filter units. Since no protein is detected in the filtrate upon 
fibril incubation with I-DOX, and given the formation of amorphous material, we 
concluded that I-DOX is able to disrupt but not dissolve the TTR fibrils. 
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I-DOX stability 
Previous work with ex vivo and in vitro amyloid fibrils defined the necessity of I-DOX to be 
freshly added everyday (Merlini et al, 1995). In fact, when a single dose of I-DOX 10" M 
was added on day one to TTR Leu55Pro initial aggregates, and the sample was further 
incubated at 37°C for 14 days, observation by TEM revealed the presence of fibrillar 
structures; these fibrils appeared shorter in length when compared to the non-treated sample 
and a mixture of round particles and short pre-fibrillar elements were visible (figure 3). In 
contrast, when the drug is added daily, round particles were observed (see figure 2), which 
suggests that the drug is inactive after some time, probably due to a destabilization process, 
and loses its activity as a fibril disrupter. 
Figure 3- TTR Leu55Pro incubated for 15 days at 37°C in the absence (right panel) or in the 
presence of I-DOX 10"5 M added solely once on day 1 (left panel) in the dark. Scale bar = 100 nm. 
I-DOX concentration effect 
I-DOX ability to interact with amyloid fibrils has been preferentially studied in AL-related 
amyloidosis and used in concentrations ranging from 10"6 to 10"5 M (Merlini et al, 1995). 
To determine the optimal concentration at which I-DOX acts on TTR Leu55Pro fibrils, 
TTR Leu55Pro initial aggregates were incubated at 37°C and allowed to grow into fibrils 
for 10 days. After this period of time, aliquots of 100 ug were separated and incubated with 
one single dose of I-DOX at 10"4, 10"5, 10"6 or IO"7 M. The samples were further incubated 
at 37°C for 5 more days in the dark and then analyzed by TEM. 
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Negatively stained samples were observed by electron microscopy and revealed that at I-
DOX 10"7 and 10"6 M did not disrupt completely the TTR Leu55Pro fibrils formed at 10 
days (figure 4, top panels). In contrast, the drug added at 10"5 M, it completely disrupted 
the fibrils previously produced (figure 4, bottom panel). I-DOX at IO"4 M showed the same 
effectiveness as at 10"5 M generating only round particles (data not shown). 
Figure 4- TEM negatively stained TTR 
Leu55Pro fibrils (100 ug, 2 mg/ml, 0.9% 
saline) formed for 10 days at 37°C. After 
this time period, one dose of IDOX 10"7 
(top left panel), 10"6 (top right panel) or 
IO"5 M (bottom) was added to the fibrils. 
The samples were incubated at 37°C in the 
dark for 5 more days and then analyzed by 
TEM. Scale bar =100nm. 
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The latter experiment, using a single dose of I-DOX on pre-formed fibrils grown for 10 
days, allowed the assessment of the optimal concentration for I-DOX performance at 10" 
M/100ug fibrils. In addition, it corroborated the finding that I-DOX disrupts TTR 
Leu55Pro fibrils in vitro. Furthermore, it guaranteed that the effect observed when I-DOX 
was added everyday for 15 days to TTR Leu55Pro initial aggregates was not due to a 
cumulative concentration effect of the drug. 
In addition the data showed, for the first time, at which stage of fibril formation is I-DOX 
interfering with the amyloidogenic cascade. 
Study of TTR fibril disrupters 
1. I-DOX analogues 
The results described above, indicate I-DOX as a good candidate to treat advanced cases of 
amyloid deposition. However, I-DOX cardiotoxicity is a limitation for its wide use and that 
lead us to search for similar non-toxic compounds with the ability to disrupt amyloid fibrils. 
A series of drugs synthesized based on I-DOX structure were tested. The structures of some 
of the compounds are represented on figure 5. 
Figure 5- Structures of three I-DOX-related compounds tested. 
The experiments were performed by incubating TTR Leu55Pro initial aggregates (100 ug, 2 
mg/ml, 0.9% saline) with 10"5 M of 10 different compounds, at 37°C in the dark. The 
observation that some variability concerning fibrils formation occurred between protein 
batches, leads us to include in the experiment the drug I-DOX as a control. The compounds 
were added freshly everyday and shown to act only as disrupters. Two out of 10 compounds 
CH3O 
HCIH2N 
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tested exhibited a complete disrupter activity whereas the remaining had intermediate 
activities resulting in a mixture of fibrils of different lengths, short non-fibrillar structures 
and round particles. Figure 6 shows the results obtained with two of the compounds tested 
and that are representative of two distinct groups; in one group, 2 compounds presented full 
disrupting activity whereas another group reflected partial disrupting activity. 
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Figure 6- TEM negatively stained images 
of TTR Leu55Pro incubated at 37°C in the 
dark with 10"5 M I-DOX (A-B) or I-DOX 
analogue (C-E) added everyday. (A): image 
acquired after 6 days of incubation with I-
DOX and revealing the presence of fibrils. 
(B): after 15 days of incubation with I-DOX 
no fibrils are present and only small round 
structures are visible. I-DOX analogues 
showed to act solely as fibrils disrupters as 
fibrils are observed after 6 days at 37°C (C); The continuous addition of two of the compounds 
resulted in the complete disaggregation of fibrils after 15 days (D). The other group of the 
compounds tested revealed partial disruption activity, resulting in the presence of a mixture of fibrils 
and round particles (E). Scale bar = 100 nm. 
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TEM analysis at day 6 showed fibrils, supporting the idea that this group of compounds acts 
only as disrupters but does not inhibit fibril formation. 
2. Tetracyclines 
It has been reported that tetracyclines exhibit anti-amyloidogenic properties towards Ap-
amyloid, not only by inhibiting (3-amyloid aggregates formation but also by disaggregating 
pre-formed fibrils (Forloni et al., 2001). This class of antibiotics presents a safe 
toxicological profile and thus, is a good candidate for treatment of amyloid related 
diseases. 
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Figure 7 - Structures of (i) tetracycline, (ii) rolitetracycline and (iii) doxycycline. 
We tested tetracycline and two tetracycline dérivâtes, rolitetracycline and doxycycline 
(figure 7) for their competence to interfere in the process of TTR amyloid formation and 
assessed their capacity to inhibit fibril formation and/ or disrupt TTR fibrils. Up to 17 days 
this capacity was determined by exposing TTR Leu55Pro initial aggregates to the drugs 
followed by TEM analysis. 
Our results showed that the antibiotics tested act primarily as fibril disrupters since fibrils 
were observed in intermediate time points (data not shown), before 17 days. After 17 days 
of incubation at 37°C with tetracycline, the sample clearly shows small round particles very 
abundante, when compared to the control situation. However, a small portion of fibrils with 
apparent similar lengths to the control are also observed (figure 8, right upper panel), 
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implying that although tetracycline behaves as a disrupter, it does not fully disaggregate 
TTR Leu55Pro fibrils in vitro under the tested concentrations. Rolitetracycline showed 
lower disrupting activity than tetracycline since a large amount of fibrils were still visible 
after 17 days of incubation at 37°C (figure 8, left lower panel). Nevertheless, in average, the 
fibrils appeared shorter than in the control with slightly more abundant short particles. 
Finally, doxycycline revealed as the most effective of the three compounds of this class 
tested: no fibrils were visible after incubation (figure 8, right lower panel). Doxycycline is, 
therefore, a good candidate in therapeutic approaches in TTR related amyloidosis. 
Figure 8- Effect of tetracyclines on TTR Leu55Pro fibril assembly in vitro. After 17 days at 37°C 
fibrils formed in the absence of drug were visualized by TEM (left upper panel) whereas 
incubation with drugs (i) tetracycline (right upper panel), (ii) rolitetracycline (left lower panel) 
and doxycycline (right lower panel) resulted in various degrees of fibril disruption. 
Scale bar = 100 run. 
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3. Nitrophenols 
Another group of compounds tested for their capacity to obstruct TTR fibril formation 
included 2,4-dinitrophenol (DNP) and 3-nitrophenol (NP) (figure 9). 
OH 
NO, 
N02 
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OH 
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(H) 
Figure 9 - Structure of (i) 2,4-nitrophenol and (ii) m-nitrophenol. 
Figure 10 shows that both DNP and NP disrupt TTR Leu55Pro fibrils. NP resulted in partial 
disaggregation of the fibrils whereas DNP activity resulted in complete disruption. 
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Figure 10- Effect of nitrophenols on TTR Leu55Pro assembly in vitro. Incubation for 17days in the 
absence of compound (left upper panel) and with NP (right upper panel) showing partial 
disruption of the fibrils after 17 days; DNP disruption activity is revealed by the presence of fibrils 
after 5 days of incubation (left lower panel) which are completely disrupted upon 17 days of 
incubation at 37°C (right lower panel). Scale bar = 100 nm. 
Cytotoxicity of non-fibrillar and fibrillar TTR in cell culture 
In vitro and under physiological conditions (PBS, pH 7.4), TTR Leu55Pro preparations 
start to form non-fibrillar aggregates and very short pre-fibrillar structures (figure 11 A, top 
right panel) that evolve to short fibrils (figure 11 A, bottom left panel), which elongated 
over time into fibrils approximately 8 nm wide and with variable length (figure 11 A, 
bottom right panel). Soluble protein (figure 11 A, top left panel) appears as round particles 
of 5- 6 nm of diameter. 
Toxicity of the different species observed during the TTR Leu55Pro fibril assembly 
process, including the initial aggregated non-fibrillar form of TTR (1 day incubation), and 
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fibrillar forms of different lengths (6- and 15- days incubation) was assessed by caspase-3 
activation on a Schwanoma cell line. Caspase-3 activation was observed only with the 
initial aggregates, whereas the soluble counterpart and the longer fibrils did not produce 
statistically significant caspase-3 activation (Figure 1 IB). 
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B 
Figure 11- A: TEM of negatively stained TTR Leu55Pro: soluble, initial aggregates, 6- and 15-
days fibrils. Scale bar = 100 nm. B: Activation of caspase-3 in RN22 cells exposed for 48 hours to 
2 uM of the different species shown in A: soluble TTR (sol. TTR), initial aggregates (I. Aggreg.), 
6-day fibrils (6d fibrils), and 15-day fibrils (15d fibrils). * p < 0.003. 
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These results show that non-fibrillar TTR constitute the most toxic species and that mature 
amyloid fibrils are not toxic for the cell line used. 
Cytotoxicity of the species resulting from the action of I-DOX 
Since I-DOX has the ability to interact only with fibrils formed for approximately 11-15 
days and thus, these are the most interesting species to study, in which concerns 
cytotoxicity. 
The toxicity of the species generated upon treatment with I-DOX after 15 days compared to 
different species present during the TTR Leu55Pro fibril assembly process, including the 
initial aggregates and fibrils assembled for 15 days, was assessed by caspase-3 activation 
on an Schwanoma cell line. Figure 12A depicts the results obtained showing that I-DOX 
treatment for 15 days did not produce toxic species as compared with the toxic initial 
aggregates. 
Figure 12A- Activation of caspase-3 in RN22 cells exposed for 48 hours to 2 uM of different 
species observed throughout TTR Leu55Pro formation and after I-DOX action. * p< 0.04. 
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However, at early time points, specially until 3 days, the species present both in control and 
I-DOX treated samples are small, non-fibrillar structures. Ascertaining for drug activity at 
this point is, thus, difficult. Nevertheless, it is important to assess for cytotoxicity of the 
related drug treated structures. 
Figure 12B is representative of caspase-3 activation, showing that a TTR Leu55Pro 
preparation treated with I-DOX for 3 days still retains the toxicity associated with the initial 
aggregates. This finding supports our previous observation that I-DOX has no action until a 
certain fibril length is reached, since species resulting from I-DOX action are non-toxic to 
the cell line used. 
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Figure 12B- Activation of caspase-3 in RN22 cells exposed for 48 hours to 2 uM of the different 
species. * p < 0.002. 
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Discussion 
The only therapy presently available for FAP is liver transplantation and although the 
amyloidogenic precursor protein is eliminated from blood, clinical improvement is not 
observed in all patients. Alternative therapies should therefore be considered. One possible 
route for treatment is to inhibit amyloid deposition and /or to disrupt already formed fibrils. 
In the present work we tested different classes of compounds for their ability to inhibit 
fibril elongation and/ or to disrupt TTR fibrils. 
The data presented in this study clearly showed that I-DOX disrupts in vitro pre-formed 
amyloid fibrils assembled for 15 days but does not inhibit fibril formation until a certain 
fibril length. TTR Leu55Pro fibril elongation pattern was previous ascertained (refer to 
chapter II) and shown to be sigmoidal in character. Furthermore, the fastest rate of fibril 
growth occurred between days 11 and 18, corresponding to an elongation rate of 9.2 
nm/day. The observation that I-DOX exerts its effect within this time interval suggests that 
the drug has an important action on fibril elongation and raises the question for the need of 
a structural motif that allows the drug to bind to fibrils and disrupt them. In fact, I-DOX 
was shown to very rapidly destroy TTR Leu55Pro crystals presenting an oligomeric-like 
structure, while TTR WT crystals were quite stable, under the same conditions (Sebastião 
et al, 2000). Molecular modeling studies were performed and the results suggested that I-
DOX binding site to TTR Leu55Pro crystals corresponds to a region of interaction between 
monomers. In this variant structure, the main crystal-packing interactions are loops CE, 
loop AB-a-helix and loops FG; these interactions are disturbed by I-DOX, leading to the 
disruption of the amyloid-like oligomer. Although the structures of TTR Leu55Pro 
intermediate and fibrils are different, it is conceivable that in TTR amyloid fibrils the 
interactions described above also occur and that I-DOX acts in a similar mode. 
The concentration study revealed that I-DOX holds its maximum activity towards fibrils 
disruption at 10 ~5 M/100 ug fibrils, which is within the range of concentrations regularly 
used in amyloid related studies. Anthracyclines are a well-known category of compounds 
used in clinical practice and constitute a promising group of drugs to be used in treatment 
of amyloidosis. A recent clinical trial work reports the study of I-DOX dosage in patients 
with AL amyloidosis (Gertz et al, 2002). Patients received I-DOX at a dose of 15 mg per 
m2 once a week for 4 consecutive weeks, repeated every 3 months up to 4 times. The study 
aimed at developing a dosing schedule to confirm previous reports (Gianni et al, 1995) 
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where higher doses were used (up to 30 mg per m2). The work by Gertz and colleagues 
(2002) reveals improvement of symptoms in a small number of patients but concludes that 
it failed regarding the decision of the dosage criteria. Nevertheless, the toxicity was 
minimal and future investigations concerning pharmacokinetic studies are planed. The 
results obtained infer the need for optimization of the conditions in each particular 
situation. 
I-DOX belongs to a class of chemotherapeutic agents presenting cardiotoxicity as the most 
important side effect. Nevertheless, this compound is clearly less cardiotoxic than the 
parental drug, doxorubicin (DOX) both in animal models (Podesta et al, 1994; Villani et 
al, 1988; Danesi et al, 1990) and in humans (Mross et al, 1990; Villani et al, 1991). 
However, and due to its cardiotoxicity, I-DOX use has been limited to AL-related 
amyloidosis, caused by a neoplastic plasma cell population in the bone marrow. Efforts 
should be made to find other I-DOX related compounds with anti-amyloidogenic activity 
but producing fewer side effects. We tested a group of compounds I-DOX related and 
demonstrated that they all behave like I-DOX, i.e. disrupters. Two of those compounds 
showed fibril disruption ability comparable to I-DOX (100% fibrils disruption) by 
generating round particles similar to the native protein. For the same concentrations, the 
other compounds tested partially disrupted the fibrils formed for 15 days upon incubation, 
resulting in a mixture of fibrils of various lengths, short non-fibrillar particles and round 
structures. However, these drugs may play an important role for structural comparative 
studies and thus, further studies must be conducted. 
Screening for compounds capable of inhibiting and /or disrupting amyloid fibrils must pay 
great attention not only to the compound toxicity but also to the toxicity of the structures 
resulting from the action of these drugs. The toxicity associated with Ap species has been 
generally determined based on the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) reduction assay as a measure of apoptosis. However, the nature 
of the biological activity assessed by this method is unknown. Apoptosis involves the 
activation of a proteolytic cascade where caspases have a determinant role (Hengartner, 
2000). Among the caspases, caspase-3 has been shown to play an imperative role, as it is 
activated late in apoptosis. We first studied the toxicity associated with the different species 
formed during TTR Leu55Pro fibril in vitro assembly and demonstrated that non-fibrillar 
initial aggregates are toxic to a Schwanoma cell line, as measured by caspase-3 activation. 
In contrast, soluble protein and long fibrils did not produce significant caspase-3 activation. 
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This data is in line with other observations reported: in Alzheimer's disease, the mean level 
of soluble Ap is increased and correlates very well with disease severity (McLean et al, 
1999; Naslund et al, 2000); the SH3 domain from bovine phosphatidyl-inositol-3'-kinase 
(PI3-SH3) and the amino terminal domain of the Escherichia coli HypF protein (HypF-N) 
have been shown to form fibrils in vitro under appropriate conditions (Guijarro et al, 1998; 
Chiti et al, 2001). Very recently, it has been demonstrated that species formed very early 
in the aggregation process of these proteins are highly toxic to a fibroblast cell line while 
the related fibrillar structures do not produce significant effect (Bucciantini et al, 2002). 
We also determined the toxicity of the species generated upon I-DOX treatment again by 
assessing caspase-3 activation in the same Schwanoma cell line. TTR Leu55Pro initial 
aggregates treated with I-DOX for 3 days retained cytotoxicity whereas the round particles 
resembling soluble TTR produced after 15 days of incubation with I-DOX produced non 
significant caspase-3 activation. However, a filter assay revealed that these species are not 
soluble. Consequently, different studies must be conducted to study how the tissue 
processes the generated insoluble material. It as been shown that the receptor for advanced 
glycation end products (RAGE) interacts with TTR fibrils triggering the activation of 
nuclear transcription factor kB (NF-KB) (Sousa et al, 2000d). Using the RN22 cell line, 
anti-RAGE abolished caspase-3 activation induced by TTR fibrils suggesting toxicity of 
TTR fibrils to be a RAGE mediated process (Sousa et al, 2001b). In vivo it was observed 
that RAGE expression is increased in FAP tissues overlapping with TTR deposition and 
increased with the progression of the disease. Therefore, future in vivo studies using I-DOX 
are necessary to quantify RAGE, inflammatory and oxidative stress gene expression in 
FAP tissues. 
Several other compounds have been reported as amyloid inhibitors, in particular in 
Alzheimer's disease. Some, like laminin, were found to inhibit the fibrillogenesis (Monji et 
al, 1998) and even depolymerize pre-formed fibrils (Morgan and Inestrosa, 2001); 
however, the result of this interaction on laminin is not known, and it is possible that it may 
disrupt laminin normal function, including its role on neuronal survival. Others, like short 
synthetic peptides, showed the capacity of both inhibiting and disaggregating amyloid 
fibrils (Soto et al, 1998) but they are not suitable for clinical use and several chemical 
modifications of their structure are necessary. Antibodies have also been subject of studies 
with the aim at interfering with amyloid formation (Frenkel and Solomon, 2001; Heiser et 
al, 2000). 
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A group of tetracyclines based on structural analogies with Congo red and I-DOX were 
experimentally tested and shown not only to inhibit A(3 self-aggregation but also to disrupt 
pre-formed Ap-amyloid aggregates (Forloni et al, 2001). Tetracycline also affects the 
properties of synthetic prion protein (PrP) aggregation by disrupting the fibrils and reverts 
the protease-resistence of PrP Sc from Creutzfeldt-Jakob disease (CJD) patients (Tagliavini 
et al, 2000). Doxycycline, a tetracycline derivate, is readily accessible to the central 
nervous system (CNS) (Yrjanheikki et al, 1998) and thus, makes it particularly interesting, 
especially for amyloid diseases with involvement of the central nervous system. It has been 
recently shown that another derivate of tetracycline, minocycline, exerts a neuroprotective 
effect in a transgenic model of Huntington disease (Chen et al, 2000). In this process, 
inhibition of caspase-1 and -3 has been proposed as a potential mechanism responsible for 
this drug effect. However, there are no reports on minocycline action on amyloid fibrils and 
other effects such as neuroprotection besides the anti-amiloidogenicity of the others 
tetracyclines mentioned is not known. Thus, tetracycline and derivatives needed further 
testing for their ability to prevent amyloid deposition (either by inhibiting or disrupting 
fibrils) and neuroprotection through caspase inhibition. Compounds showing both effects 
would constitute an added value in the study of amyloidosis. 
Our results suggested tetracyclines as TTR fibril disrupters but not as inhibitors. 
Doxycicline was able to completely destroy TTR fibrils, while rolitetracycline displayed 
partial activity. The finding that tetracyclines do not inhibit TTR fibril formation in 
contrast to the inhibition provoked in AP aggregation, probably reflects structural 
differences between TTR and AP unfolded intermediates. The disruption ability of this 
class of antibiotics is present towards both amyloid fibrils implying the recognition of a 
common motif present in amyloid fibrils. 
It has been hypothesized that hydrophobic interactions mediated by the C-terminal portion 
of AP are important for fibril stability (De Felice et al, 2001), leading to the investigation 
of hydrophobic compounds effective in destabilizing and disaggregating amyloid fibrils. 
The results showed that 2,4-dinitrophenol (DNP) and 3-nitrophenol (NP), the two 
compounds tested, possessed both inhibitory and disrupter activities. Our data supports 
only the latter, and DNP was shown the most active. Thus, DNP might additionally 
recognize a common amyloid fibril motif. 
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The work here described provides a strategy for studying compounds affecting the 
amyloidogenic cascade, allowing both the assessment of the stage affected and the 
relevance of the results by determining the toxicity of the generated species. 
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Abstract 
It is believed destabilizing the tetrameric fold is the basis of a series of events that lead to 
the formation of transthyretin (TTR) amyloid. Subtle structural changes are likely to occur, 
favoring tetramer denaturation and initiating the amyloid cascade. TTR mutations seem to 
destabilize the tetramer and therefore, increase the amyloidogenic potential of the protein. 
In order to address amyloidogenesis several engineered variants have been constructed. 
We evaluated the possibility of using the TTR Tyr78Phe and Leu55Pro variants to study 
inhibition of early events in TTR amyloidogenesis. We first characterized, by transmission 
electron microscopy (TEM), the time course process of TTR Tyr78Phe fibril assembly, 
starting from the soluble tetramer under physiological conditions (PBS, pH 7.4; 37°C) and 
showed that this variant evolves from round particles identical to TTR WT to soluble 
oligomers within 48 hours and slowly aggregate; after 15 days discrete fibrils of 
approximately 8 nm are clearly visible. This variant was selected to study compounds able 
to inhibit tetramer destabilization and formation of soluble oligomers (priming). 
TTR Leu55Pro was chosen to test drugs that interfere with fibril extension as its kinetic 
fibril assembly process during that step was previously ascertained. 
In order to screen a large number of compounds, we set up an immunoreactivity assay using 
a monoclonal antibody (Mabl5). This antibody detects subtle conformational alterations 
occurring in the process of priming and extension. The drugs tested included benzofurans, 
non-steroids anti-inflammatory molecules, tetrameric stabilizers, extracellular matrix 
(ECM) components, a porphyrin and aprotinin, among others. The results indicated that 
benzofurans are good candidates as inhibitors for both priming and extension, ranging from 
approximately 57% to 64% of inhibition; ibuprofen displayed intermediate strength for 
inhibiting priming and extension, with 20% and 37% of inhibition, respectively; with 
respect to the tetrameric stabilizers tested included diethylstilbestrol (DES), sulphite, a 
diflunisal derivative, a flufenamic acid derivative, a xanthone, and a pyridine derivative. 
DES presented activity against both stages inhibiting the process in about 50% whereas the 
flufenamic acid derivative presented about 50% inhibition but only against extension; 1, 3-
diidroxixanthone and a pyridine derivative interfered with priming, inhibiting it by 
approximately 30%. Among the ECM components, laniinin showed the highest activity of 
all compounds but only concerning the extension stage, with 70% inhibition; hemin 
produced over 50% inhibition in both stages and aprotinin caused 34% of inhibition of 
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priming. For some of the compounds the results were confirmed by TEM and seemed to 
correlate well. 
In addition, we generated an in vitro cellular system for TTR intermediate/aggregate 
formation and for screening for inhibitors in cell culture. Constructs carrying the TTR WT, 
VaDOMet or Leu55Pro cDNA were transfected into a rat Schwanoma cell line and studied 
for the ability to form aggregates by a dot blot filter assay followed by immnunodetection. 
The results showed that TTR Leu55Pro forms aggregates after 24 hours whereas no 
aggregation was detected for TTR WT and VaBOMet up to 72 hrs. The formation of 
aggregates by TTR Leu55Pro was not lysosome dependent and seemed to occur 
extracellularly. Moreover, TTR Val30Met and Leu55Pro reacted with Mabl5 prompting 
this cellular model as a potential tool in the study of conformational changes occurring very 
early and prior to TTR dissociation and aggregation. 
Keywords: Transthyretin; amyloid; priming; fibril extension; intermediate species. 
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Introduction 
The knowledge acquired in the last years on structural and biochemical features 
characteristic of amyloidogenic intermediates, paved the way for the investigation of drugs 
capable of interfering early on the amyloidogenic pathway. For TTR related amyloidosis, 
the first step of intervention is to obstruct tetramer dissociation and thus, prevent potential 
species from being generated (hereafter designated as priming). A second target is to 
inhibit the association between intermediate species that lead to fibril elongation (hereafter 
designated as extension). Several authors have reported the identification of compounds 
capable of inhibiting TTR fibril formation (Klabunde et al, 2000; Oza et al, 1999; Baures 
et al, 1998; Baures et al, 1999). However, most of these studies were performed under 
non-physiological acidic conditions, which are believed to induce rapid conformational 
changes and no specific distinction is made regarding the species affected by those drugs. 
In these studies, the methodology used consisted in measuring the turbidimetry of the 
samples in the presence of absence of inhibitors and thus, polymerazation into soluble 
oligomeric species might have gone undetected. 
Other tools need to be developed to assess TTR fibrillogenesis under physiological 
conditions, namely to detect early subtle conformational changes. In this regard, an 
engineered TTR variant, TTR Tyr78Phe has recently been proposed as an early 
intermediate in the amyloidogenic cascade. This mutant is recognized by a monoclonal 
antibody raised against an engineered synthetic TTR with a triple substitution at positions 
53, 54 and 55 (Gly53Ser, Glu54Asp, Leu55Ser) (Goldsteins et al, 1999). The observation 
that Mabl5 reacts with sera of patients with different TTR mutations, but not with sera of 
normal individuals, further suggests the presence of modified circulating soluble TTR 
species in FAP patients (Palha et al, 2001), and increases the significance of the Mabl5 
antibody in recognizing conformational intermediates. 
In the present study we used this antibody to investigate the ability to recognize 
intermediary species in fibrillogenesis. Therefore, studying the reactivity of this antibody 
towards different species formed in vitro was applied as mean for screening compounds 
able to inhibit subtle TTR in vitro conformational changes. 
Cellular systems, not yet available for TTR, represent a more physiological approach to 
study inhibitors of amyloidogenesis in vitro. Such systems do not require isolation of the 
target protein, enable to follow up of the complete amyloidogenic process, and include 
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modulating factors such as chaperones and the eventual cellular processing of the formed 
fibrillar structures. We developed a cellular system to study the kinetics and dynamics of 
TTR amyloid formation. 
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Materials and Methods 
Isolation and purification of TTR 
TTR proteins were produced in an E. coli expression system (Furuya et al, 1991), isolated 
and purified as previously described (Almeida et al, 1997). Briefly, after growing the 
bacteria, the protein was isolated and purified by preparative gel electrophoresis after ion 
exchange chromatography. Protein concentration was determined using the Lowry method 
(Lowry eia/., 1951). 
Preparation of amyloid fibrils 
TTR Tyr78Phe was dialyzed against phosphate buffered saline (PBS) and incubated at 37°C 
at 2 mg/ml. 
TTR Leu55Pro was dialyzed against water pH ~ 7.0 and concentrated to 5 mg/ml. At this 
point the preparation was centrifuged at 15,000 g for 30 minutes at 4°C. The pellet was then 
washed and re-suspended in PBS, at 2 mg/ml and incubated at 37°C. 
Fibril concentrations were assessed by the Lowry method (Lowry et al, 1951). 
At given time points, samples were analyzed by transmission electron microscopy (TEM). 
Transmission electron microscopy (TEM) 
For visualization by TEM, sample aliquots were diluted (1:50) in PBS and immediately 
adsorbed to glow-discharged carbon-coated collodion film supported on 200-mesh copper 
grids. For negative staining, grids were washed with deionized water and stained with 1% 
uranyl acetate. The grids were visualized with a Zeiss microscope, operated at 60kV. 
Measurements of fibril widths and lengths were made from enlarged prints of the electron 
micrographs using a magnifying glass with a built-in calibrated ruler. 
Screening for compounds 
A series of compounds were tested for the ability to inhibit TTR priming and/or extension. 
The different drugs were included into 6 groups: 
Group 1 (control)- compounds able to disrupt amyloid fibrils, enabling priming and 
extension, as previously described (chapter III): tetracycline (Sigma); tetracycline 
derivatives rolitetracycline and doxycycline (a kind gift of the Department of Neuroscience, 
SmithKline Beecham_Pharmaceuticals, UK); 2,4-dinitrophenol (DNP) and 3-nitrophenol 
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(NP) (Sigma). 
Group 2- six benzofuran compounds (a kind gift of the Department of Neuroscience, 
SmithKline Beecham Pharmaceuticals, UK), previously shown to inhibit Ap* fibrillogenesis. 
Group 3- (non-steroid anti-inflammatory drugs)- diflunisal, ibuprofen, and diclofenac, 
purchased from Sigma. 
Group 4- (tetrameric stabilizers/T4 competitors)- diethylstilbestrol (DES) (Sigma), sulphite 
(Merck), modified diflunisal and modified fiufenamic acid (provided by the Centro de 
Investigacion y Desarrolo, Barcelona), one xanthone, 1,3-diidroxixanthone (a generous gift 
of Dr. Madalena Pinto), and pyridine derivative, 2-amino-7-bromo-5-oxo-
5H[l]benzopyrano[2,3-b]pyridine-3-carbonitrile (Aldrich). All compounds were shown to 
compete with T4 by 125I-T4 competition binding assays; sulphite and modified diflunisal 
were also shown to stabilize the tetramer by isoelectric focusing, by Drs. Rosário Almeida 
and Bárbara Macedo; the methodology has been previously described (Almeida et al., 
2000). 
Group 5- (ECM compounds)- heparin, dextran sulphate, heparan sulphate, laminin, 
fibronectin and matrix gel (Sigma). 
Group 6- (others)- Hemin (a porphyrin kindly provided by the Department of 
Neuroscience, SmithKline Beecham Pharmaceuticals, UK), aprotinin (Sigma) and aprotinin 
peptide (APR2, residues 16-37). 
The compounds were weighted and dissolved at approximately 10 mg/ml in 
dimethylsulphoxide (DMSO), with the exception of sulphite, aprotinin, aprotinin peptide 
and the ECM components that were dissolved in water. Soluble TTR Tyr78Phe and 
Leu55Pro aggregates prepared were incubated with or without each one of the compounds 
above described at a molar ratio 1:10 for 48 hours at 37°C. Control samples were incubated 
with DMSO or water alone. 
Anti-fibrillogenic activity was tested by immunoassay and/or TEM. 
Immunoassay for priming/ extension 
96 well plates (Maxisorp-Nunc) were coated for 1 hour at 37°C with 1:500 diluted 
polyclonal rabbit anti-human TTR (Dako) and blocked overnight at 4°C with 5% skim milk 
in PBS. Soluble TTR WT, soluble TTR Tyr78Phe, and Leu55Pro initial aggregates, with or 
without drugs, were applied to the wells (2 ug/100 ul) for 1 hour at 37°C, followed by 
incubation with Mabl5 (1:10 in PBS) for another hour. Peroxidase conjugated anti-mouse 
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IgG (Amersham) 1:5000 was used as secondary antibody and development was performed 
with 2,2"-azino-bis (3-ethylbenzthiazoline-6-snlfonic acid) (ABTS, Sigma) IH2O2 (Merck). 
For each compound a minimum of two independent experiments, each of which analyzed in 
duplicate, were performed. 
Vector constructions 
Vectors pl69ZT carrying human wt TTR (pl69ZT-hTTRwt) and pl69ZT carrying human 
TTR Leu55Pro (pl69ZT-hTTR55) (figure 1) were available in the laboratory (Sousa et al, 
submitted). These constructs were obtained as follows: pBluescript II KS (pKSII) 
(Stratagene) carrying the sheep methalothionein promoter-1 (SMT-1) between EcoRI and 
BamHl sites (this vector was termed pi69 and was kindly provided by Dr Kevin Ward, 
Commonwealth Scientific and Industrial Research Organization, Australia) was cut with 
Sacl, blunted with T4 DNA polymerase by standard procedures, and subsequently digested 
with BamHl. All the restrictions were made following the manufacturer's instructions for 
each enzyme. The P-globin splice site (p-SS) and the SV40 poly A tail (pA) were excised 
from pZT (a generous gift of Dr. José Belo, IGC Portugal) with Kpnl and BamHl. The Kpnl 
site of the above excised insert was blunted with T4 DNA polymerase I and the insert was 
subcloned in Sacl blunted- BamHl sites of pi69. The vector so generated, carrying SMT-I, 
P-SS and pA was termed pl69ZT (Figure la). Both the splice site and the polyA tail were 
used to ensure a correct transcription and mRNA processing since this vector was used to 
subclone TTR cDNA and not a genomic clone. Human WT TTR full-length cDNA, 
available in the laboratory, was excised from pKSII with EcoRV and Notl. The TTR insert 
was cloned in Nhel blunted (using Klenow fragment of DNA polymerase I by standard 
procedures) site of pl69ZT (Figure lb). The Leu55Pro mutation was inserted by site-
directed mutagenesis using the Quickchange mutagenesis kit (Stratagene) following the 
manufacturer's instructions and the appropriate primers: 5"-
TCTGGAGAGCCGCATGGGCT^ and 5,-AGCCCATGCGGCTCTCCAGA-3\ We 
further generated the construct carrying the Val30Met TTR mutation by site directed 
mutagenesis as described above and using the following primers: 5'-
AATGTGGCCATGCATGTGTTC-3' and 5'-GAACACATGCATGGCCACATT-3\ 
132 
Screening for TTR inhibitors 
Figure 1- Schematic representation of pl69ZT-TTR vector construction. 
In this figure, TTR can either represent human TTR WT, VaBOMet or Leu55Pro. 
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Transfection and TTR expression in cell culture 
Rat Schwanomas (RN22) (American Type Cell Collection) were stably co-transfected with 
each of the constructs carrying the TTR cDNA (WT, VaBOMet or Leu55Pro) plus a 
plasmid with resistance to neomycin (pLNeo, kindly provided by Dr. Paulo Vieira, IGC, 
Portugal), following the CaPCu-DNA precipitate method (Sambrook et al, 1989). Briefly, 
cells were grown to approximately 30-50% confluence in 10 cm dishes (Costar). 25 ug of 
the appropriate plasmid carrying the TTR cDNA plus 5 ug of pLNeo purified using 
QUIAGEN columns were ressuspended in 500 ul of 250 mM CaCk and diluted with 500 ul 
2X Hepes-buffered saline (2X HeBS). The CaP04-DNA precipitate was allowed to form by 
standing the mixture 20 min at room temperature and was subsequently added to the cells. 
After 5 hours incubation, cells were washed twice with phosphate-buffered saline (PBS) 
and fed with 10 mL complete medium. 24 hours later, transfection medium was replaced by 
complete medium supplemented with G418 (1 mg/mL). Resistant colonies arose 
approximately after 7 days of selection and were isolated and separated over the course of 
the following weeks. 
Quantification of TTR 
The presence of TTR in conditioned media of cells transfected with constructs bearing 
human TTR (pl69ZT-hTTRWT, Met30 and Pro55) was tested by quantitative enzyme 
linked immunoreactive assay (ELISA) (Sousa et al, 2000a): 96 well plates (Maxisorp-
Nunc) were coated overnight at 4°C with 1:500 diluted polyclonal rabbit anti-human TTR 
(DAKO) and blocked with 5% skim milk in PBS; each sample, diluted in PBS, was applied 
to the wells for 1 h at room temperature; as secondary antibody, peroxidase conjugated anti-
human TTR (The Binding Site) 1:500 diluted in PBS-0.05% Tween 20 (PBS-T) was used. 
Development was performed with ABTS (Sigma) / H2O2 (Merck). 
For all constructs, experiments were performed both in the absence and presence of 100 uM 
ZnSCU in the cell culture media in order to test activation of the sheep MT-1 promoter. 
Immunoprecipitation 
Selected cells expressing TTR and induced with 100 uM ZnS04 were grown to 
approximately 100% confluence in complete medium. Complete medium was then replaced 
by 14C-Leucine containing medium, which was subsequently collected 4 hours later. Cells 
were harvested and then lysed with 1 ml of lysis solution (30 mM Tris pH 7.5, 300 mM 
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NaCl, 1% triton x-100, 10 uM PMSF), centrifuged 30 minutes at 14,000 rpm. The pellet 
was discarded and the supernatant collected. 
Both medium and cell supernatant were incubated with rabbit anti-human TTR 1:20 (Dako) 
overnight at 4°C with agitation. Next, 150 ul of protein A sepharose (62.5 ug/ul in 30 mM 
Tris pH 7.5) (CL-4B, Pharmacia) were added and allowed to incubate for 1 hour at room 
temperature with agitation. The immunoprecipitated complex was washed 3 times with 
washing solution (30 mM Tris pH7.5, 300 mM NaCl, 1% triton x-100) and the complex 
eluted with SDS loading buffer. Finally, samples were separated on a 15% polyacrylamide 
gel under denaturing conditions (SDS-PAGE) and processed for autoradiography. 
Dot blot filter assay for aggregate detection 
Cells expressing TTR as well as non-transfected RN22 induced with ZnSC>4 for 3 days were 
grown to about 80% confluence and then incubated with serum-free medium for different 
periods of time. In one set of experiments cells were also incubated with chloroquine 10 uM 
in serum-free medium for 24 hours. 
TTR in the medium was quantified by ELISA as described above, and 500 ng were applied 
onto a 0.2 urn pore cellulose acetate membrane filter (Schleicher & Schuell) using a manifold 
system (Gibco BRL) under vacuum to separate soluble proteins from aggregates. The filter 
was washed 3 times with PBST and processed for TTR immunodetection Briefly, the 
membrane was blocked with 5% skim milk in PBS for 1 hour at room temperature, and then 
incubated with 1:500 rabbit anti-human TTR (Dako) for another hour; anti-rabbit HRP 
1:500 was used as secondary antibody. Detection was performed with enhanced 
chemiluminescence (ECL, Amersham). 
Western blotting 
Alternatively, after applying the medium on the membrane filter, the area of each dot was 
cut and boiled with SDS loading buffer. The material removed was run on a 15% denaturing 
acrylamide gel and then transferred to a nitrocellulose membrane (Amersham). The 
membrane was blocked with 5% skim milk in PBS for 1 hour at room temperature and then 
incubated with 1:500 rabbit anti-human TTR (Dako) for another hour at room temperature; 
as secondary antibody, 1:5000 peroxidase-conjugated anti-rabbit IgG (Amersham) was 
used. Development was performed with 3', 3'-diaminobenzidine (DAB) (Sigma). 
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Immunoassay for conformational changes in TTR in cell culture 
Transfected cells were grown and induced to express TTR as previously described. Serum-
free media was collected at different time points and TTR quantified by ELISA, as already 
described. The reactivity with Mabl5 antibody was assessed using the same amount of 
mutant or WT TTR in each well, following the conditions described for the immunoassay of 
priming and extension. 
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Results 
1- Priming - morphological characterization 
TTR Tyr78Phe variant was designed with the purpose of destabilizing the AB loop 
(Redondo et al, 2000b) thought to be involved in amyloidogenesis. The resulting mutated 
protein revealed to be very prone to fibril formation under acidic conditions as assessed by 
thioflavin T binding. 
We investigated the capacity of TTR Tyr78Phe to aggregate and form amyloid-like fibrils 
under physiological conditions (PBS pH 7.4, 37°C). Morphologically, soluble TTR 
Tyr78Phe appears as rounds particles identical to native TTR WT. After 24 hours at 37°C, 
no alterations were visible under the electron microscope (figure 2A). The protein started to 
aggregate and within 48 hours, oligomeric species were clearly visible (figure 2B), 
increasing after 4 days (figure 2C). Further incubation extended the degree of aggregation 
and at 8 days large clusters of aggregated protein as well as short pre-fibrillar structures 
were visualized (figure 2D). This material organized into well-defined amyloid-like fibrils 
after 15 days (figure 2E). 
The morphological data presented here reinforces the biochemical evidences suggesting that 
this variant possesses a high amyloidogenic potential. Moreover, the morphological 
characterization of TTR Tyr78Phe aggregation pathway from the soluble counterpart 
enables us to test compounds that may inhibit fibril formation. In particular, the changes 
taking place within 48 hours, most probably corresponding to early tetrameric dissociation 
and unfolding events provide an opportunity to screen for compounds that inhibit the 
priming stage. 
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Figure 2- TTR Tyr78Phe aggregation observed 
by TEM. At up to 24 hours the preparation 
shows round particles indistinguishable from 
TTR WT (A). Within 48 hours oligomers of 
TTR Tyr78Phe are present (B). Further 
incubation at 37°C for 4 days results in 
aggregation (C), which increases up to 8 days 
(D). After 15 days at 37°C, amyloid-like fibrils 
are observed (E). Scale bar (A-F) = 100 run. 
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2- Extension- morphological characterization 
The extension stage refers to the association of potential amyloidogenic species generated 
during the priming period; it also relates to fibril elongation. 
We previously characterized this phase in chapter II using the TTR Leu55Pro variant; in the 
extension reaction we used TTR Leu55Pro initial aggregates instead of soluble TTR 
Leu55Pro. 
3- Immunoassay 
Although transmission electron microscopy allowed the ultrastructural characterization of 
fibril assembly and the identification of several different species present throughout the 
process, this method, apart from being time consuming, does not enable the detection of 
subtle structural modifications or their quantification. Aiming at screening a considerable 
amount of drugs, we therefore investigated the possibility of studying the progress of 
fibrillogenesis by immunoreactivity with the specific monoclonal antibody Mabl5 that 
recognizes cryptic epitopes of TTR amyloid and modified soluble TTR. 
3.1- Immunoassay for priming 
A previous work demonstrated that Mabl5 reacts with soluble TTR Tyr78Phe in the 
sandwich ELISA (as described in Material and Methods) (Redondo et al, 2000b) but does 
not recognize TTR WT or Leu55Pro under the same conditions. Here we investigated the 
immunoreactivity of the species generated upon incubation of TTR Tyr78Phe at 37°C for 48 
hours under the same conditions. 
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Mab15 reactivity with TTR Tyr78Phe species 
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Figure 3- Mabl5 reactivity towards TTR Tyr78Phe species. Soluble TTR WT (Sol.WT) does not 
react with this antibody while soluble TTR Tyr78Phe (Sol.Tyr78Phe) is recognized. 
Immunoreactivity against TTR Tyr78Phe species decreases upon incubation for 48 hours at 37°C 
(Tyr78Phe 48hrs species). (* p< 0.0005; § p< 0.004). Inset: soluble TTR Tyr78Phe and TTR 
Tyr78Phe 48 hours species tested with an anti-human TTR polyclonal antibody showed no 
differences in affinity. 
While Mabl5 does not recognize WT, soluble TTR Tyr78Phe strongly reacts with the 
antibody (figure 3). However, after 48 hours of incubation the reactivity is 2.5-fold 
decreased compared to the soluble TTR Tyr78Phe (figure 3), suggesting that 
conformational changes occurred upon incubation, leading to a decrease of the specific 
epitopes available for antibody recognition. These conformational changes are most 
probably related to aggregation, which occurs readily with this variant. 
The ability provided by Mabl5 in discriminating between native TTR Tyr78Phe and species 
lacking the tetrameric fold, constitutes an opportunity to identify drugs inhibiting the 
priming stage. 
To ensure that the observed distinction of species by Mabl5 was not a consequence of 
different affinities towards those species by the polyclonal antibody used in coating, an 
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immunoassay for TTR quantification (see Material and Methods) was performed using an 
anti-human TTR HRP antibody as secondary antibody. In this case, soluble TTR Tyr78Phe 
and species formed upon incubation at 37°C for 48 hours presented identical reactivity 
(figure 3, inset), further supporting that the differences previously detected were due to 
differential interaction with Mabl5. 
3.2- Immunoassay for extension 
We also tested whether Mabl5 could distinguish species formed during the extension step, 
using TTR Leu55Pro aggregates as the starting material. 
The reactivity of this antibody was high for the initial aggregates but decreased as fibrils 
assembled under physiological conditions (PBS, pH 7.4, 37°C) for 5 and 15 days (figure 4). 
As expected soluble TTR Leu55Pro did not significantly react with Mabl5. We attributed 
this result to lower epitope accessibility in the fibril. The different species of TTR Leu55Pro 
presented identical affinity to the polyclonal antibody used (figure 4, inset) and thus, the 
ability of Mabl5 to discriminate early aggregates from fibrils enables the screen of drugs 
inhibitory of extension. 
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Mab15 reactivity with TTR Leu55Pro species 
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Figure 4­ Mab 15 Immunoassay for different species of TTR Leu55Pro. 
Reactivity of recombinant TTR Leu55Pro (Sol.TTR), TTR Pro55 initial aggregates (LAggreg.) (24 
hours), and fibrils assembled for 5 (5d.fibrils) and 15 days (15d.fibrils) at 37°C, respectively. Mabl5 
reactivity is significantly decreased as TTR Leu55Pro fibrils assembled for 5 and 15 days; * p< 
0.02. Inset: TTR Leu55Pro initial aggregates, 5 and 15 days fibrils, tested with an anti­human TTR 
polyclonal antibody, revealed identical affinity. 
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4­ Screening of compounds interfering with TTR amvloidogenecity 
A series of compounds were tested for their ability to interfere with TTR priming and/or 
extension and thus, to affect the reactivity of TTR species with Mabl5. The drugs studied 
were grouped according to their structure and/or biological activity. 
Table 1 discriminates the drugs tested, and figure 5 displays the structures of some of these 
drugs. 
Table 1­ Compounds tested for inhibition of priming and extension. 
Compound group Compound number Compound name 
Group 1 
Control 
1 tetracycline 
2 rolitetracycline 
3 doxycycline 
4 2,4­dinitrophenol 
5 3­nitrophenol 
Group 2 
Benzofurans 
6 SKF 99130 
7 SKF 73033 
8 SKF 64346 
9 SKF79313 
10 SKF74652 
11 SB205550 
Group 3 
Non­steroid anti­
inflammatory 
12 diflunisal 
13 ibuprofen 
14 Diclofenac 
Group 4 
Tetrameric 
Stabilizers and/or T4 
competitors 
15 DES 
16 sulphite 
17 modified diflunisal 
18 modified flufenamic 
acid 
19 1,3­diidroxixanthone ■ 
20 
2­amino­7­bromo­5­
0X0­
5H[ 1 ]benzopyrano[2,3 
­b]pyridine­3­
carbonitrile 
Group 5 
ECM components 
21 heparin 
22 dextran sulphate 
23 heparan sulphate 
24 laminin 
25 fibronectin 
26 matrix gel 
Group 6 
Others 
27 hemin 
28 aprotinin 
29 aprotinin peptide 
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SKF 99130 
OMe 
SKF 73033 SKF 64346 
SKF 79313 
OMe 
SKF 74652 
COOH 
Diflunisal 
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COOH 
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CI 
O OH 
OH 
1,3-diidroxixanthone 
CI 
OH 
Diclofenac 
2-amino-7-bromo-5 -oxo-
5H[ 1 ]benzopyrano[2,3-
b]pyridine-3 -carbonitrile 
Hemin 
Figure 5- Structures of some of the drugs tested for inhibition of priming and extension. 
144 
Screening for TTR inhibitors 
4.1­ Selection of priming inhibitors­ immunoassay 
To select for compounds that inhibit priming, soluble TTR Tyr78Phe was incubated with or 
without different compounds for 48 hours at 37°C, and then tested for Mabl5 reactivity (see 
Materials and Methods). An aliquot of TTR Tyr78Phe alone was kept at ­20°C and used as 
control. The percentage of inhibition was calculated as follows: 
% inhibition = [(Abs 405 nm (sample with inhibitor) ­ Abs 405 nm (sample without inhibitor)) * 
100]/ [Abs 405 nm (Soluble TTR Tyr78Phe) ­ Abs 405 nm (sample without inhibitor)] 
Figure 6 depicts the results obtained, showing the percentage of priming inhibition by each 
compound. 
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Figure 6 ­ Mabl5 reactivity with TTR Tyr78Phe species after incubation of soluble Tyr78Phe with 
different drugs for 48 hours at 37°C (refer to table 1 for compound identity). 
145 
Screening for TTR inhibitors 
Control samples of TTR Tyr78Phe containing the same percentage of DMSO, as the 
resulting from the addition of compounds, were prepared; DMSO revealed no influence in 
Mabl5 reactivity. Control tests in which each compound was added to the TTR Tyr78Phe 
protein at time t = 0 were also performed and showed no influence on the reaction with 
Mabl5 (data not shown). 
Tetracycline and its derivatives and nitrophenols were used as control since they were 
previously shown to act primarily as fibril disrupters. The immunoassay also showed that 
these compounds had no inhibitory effect on both priming and extension and thus, validated 
this new method. 
Results showed that benzofurans compounds (group 2) were among the most effective on 
inhibition of priming; SKF 99130 and 64346 had inhibitory capacities above 50%, while 
SKF 79313 and SB 205550 inhibited approximately 35% of priming; SKF 73033 and 74652 
failed to efficiently inhibit TTR fibrillogenesis at this stage. Non-steroid molecules did not 
present important inhibitory abilities (group 3) and among the three drugs tested only 
ibuprofen showed some capacity, though intermediate, with 20% of priming inhibition. The 
4 group of compounds studied included tetrameric stabilizers and compounds that compete 
with T4 for TTR binding. Inhibition of priming by these drugs varied from approximately 
50% (DES) to intermediate values of approximately 30% (compound 19 and 20). Modified 
diflunisal and modified flufenamic acid had no activity. The group composed of ECM 
components presented no activity regarding inhibition of priming. Finally, the porphyrin 
hemin revealed about 58% of priming inhibition; aprotinin presented mild activity, with 
34% whereas the peptide derived from this anti-protease showed no activity. Compounds 
with less than 20% inhibitory effect were not considered relevant. 
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4.2­ Selection of inhibitors of extension­ immunoassay 
The same approach and the variant TTR Leu55Pro were used to screen for compounds 
affecting extension, using the variant TTR Leu55Pro. The percentage of inhibition was 
calculated as before as well as the control experiments. Figure 7 depicts the results obtained. 
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Figure 7­ Mabl5 reactivity with TTR Leu55Pro species after incubation of Leu55Pro initial 
aggregates with a series of drugs for 48 hours at 37°C. 
The same group of control compounds, i.e., fibril disrupters, was used in this experiment, 
revealing no inhibition against TTR extension. Among the benzofurans, SKF 99130 and 
64346 were the compounds with the highest inhibitory effect on TTR extension, with 
approximately 57% and 64% inhibition, respectively; SKF 73033, 79313 and SB 205550 
showed intermediate activities and SKF 74652 had no significant effect. In the group of 
non­steroid anti­inflammatory drugs, only ibuprofen showed expressive inhibition (37%); in 
the group of the tetrameric stabilizers/T4 competitors, DES and modified fiufenamic acid 
were able of inhibiting extension almost by 50% whereas the remaining drugs in that group 
did not significantly affect extension. ECM components also did not interfere with TTR 
extension, with the exception of laminin, which showed the highest inhibitory effect of all 
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compounds tested. In the last group, only hemin presented expressive inhibition of 
extension with 52%. 
Table 2 summarizes the results obtained for both priming and extension. 
Table 2- Inhibition of TTR fibril priming and extension by different classes of compounds. 
Compound 
group 
Compound 
number 
Compound name % inhibition 
Priming/TTR Tyr78Phe 
Method- Mabl5 reactivity 
% inhibition 
Extension/TTR Leu55Pro 
Method- Mabl5 reactivity 
Group 1 
Control 
1 tetracycline 10.5 10.0 
2 rolitetracyc. 8.5 -
3 doxycycline - 7.5 
4 DNP - -
5 NP - -
Group 2 
Benzofurans 
6 SKF 99130 64.5 57.3 
7 SKF 73033 11.7 20.0 
8 SKF 64346 63.2 64.1 
9 SKF79313 34.0 31.2 
10 SKF74652 3.0 3.0 
11 SB205550 34.1 21.5 
Group 3 
Non-steroid anti-
inflammatory 
12 diflunisal 4.5 -
13 ibuprofen 20.0 37.0 
14 Diclofenac - -
Group 4 
Tetrameric 
Stabilizers/T4 
competitors 
15 DES 50.2 49.6 
16 sulphite 2.3 19.5 
17 Modified diflunisal 0.5 12.8 
18 Modified flufenamic acid 10.5 51.2 
19 1,3 diidroxixanthone 30.0 -
20 
2-amino-7-bromo-5-oxo-
5H[ 1 ]benzopyrano[2,3-
b]pyridine-3-carbonitrile 
29.0 4.9 
Group 5 
ECM 
components 
21 heparin - 13.5 
22 dextran sulphate - 18.0 
23 heparan sulphate - -
24 laminin - 70.0 
25 fibronectin - 14.4 
26 Matrix gel 3.4 -
Group 6 
Others 
27 hemin 58.3 52.0 
28 aprotinin 34.0 -
29 Aprotinin peptide 6.4 -
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4.3- Electron microscopy 
To ascertain the reliability of the previous method, we investigated the influence of some of 
the compounds on priming and extension by TEM. Drugs with high, intermediate or no 
inhibitory capacity, as assessed by immunoreactivity, were tested. Due to certain batch 
variability, in each experiment a control preparation was included. 
4.3.1- Electron microscopy- Priming inhibition 
Concerning priming inhibition, after incubating soluble TTR Tyr78Phe at 37°C for 48 
hours, substantial aggregates are visible in the control preparation (figure 8, no drug). When 
pre-incubated with SKF 99130, no large aggregates were visible (figure 8, plus SKF 99130) 
and only a few oligomers were identified (figure 8, plus SKF 99130, arrow), which 
supports the results obtained by immunoassay (64.5% inhibition). In the presence of SKF 
64346, a higher amount of oligomers and small aggregates (figure 8, plus SKF 64346, 
arrow) were present in the preparation when compared to the aliquot with SKF 99130, 
although similar results were obtained by antibody recognition (63.2% inhibition). Round 
particles were also present (figure 8, plus SKF 64346, arrowhead). Ibuprofen was shown to 
inhibit priming only by 20% by immunoassay; in fact, although the aggregates observed are 
not as large and numerous as in the control (figure 8, plus ibuprofen), they represent a 
significant portion of the material present in the respective preparation. Pre-incubation with 
modified diflunisal did not avoid the formation of very large aggregates after 48 hours (plus 
modified diflunisal) as observed in the control situation (no drug added), strengthening the 
results obtained by immunoassay which suggested that this compound did not inhibit TTR 
Tyr78Phe priming. The same results were obtained for diclofenac (data not shown). 
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99130), revealing the presence 
of round particles and a few oligomers (arrow); SKF 64346 (plus SKF 64346), showing 
oligomers and small aggregates (arrow) and round particles (arrowhead); ibuprofen (plus 
ibuprofen) and modified diflunisal (plus modified diflunisal). Scale bar = 100 nm. 
4.3.2- Electron microscopy- Extension inhibition 
Some of the compounds were also tested by TEM for their ability to inhibit TTR Leu55Pro 
extension, and results are shown in figure 9. 
SKF 99130 was very active at inhibiting TTR extension resulting mostly in round particles; 
a few short fibrils were also observed (figure 9D). SKF 64346 seemed even more active and 
no fibrillar structures were visible (figure 9C). The presence of round species resembling 
soluble protein suggests that both SFKs, in addition to inhibiting extension, also have the 
ability to disaggregate the initial aggregates (compare figure 9A and C). Pre-incubation with 
SKF 73033 also inhibited the extension stage but not as strongly as the previous compounds 
since fibrils were occasionally observed (figure 9E). The results obtained with hemin 
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suggest that it has the capacity of inhibiting extension as no fibrils like those observed in the 
absence of drug (figure 9B) were visualized. However, it is unable to disaggregate the initial 
aggregates (figure 9F), as the resulting material was very similar to the initial preparation 
used in this experiment (figure 9A). These results are in good agreement with those 
obtained by the Mabl5 immunoassay. By TEM only SB205550 did not show inhibitory 
activity against TTR Leu55Pro extension, although the immnunoassay indicated 21,5% 
inhibition. 
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Figure 9 - TTR Leu55Pro initial 
aggregates at time zero (A) and incubated 
for 3 days at 37 °C in the absence (B) or in 
the presence of different compounds with 
descending inhibitory effect on extension: 
SKF64346 (C); SKF99130 (D); 
SKF73033 (E); hemin (F) and SB205550 
(G) Scale bar =100 run. 
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However, further incubation with SB 205550 for 17 days, showed a mixture of fibrils and 
round particles (figure 10, right panel) suggesting that this particular compound acts 
primarily as a fibril disrupter. When compared to the preparation control (in the absence of 
drug, figure 10, left panel), it is clear that SB 205550 originated a large amount of round 
species. 
Figure 10 - TTR Leu55Pro incubated for 17 days at 37°C in the absence (left panel) or in the 
presence of SB20550 (right panel). Scale bar = 100 run. 
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When analyzed by TEM, the anti-inflammatory compounds ibuprofen, modified 
iododiflunisal and diclofenac did not show significant effect on extension (data not shown), 
as fibrils similar to the ones observed in the absence of drug were detected (see figure 9B). 
While the results of modified diflunisal and diclofenac are in agreement with those obtained 
in the immunoassay the same is not the case for ibuprofen since it revealed 37% inhibitory 
effect in the immunoassay. It is possible that further incubation times are needed to see the 
effect of ibuprofen by TEM as was shown for SB 205550 (figure 10, right panel). This 
might also reflect different sensitivities of the two methodologies and it is possible that the 
inhibitory effects of ibuprofen are detected by TEM at higher concentrations of the 
compound. 
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5- The cellular system 
To set up a cellular system for the production of TTR aggregates, cells were transfected 
with TTR human constructs (pl69ZT-hTTRWT, pl69ZT-hTTRMet30, and pl69ZT-
hTTRPro55). Demonstration of TTR production was performed by quantitative ELISA, in 
conditioned media of 24 hours under serum-free conditions. Cells were previously induced 
with 10 uM ZnS04 for 3 days and showed different levels of expression. Table 3 depicts the 
interval range of TTR expression for each construct. 
Table 3- TTR secreted into the medium by RN22 transfected cells. 
Transfected RN22/ TTR expression 
Construct (ng/ml)/106cells/24 hours) 
P169ZT-hTTRWT 100-300 
P169ZT-hTTRMet30 350-1000 
pl69ZT-hTTRPro55 300-900 
Protein expression and degradation was also assessed by immunoprecipitation on both 
media and cell lysate. Figure 12 shows TTR from media (M) and cell lysate (P), separated 
under denaturing conditions (SDS-PAGE) after immunoprecipitation with anti-human TTR 
antibody and reveals that most of the protein produced is secreted into the medium. No 
degradation is observed. 
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M 1 2 3 4 P 1 2 3 4 
14,000 kDa " ► 
Figure 12- Immunoprecipitation analysis of RN22 cells medium (M) and pellet (P). 
(1) RN22 non-transfected; (2) RN22 P169ZT-hTTRWT; (3) RN22 P169ZT-hTTRMet30; and (4) 
RN22 P169ZT-hTTRPro55. 
We investigated the ability of the different constructs to induce the production of 
amyloidogenic species. Cells were grown in serum free medium for 24,48 and 72 hours and 
then analyzed for the presence of oligomers retained by a 0.2 um filter in a dot blot assay. 
While TTR produced by cells transfected with constructs carrying the TTRWT or TTR 
Val30Met cDNA was not retained in the filter even after 72 hours, TTR Leu55Pro protein 
was partially retained by the membrane filter as soon as 24 hours (figure 13 A), suggesting 
the formation of oligomers or aggregates. 
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A Non-transfected TTRWT 
r~ _>^ - \ r~ 
^K-
24h 48h 72h 24h 48h 72W 
v ^ = ^ 
TTRMet30 TTRPro55 
B 
14kDa 
Figure 13- Dot blot filter assay. 
A: RN22 cells non-transfected or transfected with plasmid pl69ZT carrying different TTR variants 
(WT, Met30 and Pro55). TTR was quantified in the medium by ELISA and 500 ng were applied in 
the filter, followed by TTR immunodetection. 
B: Western blotting of the material retained on the membrane filter, revealing the presence of TTR 
(lane 2); TTR standard (lane 1). 
To confirm the presence of TTR in the material retained on the filter, the doted area was 
cut, boiled with denaturing loading buffer and run on a SDS-PAGE gel. The proteins were 
then transferred to a nitrocellulose membrane followed by immunodetection against TTR 
(figurei3B), revealing the intact TTR monomer; under these conditions we did not have 
evidence for aggregate formation since SDS probably disrupted those aggregates. Our 
assumption of aggregate formation is thus solely based on the retention filter assay. 
We further investigated the nature of the secreted and aged TTR species by immunoassay 
with Mabl5. The cell medium of RN22 TTR WT, RN22 TTR VaBOMet and RN22 TTR 
Leu55Pro was collected at different time points and TTR quantified by ELISA. Using equal 
amounts of TTR protein, as measured by the polyclonal antibody that recognizes equally all 
TTR variants, Mabl5 immunoassay was performed showing that TTR WT was not 
recognized by this antibody up to 72 hours (data not shown). In contrast, TTR VaBOMet 
and Leu55Pro were recognized as early as 18 hours (figure 14) with a maximum reactivity 
157 
Screening for TTR inhibitors 
at 24 hours. TTR Leu55Pro expressed protein showed a higher reactivity when compared to 
the TTR VaBOMet counterpart. 
0,7 
Mab15 reactivity TTRLeu55Pro TTRVal30Met 
0,6 
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Figure 14­ Mabl5 reactivity towards TTR VaBOMet and Leu55Pro variants expressed and secreted 
into the medium by RN22 transfected cells. 
In this system, Mabl5 recognizes TTR VaBOMet and Leu55Pro, probably in a similar way 
to what happens in the serum of FAP patients. However, for the time points analyzed TTR 
VaBOMet does not aggregate whereas TTR Leu55Pro does, as demonstrated by dot blot 
filter assay. 
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The ability of producing TTR amyloid-like fibrils by lowering the pH in vitro lead to the 
hypothesis that the lysosomal acidic environment might play a major role in TTR fibril 
formation (Colon and Kelly, 1992), although no intracellular deposits have ever been 
observed in FAP patients. We investigated the participation of these organeles in the 
formation of the TTR Leu55Pro aggregated species by inhibiting lysosomal activity with 
chloroquine (figure 15) and results showed that TTR Leu55Pro is still retained in the filter 
in the presence of this lysosomal inhibitor. 
chloroquine 
+ 
Figure 15- Dot blot filter assay. Lysosomal influence on the formation of TTR Pro55 aggregates. 
RN22 cells medium expressing TTR Pro55 protein for 24 hours (-) and in the presence of 
chloroquine 10 uM (+). 
These data suggest that the species retained in the filter and recognized by Mabl5 are 
formed independently of lysosomal activity and are probably generated extracellularly in 
the medium, after secretion. 
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Discussion 
The process that converts a soluble protein into amyloid is complex and not fully 
understood. In the literature, TTR amyloid deposits are indicated as the causative agent of 
FAP. However, the finding that asymptomatic individuals carrying the TTR VaBOMet 
mutation show a positive reaction for inflammatory markers and present non fibrillar TTR 
deposits in the nerve, raised the possibility that others species besides mature fibrils could 
be involved in disease (Sousa et al, 2001a). In fact, in vitro studies showed that TTR 
Leu55Pro initial aggregates are toxic to a Schwanoma cell line, inducing caspase-3 
activation, while long fibrils do produce significant caspase-3 activation (chapter III). These 
observations suggest that a major target on FAP therapy is to inhibit the formation of 
intermediate species and that the study of how native TTR converts into toxic species is of 
major importance. 
We used TTR Tyr78Phe to follow fibril formation progress by TEM and observed the 
morphological changes for up to 15 days. The initial round particles (native protein) lead to 
oligomers and after further incubation produced large aggregates and finally fibrils. So far, 
the data available on this variant consisted on biochemical properties, namely that this 
variant possesses an amyloid-like fold in its soluble form, as judged by its reactivity with 
Mabl5 (Redondo et al, 2000b). The work by Anesi and co-workers (Anesi et al, 2001) 
showed TTR Tyr78Phe ex vivo amyloid fibrils by TEM; however, no kinetic 
characterization was performed. We presented here a morphological characterization and 
time progression evaluation for TTR Tyr78Phe under physiological conditions. In 
particular, the changes observed within 48 hours may mimic very early events occurring in 
vivo and therefore, this variant was selected to study the influence of several compounds on 
TTR priming, the first stage of the amyloidogenic cascade. Since we had previously 
characterized the second amyloidogenic stage (extension) we used TTR Leu55Pro to search 
for compounds affecting this step. 
Using the above TTR mutants, we studied the possibility of screening drugs affecting TTR 
priming and/ or extension by using a monoclonal antibody (Mabl5) known to distinguish 
between amyloidogenic and non-amyloidogenic structures. Although Mabl5 reacts with 
TTR Tyr78Phe, 48 hours after incubation at 37°C, by the time TTR Tyr78Phe produces 
oligomers, the reactivity decreases about 2.5 times, suggesting that the epitopes necessary 
for recognition are no longer accessible available upon polymerization. The decrease in 
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Mabl5 reactivity was also observed when TTR Leu55Pro maturated from non-fibrillar 
aggregates and oligomers into short fibrils; moreover, Mabl5 detected changes associated 
with oligomers formation since soluble TTR Leu55Pro is not immunoreactive. 
It is possible that the conformational changes that occur during fibrillogenesis differ 
between TTR Tyr78Phe and Leu55Pro. The kinetics of polymerization seems also to be 
different: macroscopically, no precipitation is observed in the TTR Tyr78Phe sample until 
8-10 days; in contrast, the TTR Leu55Pro initial aggregates are isolated by centrifugation 
(see Materials and Methods). This type of aggregate might also be present during TTR 
Tyr78Phe fibrillogenesis but at a different time. Further structural studies are necessary to 
clearly identify the motifs recognized by Mabl5 in these TTR species. It is also important to 
determine the three-dimensional structure of TTR Tyr78Phe in order to ascertain the 
differences between the two mutants. Nevertheless, within each step of fibrillogenesis of the 
two tested variants a consistent conformational behavior is observed making this 
methodology adequate for testing compounds inhibiting priming and/or extension of TTR 
amyloid fibrils. 
A panel of compounds belonging to different structural classes was tested (see table 1) 
using the Mabl5 immunoassay. Tetracyclines and nitrophenols have been shown to act 
primarily as fibril disrupters by TEM (chapter III) and thus, they were used as negative 
controls in this new method. Mabl5 detected no priming or extension inhibition by these 
compounds, which confirmed the TEM results. 
Benzofurans have been shown to inhibit A(3 fibril formation (Howlett et al, 1999a). The 
effectiveness of these compounds in preventing the formation of a fibrillar A0 form seemed 
to involve the binding of benzofuran to soluble peptide. Among the benzofurans tested for 
inhibition of TTR fibril priming and extension, SKF 99130 and SKF 64346 were the most 
effective while SKF 73033, SKF 79313 and SB 205550 were considerably less effective; 
SKF 74652 revealed no inhibitory activity under the conditions tested. Similar results were 
found for the degree of inhibition of SKF 64346 and 73033 against A0 fibrillogenesis 
(Howlett et al, 1999a), and an explanation advanced for the distinct two activities was the 
positioning of the bulky 3,5-diethyl-substituted phenyl ring in relation to the basic 
ethanolamine side chain. SKF 99130 was also shown to be a major inhibitor of Ap 
fibrillogenesis (Howlett, 2001). The main differences towards inhibition of fibrillogenesis 
of TTR and Ap were for SKF 79313, SB 205550 and SKF 74652; SKF 79313 and SB 
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205550 showed only intermediate inhibitory capacity towards TTR priming and extension 
while they were highly effective against Ap (Howlett, 2001); SKF 74652 was completely 
unable to inhibit both TTR priming and extension, whereas it was a major inhibitor against 
Ap fibrillogenesis (Howlett et al, 1999a). Thus, although some structural motifs might be 
common for Ap and TTR oligomers and protofibrils, others certainly differ. 
Non-steroid anti-inflammatory compounds, including flufenamic acid, difiunisal and 
diclofenac have been investigated and shown to inhibit TTR fibrillogenesis under acidic 
conditions. Flufenamic acid was shown to inhibit the conformational changes of TTR 
associated with amyloid formation under acidic conditions, using both TTR WT and 
Leu55Pro (Peterson et al, 1998). Sedimentation velocity and sedimentation equilibrium 
ultracentrifugation studies showed that in the presence of flufenamic acid on acidic 
environment, TTR adopts its normal tetrameric conformation (Peterson et al, 1998). Under 
these conditions and in the absence of drug, it would normally result in the dissociation of 
the TTR tetramer and in conformational changes leading to amyloid formation (Miroy et 
al, 1996). The crystal structure of TTR complexed with flufenamic acid indicated that this 
drug mediates intersubunit hydrophobic interactions and intersubunit hydrogen bonds, 
promoting the normal tetrameric fold of TTR (Peterson et al, 1998). Rational drug design 
centered on the identification of important substructures of flufenamic acid, lead to the 
selection of difiunisal as a potent fibril inhibitor (Baures et al, 1998; 1999). Diclofenac 
(Baures et al, 1999) and its derivatives (Oza et al, 2002) were also reported to strongly 
inhibit TTR fibril formation, under acidic conditions. Under physiological conditions and 
using the immunoassay here described, no inhibitory activity was detected for difiunisal or 
diclofenac, either for priming or extension. In the case of diclofenac, TEM studies revealed 
discrete fibrils approximately 7 nm wide that constituted the great majority of the 
preparation. Thus, we showed, by making use of two different methodologies under 
physiological conditions, that difiunisal and diclofenac are not sufficiently strong (adequate) 
to stabilize the tetrameric fold of TTR (priming) or to inhibit the polymerization reaction 
(extension). 
We also selected ibuprofen, another non-steroid anti-inflammatory drug, that has been 
tested preferentially in studies related to Alzheimer's disease and associated with inhibition 
of toxicity of Ap aggregates (Lim et al, 2000; Frautschy et al, 2001; Lim et al, 2001; 
Blasko et al, 2001). The mechanism behind ibuprofen action is not known and weather it 
acts directly on the amyloid precursor/ intermediates or indirectly affects amyloid 
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deposition is yet to be determined. This drug was shown to cause modest reductions in AP 
load but not in Congo red staining leading the authors to suggest that the effects of 
ibuprofen were restricted primarily to non-fibrillar deposits (Jantzen et al, 2002). In our 
study, ibuprofen showed intermediate inhibitory effects against both TTR priming and 
extension. Further studies on FAP animal models, namely the effect on oxidative stress as 
performed in Alzheimer's, should be done to assess the usefulness of this compound in FAP 
therapy. 
We assessed a group of compounds including DES, sulphite, modified diflunisal, modified 
flufenamic acid, one xanthone and a pyridine derivative, with stabilizing effects on soluble 
tetrameric TTR as ascertained by isoelectric focusing and/or competition with T4 for TTR 
binding. In this group, DES presented high inhibitory capacity for both priming and 
extension (approximately 50%), whereas the others had effect only either on priming or on 
extension. These results are unexpected, as tetrameric stabilizers should also inhibit 
priming. One possible explanation for these apparently discrepant results might be the 
different TTR variants used in the different methodologies: while the stabilizing studies by 
isoelectric focusing were performed with TTR VaBOMet, the assessment of inhibitory 
effects on priming were done with TTR Tyr78Phe. In contrast with TTR VaBOMet, TTR 
Tyr78Phe possesses amyloid-like properties in its soluble form and thus, some tetrameric 
stabilizer compounds might not be able to bind to already amyloidogenic conformations. 
Further binding studies of these class of compounds to TTR Tyr78Phe might clarify this 
issue. Tetrameric stabilizers should also be able to inhibit extension when starting with 
soluble protein. However, in our study, potential inhibitors of extension were tested using 
TTR Leu55Pro initial aggregates, implying that intermediate species were already formed 
and soluble tetrameric TTR was no longer available. 
In this study we also included a group of ECM components, thought to play a role in 
amyloidogenesis. No important inhibitory competences were found, except for laminin, 
which presented the highest percentage of inhibition of extension (70%) among all the 
compounds tested. Similarly to the other ECM components tested, laminin did not affect 
priming. In the literature, a large number of reports describe the influence of laminin on Ap 
aggregation. Different authors refer to the anti-amyloidogenic properties of laminin both by 
inhibiting fibril formation (Monji et al, 1998a; Monji et al, 1998b; Monji et al, 1999; 
Bronfman et al, 1998) and disaggregating pre-formed fibrils (Morgan and Inestrosa, 2001; 
Castillo et al, 2000). Laminin is also able to reverse the toxic effects of Ap aggregates on 
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cultured cells (Drouet et al, 1999). Castillo and co-workers (Castillo et al, 2000) studied 
the effect of several ECM components, including laminin, perlecan, type IV collagen and 
fibronectin, on Ap fibrillogenesis and concluded that laminin had the greatest inhibitory 
effect. In our work we demonstrated, by immunoreactivity with Mabl5, that laminin 
inhibits TTR extension. However, structural studies are necessary to confirm this result. 
Also, at this point, we have no indication if laminin acts as TTR fibril disrupter and thus, 
different amyloidogenic assays should be performed addressing this issue. 
Hemin and other heme-containing compounds were found to prevent Ap fibril formation 
(Howlett et al, 1997). The mechanism underlying this process is not known. Free iron has 
been reported to promote p-amyloid aggregation (Mantyh et al, 1993) whereas iron 
chelation was protective (Schubert and Chevion, 1995). Evidences point out that APP level 
shows a direct relationship with free iron levels and indirect relationship with hemin and 
iron chelators (Bodovitz et al, 1995). Furthermore, hemin prevents the formation of toxic 
Ap species as measured by MTT assays (Howlett et al, 1997). Our data suggests that hemin 
prevents both TTR priming and extension in about 50%. In the case of extension, we also 
analyzed the effect of hemin by TEM and although it prevented fibril elongation, unlike 
other compounds such as the SKF series, hemin was not able of disaggregate the TTR 
Leu55Pro aggregates as the resulting species were morphologically similar to the starting 
material. 
Aprotinin and aprotinin peptide were shown to bind amyloid fibrils (chapter I) and were 
presented as possible markers in the diagnosis of TTR related amyloid. Aprotinin was found 
to inhibit priming (34%) while the respective peptide (aa residues 16-37) did not show any 
activity for either priming or extension, suggesting that more organized structural motifs, 
probably absent in the peptide, are necessary to interfere with fibrillogenesis. 
We intend to perform further studies to establish the binding sites of the tested molecules to 
soluble and aggregated TTR. Furthermore, cytotoxic studies should be developed in order to 
determine the usefulness of these compounds. In this regard the cellular model we 
developed is an important tool to be used. Different cellular models have been generated in 
order to study amyloidogenesis. A cell culture system for generation of AA amyloid was 
established using mice peritoneal macrophages that had received repeated injections of 
Hammersten casein (Palm et al, 1997). Staining with Congo red, thioflavin T, and anti-AA 
revealed amyloid-like structures associated with macrophage clusters. Such systems can be 
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useful in studies of the influence of chaperone molecules and other factors on the formation 
and degradation of amyloid fibrils. Transfected cells with the presenilin 2 (PS2) gene were 
used to examine the processing and degradation pathways of PS2 (Kim et al, 1997). 
Mutations in the presenilin genes (PS1 and PS2) are related to familial Alzheimer's disease 
although the reasons are not known. Results suggested that PS2 normally undergoes 
endoproteolytic cleavage and is degraded via the proteasome pathway. 
A major question concerning amyloid formation is whether deposits are formed extra or 
intracellularly. In Ap fibrillogenesis, it has been proposed that oligomers formation might 
first form intracellularly. Studies revealed the presence of SDS-stable Ap dimers in the CSF 
from patients suffering from Alzheimer's disease and in the conditioned medium from CHO 
transfected cells expressing mutated APP (Val717Phe, associated with familial AD); 
incubation of these samples at 37°C did not lead to new oligomer formation (Walsh et al, 
2000). In a different study, cells transfected with the APP gene, carrying the same mutation 
as above, were treated with cysteine protease inhibitors and shown to accumulate a novel 22 
kDa carboxyl-terminal fragment; treatment with chloroquine, a lysosomal inhibitor, 
completely blocked the generation of this fragment (Knops et al, 1992). The authors 
suggested that the results revealed a non-secretory pathway for APP degradation mediated 
by cysteine proteases in an intracellular acidic compartment; inefficient degradation of the 
22 kDa intermediate might lead to the formation of aggregating P-peptide. A different 
cellular model was created for AL-amyloid formation using mesangial cells exposed to 
amyloidogenic light chains (Isaac et al, 1998); in this system treatment with chloroquine 
significantly attenuated amyloid formation, suggesting that AL-amyloid formation may 
begin intracellularly, in the lysosome. In our system, the event leading to the generation of 
oligomers or aggregates is probably occurring extracellularly, in the medium, as lysosomal 
inhibition did not avoid their formation. Our result is in agreement with the in vivo 
observations since, so far, no intracellular deposits were detected in patients. 
TTR Leu55Pro protein secreted in our culture system was shown to form species that were 
retained by a filter. Mabl5 also reacted with the material secreted by cells expressing the 
Leu55Pro and the VaBOMet variants, although the last was not retained on the membrane 
filter. This observation might imply that although TTR Val30Met does not aggregate, it 
undergoes conformational changes determinant for Mabl5 recognition, probably mimicking 
the events occurring with serum from FAP patients, which also react with this monoclonal 
antibody. Such model can provide the means to study compounds affecting events prior to 
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TTR aggregation avoiding species with an altered tetrameric fold. Although TTR Tyr78Phe 
is produced as a tetramer in its soluble form, probably the transformations leading to 
aggregate formation, upon incubation at 37°C, occur very fast due to the in vitro conditions. 
The generated cellular model constitutes an opportunity to study compounds classified as 
tetrameric stabilizers that failed to inhibit priming and/ or extension. 
The proposed system needs further assessment, including the morphological 
characterization of the species present. The lower amount of protein secreted by the cells 
may constitute a draw back in this study, as amyloidogenesis is concentration-dependent. 
Although this is not an in vivo model, it has the advantage of reuniting a number of 
biological factors absent in the other in vitro systems used (TEM and immunoassay). 
In summary: we developed an immunoassay based on the different reactivity of 
intermediary TTR species during fibrillogenesis with the monoclonal antibody Mabl5, and 
applied it to test different compounds for their ability to interfere with the progression of 
aggregate growth. The immunoassay permits screening of compounds and overcomes 
difficulties that are usually present in assays with colored or fluorogenic markers. 
Although at this point TEM analysis does not allow quantification of compound activity, the 
morphological results seem to be in good agreement with the specific immunoassay, thus, 
validating the latter. 
We suggest that during the study and screening of compounds for therapeutic use in FAP, 
several steps should be followed: 
1- For compounds with high activity on priming and extension proceed with cell assays 
to assess toxicity of the compound per se, and of the species generated by its action 
(activation of caspase-3 assays-chapter III), followed by animal studies for the non-
toxic drugs and structural analysis to design non-toxic compounds. 
2- Compounds with intermediate activity on priming and/or extension should be further 
characterized, especially if the drug has anti-inflammatory properties. Such 
characterization encompasses TEM analysis with different concentrations, cell 
toxicity as above, and tests of inhibition of aggregate formation by filter assays and 
ELISA in the cellular system here described. 
Animal studies and structural analysis for design of derivatives should follow. 
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3- Compounds with no activity should go for TEM analysis to assess disrupting 
activity; drugs with high disrupting activity need to go through toxicity assays 
before animal and structural studies. 
In the future, modeling studies may contribute to determine common structural 
motifs in amyloid fibrils and in drugs with disrupting activity, reducing the number 
of compounds that need to be studied by TEM. 
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3- Conclusions and Perspectives 
Non-invasive procedures for whole body imaging amyloid are crucial not only for 
diagnostic purposes but also for follow up of therapies aiming at reducing the amyloid load 
in organs and tissues. The available methodology for imaging amyloid deposition in 
systemic amyloidosis uses human serum amyloid P component - SAP- a component that 
binds all types of amyloid, but that has limitations related to risks of viral contamination, 
and reduced affinity for certain tissues. We investigated aprotinin as a marker for several 
types of amyloid. Two aprotinin peptides were designed and shown to bind specifically to 
different types of amyloid and not the soluble protein precursor. This opens perspectives for 
their use in imaging amyloid deposits, including systemic and cerebral forms (Alzheimer's 
disease) of amyloidosis. 
The ability to study the pathogenic mechanisms associated with FAP and in particular the 
amyloid deposits, implies the fully characterization of the dynamics of fibril formation, the 
identification and structural characterization of the different species generated in the course 
of such process, and the assessment of toxicity associated with them. 
We studied the fibril assembly progression of the TTR variants TTR Tyr78Phe and 
Leu55Pro, under physiological conditions, corresponding to two different stages in 
amyloidogenesis, priming and extension, respectively. The building blocks of TTR amyloid 
fibrils have been the subject of controversy. We showed by STEM that both TTR Leu55Pro 
fibrils under physiological conditions and TTR WT fibrils produced by acidification are 
assembled from TTR monomers, probably with an altered structure. 
The toxicity of the species generated, including initial aggregates, short and long fibrils, was 
investigated: we demonstrated that the toxic species are the initial aggregates while fibrils 
did not significantly produce toxic effects on the cell line used. Although non-fibrillar TTR 
aggregates are observed in the pre-clinical phase of asymptomatic carriers of mutant TTR, 
no direct evidence exist that in vivo mature amyloid fibrils are originated from non-fibrillar 
deposited TTR. Further studies are necessary to establish a relation between the non-
fibrillar deposits and the disease. The possibility of extracting these aggregates should also 
be considered in future work, creating the opportunity for studying the assembly of ex vivo 
fibrils and determining the basic units constituting them. With this respect, the available 
animal models might prove important tools. 
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Based on the gained knowledge, several drugs have been tested for their ability to interfere 
with TTR amyloidogenic cascade at different stages. Those compounds included 
anthracyclines, tetracyclines, nitrophenols, benzofurans, non-steroid anti-inflammatory 
molecules, ECM components, and a few others. 
In the present work we tested I-DOX and a group of I-DOX derivatives and showed that 
they act as disrupters and not as inhibitors of the amyloidogenic process. The species 
generated by I-DOX 15 days after addition of the drug were non-toxic, raising in possibility 
to use this drug or its derivatives in FAP treatment. A group of three tetracyclines and two 
nitrophenols also revealed to act primarily as TTR fibril disrupters. Similar studies should 
be conducted in order to assess the toxicity of the species generated by I-DOX derivatives 
and the other classes of disrupters. 
An extended group of drugs was investigated for the ability of interfering with both priming 
and extension of TTR amyloid. Benzofurans and anti-inflammatory compounds were 
among the most effective, inhibiting both stages. Studies in a cell culture system using a 
Schwannoma cell line and caspase assays, are necessary to evaluate toxicity and further use 
in in vivo studies. 
We also generated a cellular model capable of producing TTR Leu55Pro aggregates. 
Further investigation is necessary to determine the morphological, conformational and toxic 
characteristics of the secreted TTR. This system can provide the means to evaluate the 
cellular events underlying amyloid formation and the mechanisms responsible for inhibitory 
effects of therapeutic drugs. 
In the future, investigation should be conducted to assess toxicity in vivo and maximal dose 
allowance as well as pharmacokinetics of the different compounds selected in this work. 
Studies on selected non-toxic and stable compounds should then be conducted in animals 
presenting TTR deposition to evaluate subsequent protocols of drug administration and to 
compare pharmacokinetics. The effects of the different drugs on TTR deposition need to be 
evaluated on transgenic animal models generated in our laboratory (Sousa et al, submitted). 
These models present TTR deposition as oligomeric species between 3 and 6 months of age 
and as amyloid fibrils after 9 months of age. Thus, administration of the selected drugs 
could take place at different times ranging from 1 to 3 months for inhibitors of priming and 
extension, from 3 to 6 months for inhibitors of extension and after 6 months for amyloid 
disrupters. The effect of the drugs on the different stages of animal amyloidogenesis (early, 
central, late) can be evaluated histologically, by quantitative image analysis (Sousa et al., 
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2001). Different regimens of drug application, i.e., mixed regimens of priming and 
extension inhibition and disruption, at different time intervals on the same animal have to be 
tested. Additional studies concerning reduction of inflammatory and apoptotic effects 
resulting from the administration of the selected drugs need to be conducted since tissue 
stress markers increase with age and deposition load in these animal models as our 
laboratory as recently demonstrated (Sousa et al., submitted). 
Drugs with evident in vivo activity on TTR deposition and/or disrupting activity will set-up 
the stage for future clinical application. 
In summary, the work presented in this thesis provided new information on the 
amyloidogenic cascade and contributed to the methodology for selection of drugs with 
potential therapeutic use in FAP. 
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Abbreviations 
Abbreviations 
Abbreviations 
0.6-TTRMet30: transgenic mouse containing the entire human TTR VaBOMet gene with 
600 bp of upstream sequence including the native promoter. 
6-TTRMet30: transgenic mouse containing entire human VaBOMet gene with about 6 kb 
of the upstream region. 
A|3(l-42): amyloid derived from p-peptide residues 1-42 
Ap(l-40): amyloid derived from p-peptide residues 1-40 
AP: amyloid P-peptide (AP) or P-peptide amyloidosis 
aa: arninoacids 
AA: amyloid A associated amyloidosis 
AANF: ANF amyloidosis 
AANP: a-atrial natriuretic peptide 
ABTS: 3-ethylbenzethiazoline-6-sulfonic acid 
ACalc: Calc amyloidosis 
Acys: cystatin C related amyloidosis 
AD: Alzheimer's disease 
AEF: amyloid enhancer facctor 
AFM: atomic force microscopy 
AGel: gelsolin related amyloidosis 
AH: heavy immunoglobulin chains associated amyloidosis 
A Ins: insulin related amyloidosis 
AL: light chain type amyloidosis 
ALac: lactoferrin related amyloidosis 
ANF: atrial natriuretic factor 
ApoAI, ApoAH, ApoE, ApoJ: apolipoproteins AI, All, E and J, respectively 
ApoSAA: serum precursor of AA amyloid 
APP: amyloid precursor protein 
APro: prolactin related amyloidosis 
aprotinin Lysl5Val, Argl7Leu, Met52Glu: valine for lysine exchange at residue 15, 
leucine for arginine exchange at residue 17 and glutamate for methionine exchange at 
residue 52 of aprotinin 
APrP: prion protein diseases 
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BBB: brain blood barrier 
BJP: Bence Jones Proteins 
bp: basepairs 
BPTI: bovine basic pancreatic trypsin inhibitor or aprotinin 
BSA: bovine serum albumin 
BSB : {trans, trans)-1 -bromo-2,5 -bis-(3 -hydroxycarbonyl-4-hydroxy)styrylbenzene 
Calc: calcitonin 
CD: circular dichroism 
CG: chrysamine G 
CJD: Creutzfeldt-Jakob disease 
CNS: central nervous system 
CSF: cerebrospinal fluid 
CU: calibration uncertainty 
Da: dalton 
DES: diethylstilbestrol 
DMEM: Dulbeco's minimal essential medium 
DMSO: dimethylsulphoxide 
DNA: desoxiribonucleic acid 
DNP: dinitrophenol 
DOX: doxorubicin 
ECL: enhanced chemiluminescence 
ECM: extracellular matrix 
ELISA: enzyme linked immunoreactive assay 
FAC: familial amyloidotic cardiomyopathy 
FAO: rat hepatomas 
FAP: Familial amyloidotic polyneuropathy 
FBS: fetal bovine serum 
FCS: fetal calf serum 
FMF: familial Mediterranean fever 
FWHM: full-width-half-maximum 
GAG: glycosaminoglycan 
HBSS: Hank's balanced salt solution 
HDL: high density lipoproteins 
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HeBS: HEPES buffered saline 
HepG2: human hepatoma cells 
HSPG: heparan sulphate proteoglycans 
hTTR55- transgenic mouse containing the entire human Leu55Pro TTR cDNA 
hTTRwt- transgenic mouse containing the entire human wt TTR cDNA 
HypF-N: amino terminal domain of the Escherichia coli HypF protein 
IAPP: islet amyloid polypeptide derived amyloidosis 
I-DOX:4'-iodo-4'-deoxydoxorubicin 
Ka: binding affinity constant 
kb: kilobase 
kDa: kilodalton 
LDL: low density lipoprotein 
LDLr: low-density lipoprotein receptor 
MHCI: major histocompatibility complex of type I 
MPL: mass-per-length 
mRNA: messenger RNA 
MT: metallothionein promoter 
MTl-TTRMet30, MT2-TTRMet30: transgenic mouse containing the mouse MT fused to 
a human ttr gene containing the Val30Met mutation 
MTT: 3-(4,5-dimemyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
n: number of segments included PBS 
NF-kB: nuclear transcription factor kB 
NFT: neurofibrillar tangle 
NMR: nuclear magnetic ressonance 
NP: nitrophenol 
orf: open reading frames 
pA: SV40 poly-A tail 
PAGE: polyacrylamide gel electrophoresis 
PBS: phosphate-buffered saline 
PBST: phosphate-buffered saline with 0.05% tween20 
PDB: protein data bank 
PG: proteoglycan 
pi: point isoelectric 
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PI3-SH3: SH3 domain from bovine phosphatidyl-inositol-3'-kinase 
PLNeo: plasmid with resistance to neomycin 
PrP: prion protein 
PS: presenilin gene 
PSP-II: spermadhesin 
RAGE: receptor for advanced glycation end products 
RAP: receptor-associated protein 
RBP: retinol-binding protein 
RNA: ribonucleic acid 
sAP: soluble P-peptide 
SAA: serum amyloid A 
SAP: serum amyloid P component 
SD: standard deviation 
SDS: sodium dodecyl sulphate 
SE: standard error 
SMT-1: sheep MT-1 promoter 
SP: senile plaques 
SPR: surface plasmon resonance 
sRAGE: soluble RAGE 
SSA: systemic senile amyloidosis 
STEM: scanning transmission electron microscopy 
STI: soybean trypsin inhibitor 
sTTR: soluble TTR 
T3; triiodothyronine 
T4: thyroxine 
TBG: thyroxine binding glubulin 
TcA: technetium-99m 
TCA: trichloroacetic acid 
TEM: transmission electron microscopy 
TFA: trifluoroacetic acid 
Th T: thioflavin T 
TTR Leu55Pro: leucine for proline exchange at position 55 of transthyretin. 
TTR Tyr78Phe: tyrosine for phenylalaline exchange at position 78 of Transthyretin 
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TTR VaBOMet: valine for methionine exchange at residue 30 of transthyretin 
TTR: transthyretin 
ttr: transthyretin gene 
TTR: transthyretin; 
ttr-: ttr knock-out mice 
VHDL: very high density lipoproteins 
VL: light-chain variable domain 
VLDL: very low density lipoproteins 
VLDLr: VLDL receptor 
WT: wild-type 
p-ss: (3-globin splicing site 
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